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Abstract 
The sesquiterpenes (+)-germacrene A and (-)-germacrene D are natural semiochemicals 
currently employed in developing alternative and more sustainable crops. In planta (or in 
Nature), these relatively complex cyclodecadienes C15 hydrocarbons are biosynthesised from 
farnesyl diphosphate (FDP) by the action of sesquiterpene synthases GAS and GDS. On the 
expectation that modifications of their chemical structure could lead to compounds with 
enhanced biological properties, a small library of alkyl- and fluorine-modified germacrene A 
and D analogues were synthesised upon exposure of the corresponding FDP analogues to (+)-
germacrene A or (-)-germacrene D synthases from Solidago canadensis. Two novel 
incubation procedures were developed to secure the production of these valuable 
germacrenes in sufficient amounts for NMR characterisation as well as for their in vivo 
evaluation against aphids. While the use of deuterated extracting solvents in batch 
experiments was essential to characterise the enzymatic products and monitor their relative 
stability, the production of these novel bioactive semiochemicals was substantially boosted 
through the use of modern continuous flow extraction techniques. In addition, the synthesis 
and enzymatic evaluation of two hydroxylated FDP analogues as mechanistic probes 
provided evidence in support of a 1,10-cyclisation reaction under (+)--cadinene synthase 
catalysis. 
Results obtained from the in vivo evaluation of novel analogues of (+)-germacrene A or (-)-
germacrene D can be use in the future for designing agrochemicals with enhance repellent 
activity for pest control.  Further optimisation of flow chemoenzymatic preparation of 
sesquiterpenes could be performed, perhaps by including immobilised enzymes with 
improved stability in the design of the flow reactor. The potential of hydroxyl FDP analogues 
for exploring terpene synthases mechanism is yet to be evaluated.  
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CHAPTER 1 
INTRODUCTION
11 
 
 
1. Introduction to terpenes 
1.1 General background 
Terpenoids are a large and diverse class of natural organic compounds found in all kind of 
organisms. With at least 30,000 different naturally occurring terpenoids, this family 
represents the largest and most structurally diverse group of natural products.
1
 Indeed, 
terpenoids play many functional roles in terrestrial and marine plants, bacteria and fungi, 
mostly as secondary metabolites. Although the function of many terpenoids is still unknown, 
they are mostly not essential for viability of the organism, although there is a small group of 
terpenoids that are primary metabolites, such as carotenes and sterols.
2
 Terpenoids act as 
secondary metabolites, for instance as communication or defence chemicals.
3
 Additionally, 
terpenoids have found many applications in medicine as potent drugs against cancer,
4
 heart 
disease,
5
 malaria
6
 or fungi.
7
 
Terpenes can be classified according to the number of carbons included in the structure. 
Monoterpenes contain 10 carbon atoms, sesquiterpenes contain 15, diterpenes 20, 
sesterterpenes 25, triterpenes 30 and so on.
8
 
 
1.2 Examples of relevant terpenoids 
1.2.1 Monoterpenoids 
Monoterpenoids are often found in essential oils from plants. They are responsible for the 
characteristic odour of many plants and their organoleptic properties. Because of these 
properties and their high volatility, they are valuable chemicals for the flavouring and aroma 
industry.
9
 In respect to citrus aromas, for instance (R)-(+)-limonene (1), is responsible for the 
orange-like odour, whereas the enantiomer (S)-(-)-limonene (2) has a lemon-like smell 
(Scheme 1).
10
 Certain monoterpenoids may also act as pheromones and are used by some 
insects for communication. For instance, (+)-verbenone (3) is produced by mountain pine 
beetles, Dendroctonus ponderosae, as a dispersant pheromone.
11
 Camphor (4) has been 
reported as an antimicrobial agent.
12
 
12 
 
 
 
Figure 1. Examples of monoterpenoid bioactive compounds. 
 
1.2.2 Sesquiterpenoids 
Sesquiterpenoids occur in nature as hydrocarbons, or in oxygenated forms, but all of them are 
prepared from a precursor containing 15 carbon atoms. They are constituents of essential oils 
isolated from higher plants and some invertebrates.
13
 Additionally, sesquiterpenes have major 
importance in the food industry, being responsible for many flavours and odours.
14
 
For instance, -humulene (5, Figure 2) was first isolated from the essential oil of the hop 
plant (Humulus lupulus).
15
 E--farnesene (6, Figure 2) was also originally isolated from the 
essential oil of Humulus lupulus and is known to be secreted by aphids acting as an alarm 
pheromone.
16
 Presumably, some plants have evolved to produce it in order to reduce the 
attack density of these harmful insects. This repellent property makes it a good chemical to be 
used as a pest control agent.
17
 These two compounds are found in hops, and hence are of 
paramount importance in the brewing industry as flavouring compounds. -Humulene has 
been associated with delicate and refined beer flavour often described as elegant by brewers. 
It accounts for 40-45% of total oil in “noble-type” hops.18  In addition, -humulene has been 
found to have anti-inflammatory properties.
19
         
 
Figure 2. Chemical structures of -humulene (5), E--farnesene (6). 
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Sesquiterpenes are also important chemicals that have many medical applications with many 
different compounds of this family under medical study.
20
  
An example of an important sesquiterpenoid use in medicine is artemisinin (8, Scheme 1), 
first isolated from Artemisia annua by Dovek.
21
 Artemisinin (8) is a potent anti-malarial 
chemical. The World Health Organisation (WHO) has recommended this sesquiterpenoid, in 
combination with other therapies, as a preferred treatment for malaria.
22 
The parasite that 
causes malaria feeds from haemoglobin causing oxidative stress to the host.
23
 The most 
accepted theory proposes that artemisinin (8) acts through the reaction of its endoperoxide 
group with the haem group of haemoglobin, to generate reactive oxygen radicals that damage 
the parasite.
24
 Despite the fact that the endoperoxide appears to be crucial for its anti-malaria 
activity,
25
 the precise mechanism of action is still an object of discussion.
26
 Artemisinin was 
synthetically prepared for the first time from (-)-isopulegol (7, Scheme 1) in a 12-step 
synthesis process developed by Hofheinz et al.
27
 This total synthesis was recently improved 
by Cook et al.
28
 who successfully used a 5-step synthetic scheme from cyclohexenone. 
Despite these improvements, the total synthesis of artemisinin remains too laborious and 
costly process to be considered a viable alternative for supplying the market. Alternatively, 
semisynthesis has been developed from artemisinic acid (9, Scheme 1) and is produced in 
engineered yeast (Saccharomyces cerevisiae) which can produce as much as 25 g / L of 
artemisinic acid.
29
  
 
Scheme 1. Artemisinin (8) can be prepared from (-)-isopulegol (7) or artemisinic acid (9). 
 
Additionally the semisynthesis of artemisinin (8) has been implemented in a continuous flow 
reactor that converts dihydroartemisinic acid (10) to artemisinin (8) in a scalable process that 
does not require purification of intermediates. Artemisinic acid (9) is first reduced in batch to 
14 
 
dihydroartemisinic acid (10) with the remaining steps being performed in a flow reactor. The 
reaction of dihydroartemisinic acid (10) with singlet oxygen produces the tertiary allylic 
hydroperoxide
 
11 which undergoes Hock reaction when trifluoroacetic is added to give 
reactive enol 12 that then reacts with triplet oxygen to generate tertiary peroxide 13. Tertiary 
peroxide 13 produces artemisinin (8) through a cascade of condensations. Optimisation of 
these steps in a flow reactor gave artemisinin (13) from dihydroartemisinic acid with 39% 
yield (Scheme 2).
30
 
 
Scheme 2. Synthetic scheme for production of artemisinin (8) in a flow reactor. 
 
Another example of a sesquiterpenoid used in medicine, is the phytoalexin capsidiol (14, 
Figure 3), which is produced in tobacco (Nicotiana tabacum) and chilli pepper (Capsicum 
annuum)
31
 in response to fungal infection.
32
 Capsidiol (14) may be obtained on a small scale 
by inoculating whole bell peppers with aqueous cellulase. Capsidiol (14) is extracted after 24 
h incubation. This procedure was developed by Whitehead et al.
33
 and successfully applied 
by Coates et al.
34
 in a study of the reactivity of capsidiol (14) and its derivatives. Recently, 
capsidiol (14) has been reported to be a potent inhibitor of the growth of Helicobacter pylori, 
a pathogen that causes gastrointestinal ulcers.
35
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Figure 3. Structure of capsidiol (14). 
 
1.2.3 Diterpenoids and triterpenoids 
Diterpenoids and triterpenoids have great importance in the pharmaceutical industry not only 
for their pharmaceutical properties, but also as targets for drugs given their major 
physiological function and role in many diseases.
36
   
Paclitaxel (15, Figure 4) is a diterpenoid that was first isolated from the bark of the Pacific 
yew tree, Taxus brevifolia
37
 and its structure was elucidated by Wall in 1971.
38
 Paclitaxel 
(15) is one of the most remarkable anti-cancer drugs, which has shown excellent results for 
breast, non-small cell lung and ovarian cancer.
39
 In the case of ovarian cancer, statistics show 
that the use of paclitaxel (15) doubles the survival expectancy of patients.
40
 The cytotoxic 
effect of paclitaxel (15) is attributed to the stabilisation of the microtubule assembly of cancer 
cells that is required to be rapidly changing for the fast cell division characteristic of cancer 
cells.
41
 T. brevifolia produces low quantity of paclitaxel that is usually present in the bark in 
concentrations between 0.01 and 0.05%. This extremely low concentration and the relatively 
large amount need for one treatment (2.5-3 g), which would require eight mature yew trees 
per patient, makes the harvest from nature an option that is not viable.
42
 The groups of Holton 
et al. and Nicolaou et al. published in 1994 the first total synthesis of paclitaxel using two 
different routes.
43
 Even though many different syntheses have been published since then, the 
high number of steps and the low overall yields of all synthetic routes have set back a 
successful commercial synthetic methodology.
44
 A semi-synthetic process is currently 
employed commercially, which relies on the extraction of baccatin III (16, Figure 4) as an 
intermediate for the synthesis of paclitaxel.
45
 Some steps of the paclitaxel biosynthetic 
pathway have been transferred into heterologous expression systems, including Escherichia 
coli,
46
 Saccharomyces cerevisiae
47
 and plants.
48
 The best results were obtained with plant cell 
cultures, which can produce as much as 102 mg/kg of paclitaxel (15).
49
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Figure 4. Structures of paclitaxel (5) and baccatin III (6).  
 
Cholesterol (21) is a steroid and perhaps the most famous terpene derivative given the 
correlation of high plasma blood levels and risk of heart disease.
50
 From a physiological point 
of view, cholesterol is not only used to regulate membrane fluidity in cells, but it can be the 
starting material to synthesise sexual hormones, bile acids and vitamin D.
51
 Cholesterol is 
biosynthesised from the condensation of two molecules of farnesyl diphosphate (17) to 
produce the triterpene squalene (18) and the elimination of two molecules of diphosphate. 
This reaction is catalysed by squalene synthase. Squalene is oxidised by squalene 
synthase/monooxygenase to generate epoxide 19. Epoxide 19 undergoes a cyclisation 
cascade catalysed by lanosterol synthase to yield triterpenoid lanosterol (20). Cholesterol (21) 
is finally obtained through a metabolic pathway involving 19 different steps (Scheme 3).
52
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Scheme 3. Overview of the cholesterol (21) biosynthetic pathway from two FDP (17) 
molecules. 
 
1.3 Biosynthesis of terpenes  
1.3.1 The isoprene rule 
In 1887, O. Wallach recognized for the first that all terpenoid structures were formally 
comprised of series of isoprene (22, Scheme 4) units bound together.
53
 Later in 1953, L. 
Ružička postulated that all terpenes were biosynthesised from a common precussor. Indeed, 
the carbon skeletons of most terpenes are composed of isoprene units arranged in a regular 
(head to tail, 23) or irregular pattern (tail to tail 24 or head to head 25) (Scheme 4). This 
“isoprene rule” does not postulate the exact nature of the bio-precursor and only assumes the 
isoprene nature of the structure.
54
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Scheme 4. Possible arrangements of isoprene units in terpenes 
 
Terpenes are a class of molecules composed of isoprene building blocks that undergo 
modifications, including cyclisations and further oxidations of the carbon skeleton accounting 
for the enormous diversity of terpenes. 
 
1.3.2 Biosynthesis of IDP (33) and DMADP (34)   
Although isoprene units can often be seen in the final terpene structure, the isoprene itself is 
not the biosynthetic precursor. Instead, two activated equivalents, which are the isopentenyl 
diphosphate (IDP, 33) and the dimethylallyl diphosphate (DMADP, 34), are the precursors of 
terpenes.
55
 
There are two metabolic routes leading to IDP (33) and DMADP (34) (Schemes 5 and 6): the 
mevalonate and the non-mevalonate pathways. Although they are not mutually exclusive, 
mammals, fungi, higher plants and bacteria often use the mevalonate pathway,
56
 which takes 
place in the cytosol and is primarily responsible for the formation of sesquiterpenes and 
triterpenes. On the other hand, the non-mevalonate pathway (also known as the MEP or 
DOXP pathway) often takes place in plastids and chloroplasts of algae, cyanobacteria, 
eubacteria, apicomplexa and plants.
57
 This pathway is responsible for the synthesis of 
monoterpenes, diterpenes and tetraterpenes. 
The first committed step of the mevalonate pathway (Scheme 5) is the condensation of two 
molecules of acetyl coenzyme (acetyl-CoA, 26) catalysed by acetoacetyl-CoA thiolase to 
produce acetoacetyl-CoA (27), which then condenses with a third molecule of acetyl-CoA to 
yield the six-carbon compound intermediate3-hydroxy-3-methylglutaryl-CoA (HMG-CoA, 
19 
 
28). These two reactions are catalysed by HMG-CoA synthase. NADPH-dependent reduction 
of HMG-CoA is carried out in two steps by HMG-CoA reductase to afford (3R)-mevalonic 
acid (29). The next steps feature the ATP dependent transfer of three phosphate groups, the 
first diphosphorylate to the primary alcohol of 30 to afford diphosphate 31 and subsequent 
monophosphorylation of the tertiary alcohol to afford the intermediate 3-phospho-5-
diphosphomevalonate (32). The intermediate 32 undergoes a decarboxylation with 
concomitant elimination of monophosphate to afford the final products IDP (33) and 
DMADP (34) (Scheme 5).
58
  
 
Enzymes: (i) HMG-CoA synthase, (ii) HMG-CoA reductase, (iii) mevalonate-5-kinase and phosphomevalonate 
kinase, (iv) mevalonate-5-diphosphate-3-kinase, (v) mevalonate-5-diphosphate decarboxylase, (vi) isopentenyl 
diphosphate isomerase. 
Scheme 5. The mevalonate biosynthetic pathway to IDP (33) and DMADP (34). 
 
The non-mevalonate (Scheme 6) pathway starts with the TPP dependent decarboxylation of 
pyruvate (35). The resulting enamine reacts with glyceraldehyde-3-phosphate (36) to produce 
1-deoxy-D-xylulose 5-phosphate (DOXP, 37). This reaction is catalysed by DOXP synthase 
and is followed by a pinacol-like rearrangement and reduction with NADPH of 37 to afford 
2-C-methylerythritol 4-diphosphate (MEP, 38) catalysed by DOXP reductase. Therefore, the 
20 
 
subsequent reaction of MEP (38) with cytidine triphosphate produces 39, which is 
phosphorylated by one molecule of ATP to achieve 2-phospho-4-cytidinediphosphate-2-C-
methylerythritol 40. This then undergoes an internal cyclisation that eliminates cytidine 
diphosphate to afford the cyclic intermediate 41. The elimination of two molecules of water 
assisted by two molecules of NADPH affords IDP (33) and DMADP (34) (Scheme 6).
59
 
 
Enzymes: (i) DOXP synthase, (ii) DOXP reductase, (iii) 2-C-methyl-D-erythritol 4-phosphate 
cytidylyltransferase, (iv) 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (v) 2-C-methyl-D-erythritol 2,4-
cyclodiphosphate synthase, (vi) 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase, (vii) 4-hydroxy-3-
methylbut-2-en-1-yl diphosphate resuctase. 
Scheme 6. The non-mevalonate biosynthetic pathway for production of isoprenyl 
diphosphates. 
 
1.3.3 Biosynthetic precursor of terpenes 
IDP (33) and DMADP (34) are the bioprecursors of all terpenes from isoprene (C5) to 
carotene (C40). The universal linear prenyl diphosphate substrates of terpene synthases are 
biosynthesised from DMADP by iterative condensation of IDP (33) molecules (Scheme 
20).
60
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Scheme 7. Biosynthesis of isoprenyl diphosphates from IDP (33) and DMADP (34). 
 
All diphosphates are biosynthesised by chain elongation of DMADP (34) and IDP (33) by 
isoprenyl diphosphate synthases. The mechanism proposed for this transformation starts with 
the ionisation of diphosphate group of DMADP (34) to generate the allylic carbocation 46. 
Furthermore, the addition of the double bond of IDP affords carbocation 47, and elimination 
of a proton affords GDP (43, Scheme 8).
61
 
Scheme 8. Chain elongation reaction of DMADP (34) to geranyl diphosphates GDP (43). 
 
1.4 Terpene synthases 
All diphosphates generated by elongation of IDP (33) and DMADP (34) are converted into 
the final, often cyclic terpene products by terpene synthases. These enzymes catalyse the 
conversion of their substrates into numerous acyclic and carbocyclic structures. These 
transformations are performed with high region- and stereoselectivity discriminating different 
faces of prochiral centres.
62
  
Terpene synthases can be found in any living organism from animals to plants, fungi, bacteria 
or eukariotes. Terpene synthases from fungi and bacteria bear few similarities regarding their 
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amino acid sequences, (usually ranging between 25-35%).
63
 On the other hand, terpene 
synthases from plants bear greater similarity mostly ranging from 53% up to 83%.
64
  
Despite the differences between amino acid sequences, terpene synthases display some 
common structural features. The active site of terpene synthases is surrounded by 5 -helices 
connected by loops
65
 as part of an -barrel composed of 12 -helices arranged in anti-parallel 
fashion.
66
 The contour of the active site is different in each enzyme and it serves as a template 
for the flexible substrate, giving characteristic reactivity to each enzyme. The landscape of 
the active side (contour) is composed mainly of hydrophobic residues, which helps locating 
the hydrophobic chain of the substrate in the active site.
67
  
According to the tertiary structure and general reaction mechanism, terpene syntheses can be 
classified as class I or class II. The enzymatic structure of class I terpene synthases is 
predominantly helical. A characteristic structural feature of class I enzymes is the presence of 
two binding motifs that coordinate three Mg
2+
 ions. The first specific metal binding motif is 
composed of the amino acid sequence DDXX(D/E) located placed at the entrance of the 
active site, and another binding motif is at the opposite side of the active site with the amino 
acid sequence (D/N)DXX(S/T)XXXE. The metal ions bind to these motifs and coordinate to 
the diphosphate group of the substrate, triggering ionisation of the substrate. On the other 
hand, class II terpene synthases only contain one DXDD metal binding motif. Class II terpene 
synthases initiate the enzymatic reaction with protonation of the distal C-C double bond or 
the corresponding epoxide.
68
 
The amino acid sequence that fits with these characteristic motifs helps to find the specific 
DNA sequences that encode for terpene synthases. These DNA fragments encoding for 
terpene synthases are copied and introduced in E.coli to express the corresponding enzymes 
in vitro.
69
 
Terpene synthases can be classified according to the number of carbons contained in the 
substrate used by the enzyme. Monoterpene synthases use GDP (C10) for the transformation; 
sesquiterpene synthases use FDP (C15); diterpene synthases use geranylgeranyl diphosphate 
(GGDP, C20) and so on.       
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1.4.1 Sesquiterpene synthases 
Sesquiterpene synthases catalyse the Mg
2+
-dependant conversion of FDP (17) into more than 
300 hydrocarbon skeletons.
60
 Most sesquiterpene synthases generate a single hydrocarbon 
product with remarkable region- and stereochemical fidelity. The high diversity of 
sesquiterpenes in nature is achieved not only by the large number of different sesquiterpene 
synthases, but also by promiscuity of some terpene synthases like -humulene synthase that 
can produce at least 52 different products.
70
  
The high regio- and stereochemical selective conversions catalysed by sesquiterpene 
synthases are achieved through a complex cascade of reactions. On average, these 
transformations involve changes in to two-thirds of the carbon atoms present in the 
hydrocarbon chain of FDP such as changes in bonding, hybridisation or configuration.
68
 
Reaction starts with ionisation of the diphosphate to give a carbocation often followed by 
electrophilic attack to the central or distal double bond to produce cyclic products. 
Subsequent reactions involve cyclisations, rearrangements and deprotonation of highly 
reactive carbocationic intermediates and final proton loss to quench the positive charge.
71
 
This theory is now widely accepted due to its success explaining experimental results using 
substrate analogues, inhibitors, and intermediate analogues.
72
  
Four different sesquiterpene synthases were chosen for this project due to the relevant 
agrochemical and medical properties of their enzymatic products. (+)-Germacrene A synthase 
(GAS), (-)-germacrene D synthase (GDS) and (+)--cadinene synthase (DCS) were isolated 
from plants, thus the structures of these enzymes have two domains. GAS and GDS have 
well-established reaction mechanism, whereas the mechanism of DCS is still under 
discussion. Aristolochene synthase (AS) was isolated from fungi, thus the structure of this 
enzyme has one domain. Its mechanism is also well established and has been object of 
previous studies.
73
 Whereas AS and DCS have been crystalised and their structures are 
known in detail,
74
 GDS and GAS have not been crystalised. Therefore, study of the residues 
involve in the catalytic cycle of GDS and GAS, is performed using a homology model.
75
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1.4.2 Germacrene A synthase (GAS) from Solidago canadensis 
The complete cDNA for a functional germacrene A synthase was first isolated from Solidago 
canadensis. The 80 kDa sesquiterpene synthase was overexpressed in E. coli, incubation of 
FDP (17) with the recombinant protein gave a product profile that revealed the presence of 
(+)-germacrene A (98%) and -humulene (2%) (5, Figure 2).76  
Studies with deuterium labelled FDP analogues suggested the mechanism outlined in Scheme 
9. The enzymatic conversion of FDP (17) starts with ionisation of the diphosphate (48) and 
the attack of the double bond on C10 to C1 with displacement of the diphosphate to generate 
the intermediate germacradienyl cation (49). Subsequent deprotonation at C12 affords (+)-
germacrene A (50).
77,
 
78
 
 
Scheme 9. Catalytic mechanism of GAS. 
 
Germacrene A was isolated for the first time from the E. mammosa flower by Weinheimer as 
the (-)-enantiomer.
79
 Then, it was also isolated from different organisms such as the aphid T. 
maculala,
80
 a soft coral of the genus Lobophytum,
81
 or the termites (Reticulitermes 
lucifugus).
82
 (+)-Germacrene A (50) was isolated from caraway herb and root,
83
 fresh cactus 
roots from S. lappa 
84
 and Solidago canadensis.
85
 Whereas the (-)-enantiomer of 50 is found 
in animals and insects, the (+)-enantiomer of germacrene A seems to be more common of 
higher plants.
86
 The tendency of germacrene A (50) to undergo thermal Cope rearrangement 
to -elemene (51, Scheme 10) in a steroespecific reaction was used to determine its absolute 
configuration by comparison with an authentic sample of -elemene using chiral GC.87 
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Scheme 10. Thermally induced Cope rearrangement of (+)-germacrene A (50). 
 
Germacrene A (52) has been proposed as an intermediate in the biosynthesis of many natural 
phytoalexins, such as capsidiol (14),
88
 costunolide (57)
89
 or rishitin (54).
90
 It has also been 
proposed as an intermediate in the enzymatic formation of some terpenes, like patchoulol 
(55),
91
 5-epi-aristolochene (53)
92
 or aristolochene (56, Scheme 11).  
 
Scheme 11. Some compounds that are biosynthesised from germacrene A (52). 
 
Bowers has reported the importance of (+)-germacrene A (50) as a potential chemical agent 
for pest control.
93
 Crops are affected by different species of aphids, for instance, faba bean 
crops usually suffer damages by the black bean aphid. These insects feed from this plant 
26 
 
resulting in impairment of plant growth and yield of production.
94
 In addition, these insects 
are vectors transmitting viruses to other plants and causing further damage.
95
 Small initial 
colonies may result in a large infestation in a short period due to the high rates of 
reproduction of these insects.
96
 A study of the chemical language of aphids found that (+)-
germacrene A (50) acts as repellent for the alfalfa aphid. The economic impact that this insect 
has on crops makes (+)-germacrene A (50) an attractive target to be modified and hence, 
modulate its properties. 
Additionally, -elemene has been reported as a potential chemical against leukaemia and 
carcinomas of the brain, breast, liver and lungs. These medical properties make the 
production of (+)-germacrene A (50) derivatives very attractive compounds to be easily 
transformed into -elemene (51) derivatives for testing in medicine.97  
The synthesis of (+)-germacrene A (50) presents a formidable challenge for organic chemist 
due to the decomposition resulting from heat, acid and light, thus creating complications with 
regard to purification and product analysis.
98
 Synthetic efforts to prepare the unstable 
cyclodecadiene hydrocarbon core of germacrene A have suffered from low yield, racemic 
mixtures and poor step economy.
99
 Recently Baran et al.
100
 developed an efficient synthesis 
of (+)-acoragermacrone (62) on gram scale. This work established an efficient synthetic 
methodology for preparing the hydrocarbon core of germacrene A from farnesol (58). Firstly, 
a regio- and stereoselective epoxidation of farnesol is carried out using a Sharpless 
epoxidation and then, alcohol is oxidised to aldehyde 59. Regioselective chlorination with 
transposition of the distal double bond to obtain 60 was performed according to a protocol 
developed by Tunge et al.
101
 The key step of the synthesis of 62 is the ring closure of 60 
through an umpolung allylation with subsequent reduction of epoxide 61 and oxidation of the 
resulting alcohol to afford (+)-acoragermacrone (62, Scheme 12). Alternatively, (+)-
germacrene A (50) has been produced in high yield and purity using genetically modified 
yeast.
102
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Reagents and conditions: (i) Ti(OiPr)4 (0.1 equiv), (+)-DET (0.12 equiv), t-BuOOH (2 equiv), 4Å MS, CH2Cl2, 
-50 ºC, 2 h (ii) SO3·py (4 equiv), iPr2NEt (5 equiv), DMSO (10 equiv), CH2Cl2, 0 ºC, 0.5 h (iii) PhSeCl (0.12 
equiv), NCS (1.1 equiv), CH2Cl2, RT, 1 h (iv) [PdCl2(PPh3)2] (10 mol%), K2CO3 (1.5 equiv), Et2Zn (1.5 equiv), 
DMA, 50ºC. 
Scheme 12. Synthesis of (+)-acoragermacrone (62).  
 
1.4.3 Aristolochene synthase (AS) from Penicillium roqueforti 
Two aristolochene synthases genes have been isolated from P. roquefortii
103
 and A. terreus
104
 
and, in both cases, have been cloned and overexpressed in E coli.
105
 Both enzymes possess 
the characteristic class I terpene fold, but share only around 60% of the amino acid sequence 
identity.
106
 
The proposed catalytic mechanism of AS starts with attack of the distal double bond of FDP 
(17) at C1 and then loss of diphosphate to afford the germacrydienyl cation (63). (S)-
germacrene A (64) is then formed after deprotonation at C12 (Scheme 13).
73
 This 
intermediate undergoes a protonation of the double bond on C6 and cyclisation by the attack 
of the double bond on C2 to afford the bicyclic eudesmane cation (65). Subsequent hydride 
shift from C2 to C3 affords the cation 66, followed by methyl group migration from C7 to C2 
that gives the aristolochyl cation (67). Final deprotonation of Hsi at C8 yields the final (+)-
aristolochene (56, Scheme 13). The mechanisms and the stereochemistry have been 
confirmed with various experiments involving isotopic labeled FDP.
107
 Cane et al. 
determined the absolute configuration by its comparison with an authentic sample of 
synthetically prepared (-)-aristolochene.
108
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Scheme 13. Proposed catalytic mechanism for aristolochene formation (56).  
 
(+)-Aristolochene (56) has been found in the defensive secretions of some termites.
109
 
Feeding experiments
110
 demonstrated that aristolochene (56) is the precursor of PR-toxin 
(68), which is the major toxin found in P. roqueforti.
111
  PR-toxin inhibits the synthesis of 
RNA and the activity of different protein synthases in eukaryotes.
112
 Tests in rats reveal toxic 
properties making it lethal by intraperitoneal or oral administration.
113
 The structure of the 
toxin was solved by X-ray crystallography 
114
 and spectroscopic methods (68, Scheme 14).
115
  
 
Scheme 14. PR-toxin (68) from aristolochene (56). 
 
The total synthesis of (-)-aristolochene (75) accomplished by Cane et al.
116
 using (+)-
valencene as starting material was lately improved by Pedro et al. who used (R)-carvone (69) 
as starting material.
117
 The synthesis relies on a rearrangement of a heterospecific cationic 
decalinic intermediate guided by trimethyl silyl group.
118
 R-carvone (69) was treated with 
Me3SiLi to introduce trimethyl silyl group using the conditions described by Still
119
 to afford 
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70. The decalinic core was prepared through Robinson annulation by reaction of 70 with 
methyl vinyl ketone to afford 71. Subsequent reduction and epoxidation of 71 gave epoxide 
73. The key step is the rearrangement of 73, which is initiated by the Lewis acid catalysed 
opening of epoxide 73 that generates a tertiary carbocation, subsequent methyl migration and 
elimination of trimethyl silyl group afford 74 after acetilation of the resulting alcohol. 
Reduction of ester 74 gave (-)-aristolochene (75, Scheme 15). 
 
 
Reagents and conditions: (i) (Me3Si)2 (2.5 equiv), MeLi (2 equiv), THF-HMPA (ii) Methyl vinyl ketone (2 
equiv), Ph3CSbCl3 (0.05 equiv), 0 °C and then 1 M KOH/MeOH (iii) LiAlH4 (4.3 equiv), AlCl3 (12.8 equiv), 
Et2O, 0 °C, 5 min, then 71 , 0 °C (iv) m-CPBA (1.5 equiv), NaOAc (2.5 equiv), CHCl3, 0 °C (v) TiF4 (1.5 
equiv), CH3CN, -20 °C (vi) 4-DMAP (0.46 equiv), Ac2O-Pyr (1:1) and then K (2.5 equiv), 18-crown-6 (cat), t-
BuNH2. 
Scheme 15. Synthesis of (-)-aristolochene (75). 
 
1.4.4 Germacrene D synthase (GDS) from Solidago canadensis 
Germacrene D is a repellent for some species of aphids.
120
 This repellent pheromone is 
produced as a natural defence mechanism by some plants.
121
 Two different sesquiterpene 
synthases have been cloned from Solidago canadensis. Whereas one enzyme produces (+)-
germacrene D (81), the other produces (-)-germacrene D (78).
122
 The catalytic mechanisms of 
the two-germacrene D synthases have been studied with deuterium labelled FDP analogues.  
The (-)-enantiomer (78) is generated from FDP (17) by an initial attack of the distal double 
bond to C1 to afford germacradienyl cation (76). Then, a hydride shift from the proton on C1 
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to C11 gives the allylic carbocation (77) which undergoes a deprotonation at C15 to quench 
the allylic carbocation affording the final (-)-germacrene D (78, Scheme 16).  
 
Scheme 16. Proposed mechanism for the formation of (-)-germacrene D (78). 
 
The formation of the (+)-isomer starts in the same way with the formation of the same 
germacradienyl cation (76). In this case, the subsequent hydride shift takes place from proton 
on C10 to C11 to afford the new tertiary carbocation on C10 79. The migration of the 
hydrogen in C1 to C10 affords now allylic carbocation with the opposite stereochemistry 80. 
Deprotonation at C15 gives the (+)-enantiomer (81, Scheme 17).
123 
 
Scheme 17. Proposed catalytic mechanism for the formation of (+)-germacrene D (81). 
 
(-)-Germacrene D (78) was isolated from ylang-ylang oil with 98% ee
124
 in sufficient amount 
to be used as starting material for the total synthesis of different kind of periplanones.
125
 (-)-
Germacrene D (78) is a natural intermediate in the biosynthesis of periplanone A (82) and B 
(83),
126
 which acts as sexual pheromone of male Periplaneta americana.
127
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Scheme 18. Periplanones A and B (82 and 83) from (-)-germacrene D (78). 
 
Due to its potential use as an agrochemical for pest control, a total synthesis of (-)-
germacrene D (78) was developed by Schreiber et al.
128
 The synthesis commenced with 
photocycloaddition of allene (84) and -unsaturated ketone 85 followed by stereospecific 
addition of vinylmagnesium bromide provided allylic carbinol 86 as a mixture of isomers. 
Oxy-Cope rearrangement of 86 gave cyclobutene 87, which underwent an electrocyclic ring 
opening to afford a mixture 2:1 (trans / cis) of ketone 88. The mixture was equilibrated by 
photochemical reaction obtaining a mixture 15:1 and trans isomer was separated by HPLC.
129
 
Selective enolisation of ketone 88 and subsequent sulfenilative trapping gave vinyl triflate 89. 
Stereospecific displacement of vinyl triflates with organocopper reagent was performed to 
afford (-)-germacrene D (78, Scheme 19). 
  
 
Reagents and conditions: (i) hυ, (450-W Hanovia lamp equipped with a Pyrex filter), Et2O 30 ºC and then 
CH2=CHMgBr, Et2O, -78 ºC (ii) KH, 5 equiv of 18-Cr-6, THF, 60 ºC, 25 min (iii) Toluene, 175 ºC, 20 h and 
then hυ (450-W Hanovia lamp equipped with a Vycor filter) benzene. (iv) LiHMDS, HMPA, Tf2NPh, THF -78 
ºC (v) Me2CuLi, Et2O, -78 ºC.  
Scheme 19. Synthesis of (-)-germacrene D (78) 
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In presence of acid, (-)-germacrene D (78) rearranges over time into a complex mixture of 
cadinenes, muurolenes, amorphanes, ylangane, eudesmanes, isodaucanes, oppositanes and 
axanes.
130
 (-)-Germacrene D (78) is stable up to 180 ºC but at 240 ºC rearranges to -
ylangene (90), -copaene (91), -muurolene (92) and -amorphene (93).131 Isogermacrene D 
(94) (Figure 5) was obtained when a sample of (-)-germacrene D (78, Scheme 16) was 
analysed by GC-MS at injection port temperature of 400 ºC.
132
  
 
Figure 5. Products obtained from the thermal decomposition of (-)-germacrene D (78). 
 
Due to their relevant biological properties, part of this work is aimed at the chemoenzymatic 
preparation of several analogues of aristoloche (56), as well as (+)-germacrene A (50) and (-
)-germancrene D (78) for testing their repellent properties against aphids. These analogues 
will be tested for improved environmental stability or enhance repellent properties in 
comparison with their parent compounds.  
 
1.4.5 --Cadinene synthase (DCS) from Gossypium arboreum 
The de novo synthesis of the phytoalexin gossypol from --cadinene was observed in a 
cell culture of the cotton tree Gossipium arborerum, when the fungus Verticium dahliae was 
inoculated.
133
 The study of this defence mechanism against fungal or bacterial infections, led 
to the identification of a 64 kDa sesquiterpene cyclase, --cadinene synthase.134 The DNA 
encoding for this enzyme has been isolated, cloned and over expressed in E. coli.
135 
The catalytic mechanism of DCS has been discussed in the literature and, although some 
proposals have been formulated, two mechanisms are still possible for the conversion of FDP 
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(17) to --cadinene (103).136 The first isomerisation step is common to both mechanisms; 
it begins with the isomerisation of the primary diphosphate on FDP (17) to the tertiary 
diphosphate, (3R)-nerolidyl diphosphate (NDP, 95, Scheme 20) and subsequent ionisation to 
96.
137
 Next steps of the two different proposals involve, as the key step, either a 1,10-
cyclisation or a 1,6-cyclisation, to achieve the final --cadinene (103).  
 
Scheme 20. Isomerisation of FDP (17) into (3R)-NDP (95). 
 
One of the proposed catalytic mechanisms involves a 1,10-macrocyclisation of 96 with the 
elimination of diphosphate to afford the cis-germacradienyl cation (97). Subsequent hydride 
shift leads to the allylic carbocation (98). A second cyclisation involving reaction of the 
double bond on C6 with the carbocation on C1 affords cadinenyl cation (102), which is a 
common intermediate for both mechanisms.
138
 
The proposed catalytic mechanism through a 1,6-cyclisation starts with the attack of the 
double bond in C6-C7 to carbocation on C1 of 96 affording the -bisabolyl cation (99). -
Bisabolyl cation (99) undergoes a hydride shift of the hydrogen on C1 to afford the allylic 
carbocation 100, followed by a second cyclisation by attack of the distal double bond to 
carbocation on C1 to give 101. The next step of this mechanism is a hydride shift from C7 to 
C11 to achieve the cadinenyl cation 102.
136
   
The last step of the mechanism, common to both pathways, consists of a deprotonation of the 
cadinenyl cation (102) to afford -cadinene (103, Scheme 21).  
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Scheme 21. Two possible pathways for the formation of --cadinene (103) from NDP 
(95). 
 
The production of --cadinene (103) is the first biosynthetic step in route to Gossypol 
(104).
139
 This secondary metabolite 104 is the major terpenoid produced by cotton tree and is 
its main chemical defence.
140
 Interestingly, this phytoalexin has been also studied as a male 
contraceptive drug
141
 and as a potential cancer therapeutic drug.
142
 
 
 
Figure 6. Gossypol (104) can be prepared from (+)--cadinene (103). 
  
Mizutani developed a simple total synthesis of -cadinene (103) through stereo selective 
Robinson annulation between 106 and 107 to form cadinenone (108). The oxygen of 108 was 
removed by thioketal / Ni Raney method to produce -cadinene (103, Scheme 22).  
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Reagents and conditions (i) Pyrrolidine, benzene, reflux (ii) AcONa / AcOH, benzene, 80 ºC (iii) Ethanedithiol, 
BF3OEt2, MeOH, 0 ºC and then W2-Raney Ni, EtOH / H2O.  
Scheme 22. Synthesis of -cadinene (103). 
 
The biosynthesis of -cadinene (103) is still being debated, and part of this study is focused 
on providing an unambiguous solution to this problem. 
 
1.5 Study of terpene synthase mechanism 
The reactions promoted by terpene synthases have been the subject of study for a long time 
and there seems to be general agreement in the literature that these reactions occur through a 
carbocationic intermediate.
143
 Some approaches to the study of enzymatic mechanism of 
terpene synthases include X-ray crystallography,
144
 mutagenesis,
145
 aza-analogues of 
carbocations intermediates
146
 and substrate analogues of FDP (17), particularly fluorinated 
FDP analogues.
147
 
 
1.5.1 Crystal structures in combination with mutagenesis 
Aristolochene synthase (AS) from Penicillium roqueforti provides a suitable example of how 
the crystal structure of a terpene synthase can be used to design a mutant enzyme that helps to 
uncover the role of specific amino acid in the catalytic reaction, as well as gaining more 
insight into the enzymatic mechanism. AS was the first sesquiterpene cyclase from a fungus 
to be crystallised. The 2.5 Å resolution crystal structure (Figure 7) allows identification of the 
active site and the study of the key amino acids involved in the reaction catalysed by AS.
148
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For instance, the identification of leucine 108 as part of the active site in the crystal structure 
of AS, led to the study of the role of this amino acid by preparing mutants of AS, in which 
leucine 108 was substituted with less bulky amino acids, such as alanine or serine. These 
mutants of AS did not possess the ability to produce cyclic products, generating instead a 
mixture of linear hydrocarbons. This result outlines the importance of the leucine 108 for the 
templating effect that AS has over the flexible FDP (17), placing the double bonds in the 
right orientation for cyclisation.
149
  
The presence of aromatic residues in the active site of terpene synthases has been proposed as 
a key feature for the stabilisation of carbocationic intermediates and thus reducing the energy 
required for the formation of the desired product and helping to discriminate among other 
possible pathways.
150
 This carbocationic stabilisation promoted by aromatic residues was 
investigated by preparing AS mutant F178V, which produces germacrene A (64) instead of 
aristolochene (56). Therefore, germacrene A (64) is an intermediate in the conversion of FDP 
(17) into aristolochene by AS which undergoes a second cyclisation to generate eudemane 
cation (65, Scheme 13, vide supra). F178 is hence proposed to stabilise the eudesmane cation 
(65) through π-interaction of its phenyl side chain with the carbocationic centre. The 
substitution of phenylalanine for valine thereby increases the energetic barrier for the 
formation of eudesmane cation (65), thus germacrene A (64) is produced instead.
151
    
  
 
 
Figure 7. A cartoon representation of the crystal structure of aristolochene synthase from 
Penicillium roqueforti (1DGP.pdb, left) and a model of the active side with FDP (right). 
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1.5.2 Aza-analogues of carbocationic intermediates 
Eudesmane cation (65) is predicted to be an intermediate in the catalytic mechanism of AS 
and this possibility was investigated with aza-analogues that mimic the transition state 
leading to eudesmane cation (65). Iminium salts 109 and 110 were synthesised and evaluated 
in inhibition studies under steady state conditions, showing that the two compounds were 
only moderate inhibitors of PR-AS. However, when the studies were repeated in the presence 
of diphosphate, these two salts became potent inhibitors of AS. This result highlighted 
pointed out the role of diphosphate in stabilising the eudesmane cation (65) and provides 
convincing evidence that it is an intermediate in the catalysis of AS.
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Figure 8. Aza-analogues (109 and 110) of eudesmane cation (65). 
 
1.5.3  FDP analogues 
FDP analogues are useful tools to uncover the cryptic enzymatic mechanism of sesquiterpene 
synthases. FDP containing fluorine atoms are especially useful. The small size of the fluorine 
atom does not affect the binding of the analogue to the active site,
153
 but can prevent the 
formation of carbocations  to the fluorine atom and inactivated double bonds. These 
properties can be useful to provide evidence for the formation of a specific carbocation or 
outline the role of a double bond.
154
 Many examples of fluorinated FDP analogues used as 
mechanistic probes can be found in the literature.
155
 For instance, strong evidence supporting 
the intermediacy of germacrene A (113a) in catalysis by 5-epi-aristoloche synthase (TEAS) 
was gain by characterisation of 6F-germacrene A (114) as the product from incubation with 
6F-FDP (111). The mechanism of this enzyme starts with the displacement of the 
diphosphate by attack of distal double bond to afford carbocation 112a, which is quenched by 
deprotonation to give germacrene A intermediate 113a. Protonation of double bond on C6 
triggers a cyclisation and a reaction cascade that affords 5-epi-aristolochene (53). However, 
with 6F-FDP (111), the double bond on C6 is deactivated towards protonation by the 
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presence of the fluorine atom, preventing the subsequent cyclisation thus obtaining 
exclusively 6F-germacrene A (114) as product of the incubation (Scheme 23).
154
 6F-
germacrene A (114) was also obtained when 111 was incubated with AS.
156
 
Scheme 23. Formation of 6F-germcrene A (114) from 6F-FDP (111) by TEAS.  
 
Dihydro FDP analogues have also been used to uncover the enzymatic mechanism of 
sesquiterpene synthases. For example, the 6,7-dihydro FDP (120, Scheme 25) was useful to 
provide evidence for the intermediacy of nerolidyl diphosphate (NDP, 95, Scheme 20) in the 
catalysis of trichodiene synthase. The reaction catalysed by this enzyme is proposed to start 
with an isomerisation of FDP (17) to produce nerolidyl diphosphate (NDP, 95). NDP 
undergoes then a 1, 6-cyclisation to afford the bisabolyl cation (115). Second cyclisation by 
attack of the distal double bond to carbocation on C7 to afford 116 is followed by cascade of 
methyl, hydrogen shifts and a deprotonation (116 to 119) to afford the final product 
trichodiene (119, Scheme 24).
157
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Scheme 24. Catalytic mechanism of trichodiene synthase. 
 
When 6,7-dihydro FDP (120) was incubated with trichodiene synthase, the compound is 
isomerised into 6,7-dihydro NDP (121), but the subsequent intramolecular 1,6-cyclisation is 
in this case impossible due to the absence of the double bond on C6. 6,7-Dihydronerolidyl 
diphosphate 121 is attacked by a molecule of water and 6,7-dihydronerolidol 122 is recovered 
from the incubation. Recovery of 122 supports isomerisation of FDP (17) into NDP (95) as 
first step in the mechanism of trichodiene (Scheme 25).
158
  
 
Scheme 25. Outcome of the incubation of trichodiene synthase and 1,6-dihydro FDP (120). 
 
1.6 Synthesis of FDP and analogues  
Due to the relevance of FDP analogues to the study of sesquiterpene synthases, several 
different methodologies for isoprenoid chain preparation of FDP have been developed. These 
different methodologies rely on key reactions for the formation of the hydrocarbon chain, 
such as Horner-Wadsworth-Emmons olefinations; a sequence of sulfonylation, alkylation, 
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and desulfonylation; or addition of dienolate to an electrophile. In addition, two different 
methods have been developed to convert primary alcohols into diphosphates.  
 
1.6.1 Wittig and Horner-Wadsworth-Emmons olefination 
Wittig and Horner-Wadsworth-Emmons olefinations have been used to convert a ketone to an 
isoprene unit. This method has the disadvantage of creating two isomers of the product. 
However, the two isomers can be separated by chromatography, the overall yield of this 
process is lower than other methodologies.
159
 Despite this issue, this is the preffered method 
for the synthesis of analogues containing vinylic fluorine atoms. For instance, this approach 
was used for the synthesis of 2F-FDP (126) from geranyl acetone (123) and 
fluorophosphonate 124 (Scheme 26). 
  
Reagents and conditions: (i) NaH, benzene, RT; (ii) DIBAL-H, CH2Cl2, -78 ºC to -50 ºC; (iii) CBr4, PPh3, 
CH2Cl2 and then (Bu4N)HP2O7, CH3CN, RT. 
Scheme 26. Synthesis of 2F-FDP (126) by means of Horner-Wadsworth-Emmons 
olefination. 
 
1.6.2 Sulfonylation, alkylation and desulfonylation methodology 
Biellmann and Ducep developed and used a sequence of sulfonylation, alkylation, and 
reductive desulfonylation for the first time in 1969.
160
 This method begins with the synthesis 
of a bromide and a sulfonate. Coupling of these two compounds and subsequent 
desulfonylation achieves the synthesis of the FDP hydrocarbon chain. For instance, the chain 
elongation of geraniol (127) has been achieved through a synthetic sequence involving 
sulfonylation of farnesol (127), alkylation to 129 and reductive desulfonylation to give 130 
(Scheme 27).
161
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Reagents and conditions: (i) NaH, benzyl bromide, THF, 0 ºC and then SeO2, EtOH, RT; (ii) PBr3, DCM, 0 ºC 
and then PhSO2Na, DMF, RT (iii) n-BuLi, HMPA, THF, -78 ºC (iv) Li, EtNH2, RT. 
Scheme 27. Elongation of geraniol with the sulfonylation, alkylation and reductive 
desulfonylation methodology. 
 
1.6.3 Weiler-Sum chain elongation  
The chain elongation sequence developed by Weiler and Sum
162
 in 1981, involves the 
addition of dienolate 132, which is generated in situ, to an electrophile, followed by the 
conversion of the resulting -keto ester into an alkene.163  This synthetic sequence results in 
the addition of an isoprenyl moiety to the electrophile. For example, Gibbs applied this 
methodology to the synthesis of 134. The sequence starts with the addition of dienolate 132 
to electrophile 131 to obtain 133 that is then transformed into 134 (Scheme 28).  
 
Reagents and conditions:  (i) THF, 0 °C (ii) (Me3Si)2NK, THF, -78 °C; 2-(5-chloropyridyl)N(SO2CF3)2, from -
78 °C to RT; (iii) EtMgBr, CuCN, Et2O, -78 °C. 
Scheme 28. Weiler-Sum chain elongation of 131 to 134. 
 
1.6.4 Preparation of diphosphates 
The first procedure developed for the formation diphosphates by Böhm
164
 involves the 
reaction of the corresponding alcohol with monophosphate salts and trichloroacetonitrile. 
42 
 
This procedure affords a complex mixture of mono-, di- and triphosphates. The crude 
reaction is then partially purified by cation ion exchange chromatography. Keller developed 
an improved purification protocol
165
 by finding appropriate conditions to purify this complex 
mixture of compounds by flash chromatography or preparative TLC on silica. However, in 
both cases the yields obtained were modest (24-31%). 
Significantly improved methodology was reported by Davisson et al.,
166
 who performed the 
diphosphorylation reaction with different electrophiles, such as isoprenyl chloride, bromide 
or tosylate, instead of the alcohol by reaction with tris(tetra-n-butylammonium) 
hydrogendiphosphate. The reaction exclusively afforded the desired diphosphate. The yields 
observed varied from 35 to 80% depending on the hydrocarbon chain and the leaving group 
used.  
 
1.7 Optimisation of enzymatic reactions yields 
Many natural products that are useful for artificial purposes are produced in very small 
amount in nature. Consequently, the extraction of these valuable compounds from natural 
sources is not a viable process to satisfy the market. Total synthesis of natural compounds is 
mostly an inefficient procedure that is not suitable for industrial production due to its high 
cost. A significant effort is currently focused on engineered yeast, such as Sacharomyces 
cerevisiae, or bacteria, such as Escherichia coli, that can be harnessed to produce high 
quantities of valuable natural compounds using metabolic pathways.
167
  
In spite of the extensive literature about the optimisation of the metabolic pathways of these 
microorganism for in vivo production of natural compounds,
168
 few reports has been 
published exploring the potential of isolated natural enzymes for in vitro production of highly 
valuable chemicals. Strategies to improve reaction yield rely on the modification of the 
catalyst itself. For example, directed evolution produces a large number of mutant enzymes 
that contains random mutations and then, all mutant enzymes are screened for improved 
activity.
169
 Alternatively, the de novo design of enzymes with computation can produce 
enzymes for specific tasks. However, these enzymes can suffer from lower reaction yields 
than natural occurring enzymes.
170
 Recently, Baker et al.
171
 optimised a computational 
designed Diels-Alderase
172
 obtaining an enzyme with enhanced activity (18 times higher than 
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native enzyme) by remodelling the backbone structure to enable more interactions with 
substrates using the online game foldit developed by Cooper et al.
173
   
There are some other reports about optimisation of enzymatic reactions that focus on 
strategies, such as immobilised enzymes or use of additives. For instance, Klibanov et al. 
reported an overall yield of 0.01% in the production of N-acetyl-L-tryptophan ethyl ester by 
reaction of N-acetyl-L-tryptophan and ethanol in aqueous media with chymotrypsin as 
catalyst whereas a 100% yield was obtained with immobilised chymotrypsin.
174
 In addition, 
Khmelnitsky et al. reported that some additives such as KCl could dramatically increase the 
activity of chymotrypsin and subtilisin in organic solvents achieving 100 times the initial 
activity.
175
 
 
1.7.1 Incubations of sesquiterpene synthases with their substrates 
In spite of all these strategies to improve enzyme efficiency, there are only few examples 
where optimisation of the enzymatic reactions yields has been performed. Especially, there 
has been very little work published related to the optimisation of terpene synthase efficiency 
but this little work obtained promising results. For instance, Hohn et al. reported an 
optimisation of the concentration of magnesium for the incubation of aristolochene synthase 
that enhanced the enzymatic activity 30-fold.
176
  
Extensive literature researches reveal that little work has been done to optimise the reaction 
conditions and there is no a standardised procedure for the incubation of terpene synthases 
with their substrates. Most common set ups for incubations of terpene synthases with their 
substrates includes a biphasic mixture of aqueous incubation buffer and organic solvent 
(usually hexane or pentane). Aqueous incubation buffer often contains glycerol, MgCl2, 
buffer, -mercaptoethanol, enzyme and substrate. However, the concentrations used for each 
component in the aqueous phase changes across the literature even for the same enzyme. 
Moreover, incubation procedures for extraction of volatile terpene products from the aqueous 
phase change across the literature and scale up of small incubation set up often result in low 
reaction efficiencies. All these variations led to inconsistent and often low yields in the 
enzymatic reactions of terpene synthases.   
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Part of this work was aimed at the development of a standard procedure for the incubation of 
terpene synthases with their substrates to maximise conversion and yield of the product(s) 
(Chapter 3). 
 
1.7.2 Flow chemistry 
Traditionally organic reactions have been performed in batch, which mean in a round bottom 
flask where reactants are mixed together with a magnetic stirrer. In contrast, in flow 
chemistry reactants are pumped into tubes that are joined one to another. The bulk chemical 
industry has used this approach extensively for a long time. Only in the last few years, 
continuous flow systems become popular for the preparation of chemicals on the small 
laboratory scale.  Miniaturised flow devices can perform multi step synthesis continuously. 
Flow systems allow the integration of several chemical reactions in only one system, as well 
as other operations such as quench, work up, isolation and purification.
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Chemistry in flow systems has several advantages that make it attractive over traditional 
batch reactions. For instance, flow systems are increasing its popularity due to the safety 
profile over traditional batch process. Hazards derived from stockpiling explosive, toxic, or 
sensitive intermediates of synthesis can be overcome by the continuous processing achieved 
in flow systems. Besides, relatively small volumes and its high surface-area-to-volume ratio 
that enable fast heat dissipation can prevent a runaway reaction.
178
 The precise control over 
reaction conditions performed in automated flow systems, where mixing and heat transfer is 
well characterised along with the small volume required for a reaction, allows rapid 
development of reactions by testing different conditions in a short period of time.
179
 In 
contrast with batch reactions where the mechanism of mixing is complex due to the different 
variables involve (e.g. shape of the vessel);
180
 in flow systems, the good characterisation of 
the mixing and the conditions makes reaction scaling a less complex process for bulk 
production. Indeed, scaling reactions is easier in flow systems than in batch; three general 
approaches to scale reactions have been employed: run the process for longer (scaling out), 
use a larger continuous reactor (scaling up), or use multiple reactors in parallel (numbering 
up).
181
     
One of the most important advantages of flow systems over batch process is the efficient heat 
and mass transfer, which increase the productivity of the process by increasing the reaction 
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rate. The latter is especially useful in heterogeneous systems where reaction rate is controlled 
by mass transfer. In addition, due to its nature, flow systems can be easily combined with 
other technologies such as microwave irradiation, photochemistry, inductive heating or 
sonication, which can potentially increase efficiency of the process.
182
 
All these properties make flow systems an attractive novel methodology that can help to 
increase reaction rates and simplify scalability of terpene synthases reactions. Reactions of 
terpene synthases in a flow reactor were compared with their analogous reactions in batch in 
the work described in Chapter 3. 
 
1.8 Aims of the project  
Some plants have developed a natural chemical defence mechanism against herbivorous 
insects; the plant releases a sesquiterpene that affects the behaviour of the aphids in order to 
repel them.
183
 (+)-Germacrene A and (-)-germacrene D have been reported as 
semiochemicals acting as repellents/toxins for different species of aphids, this property makes 
these two chemical compounds potential candidates for pest control.
184
 
Modification of (+)-germacrene A and (-)-germacrene D can result in modulation of their 
properties, for example, fluorinated germacrene analogues have been reported to have 
improved stability whereas alkyl substitution can reduce the volatility of these compounds 
helping them to stay on the leaf for longer period of time. However, the unstable nature of 
these two volatile compounds has set back a satisfactory synthesis,
86
 therefore development 
of a synthetic approach for the preparation of (+)-germacrene A and (-)-germacrene D 
analogues has not been closely studied. 
For this project, the chemoenzymatic preparation of (+)-germacrene A and (-)-germacrene D 
analogues by incubation of FDP analogues with the corresponding sesquiterpene syntheses 
was investigated. Towards this end, a series of FDP analogues were synthesised and tested 
with GAS and GDS. In addition, these FDP analogues were tested also with AS, due to the 
ability of this enzyme to sometimes produce the enantiomeric germacrene A from FDP 
analogues. To obtain the sesquiterpene derivatives in sufficient amount for biological testing 
and characterisation, an incubation methodology was developed and optimised for improved 
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conversion and yield. The products obtained with germacrene synthases were assessed for 
biological activity against aphids, in collaboration with the Rothamsted Research. 
Another different aim of this project was the synthesis and design of new mechanistic probes 
for the study of the reaction catalysed by sesquiterpenene synthases. These novel mechanistic 
probes contain hydroxyl groups, which were expected to quench the carbocationic 
intermediates, helping to reveal the mechanisms of these enzymes. These analogues were 
applied in the study of DCS catalysis, to distinguish between the two possible proposed 
mechanisms (1, 10 or 1, 6 cyclisation, Section 1.4.5, Scheme 21).      
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CHAPTER 2 
Chemical expansion of the terpenome: synthesis of 
farnesyl diphosphates analogues 
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2. Introduction 
Alkyl substituted FDP analogues are alternative substrates or inhibitors of protein-farnesyl 
transferases (FTase). For instance, a group of proteins called Ras proteins are involved in the 
signal cascades that control cell growth, differentiation and survival, playing crucial role in 
eukaryotes.
185
 Ras proteins increase their hydrophobicity by farnesylation, which is a crucial 
modification to exert their activity.
186
 Since Ras proteins are involved in numerous human 
carcinomas,
187
 the development of inhibitors or alternative substrates that helps to understand 
the mechanism of FTase has been an area of interest for the pharmaceutical industry.
188
 
Examples of FDP analogues that behave as an inhibitor with protein FTase are 135d and 
135e. On the other hand, FDP analogues 135a, 135b and 135c behave as substrates of protein 
farnesyl-transferase (Scheme 29). There is a relation between the presence of a double bond 
in the substituent and the ability to act as a substrate.
189
 Spielmann and his co-workers have 
demonstrated that the factors that govern substrate versus inhibitory interactions are quite 
subtle and complex.
190
 The ability of FTase to accept different FDP analogues has been 
investigated by other groups to incorporate photoaffinity labels,
191
 affinity tags
192
 and 
fluorophores.
193
 
 
Scheme 29. Example of alkyl substituted FDP analogues. 
 
Although alkyl substituted FDP analogues have been prepared before, prior to this work they 
had not been tested with germacrene synthases. In this project, alkyl modified FDP were used 
to chemoenzymatically prepare alkyl modified germacrene analogues. Alkyl groups increase 
the bulk of the hydrocarbon chain of FDP that must fit in the active site of terpene synthases. 
Alkyl-modified FDP analogues can fit more readily in the active site of germacrene synthases 
if the alkyl groups introduced are small. Methyl groups offer minimal increment in the size of 
hydrocarbon chain than any other alkyl group. Therefore, methyl substituted analogues were 
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preferred rather than larger alkyl groups. Chemical modifications of natural products by 
methylation is a rather common strategy to alter or modulate the intrinsic biological 
properties of secondary metabolites, including methylated sesquiterpenes such as TMTT, a 
potent aphid-repellent C16 homo terpene resembling (E)--farnesene (6, Figure 2).
194
 
Therefore, it seems reasonable to expect that the chemo enzymatically produced C16 homo 
germacrenes will most likely display enhanced or altered bioactivities. Evaluation of a set of 
methyl and dimethyl modified FDP analogues with germacrene synthases and AS to obtain 
modified germacrenes allowed testing of novel germacrenes for repellent activity against 
aphids. Two alkyl-FDP analogues previously described in the literature and named 14Me-
FDP (137), 15Me-FDP (138) were prepared for testing with sesquiterpene synthases. In 
addition, 12Me-FDP (136) and 14,15diMe-FDP (139) were prepared as novel alkyl-FDP 
analogues. 
Germacrenes are very unstable compounds given the disposition of the double bonds in the 
hydrocarbon cyclodecadiene core. This disposition can be changed by reducing the number 
of carbon atoms in the macrocycle, so the new germacrene analogue should have improved 
stability. Recently, Gibbs et al.
195
 synthesised a set of FDP analogues that contain one less 
CH2 spacer between isoprene units, finding that these FDP analogues can be substrates for 
protein farnesyl trasferases. This group of analogues were called frame shifted FDP 
analogues. 8nor-FDP (140) was synthesised in order to obtain a nine-membered ring 
germacrene derivative that would have improved stability.  
FDP analogues containing a hydroxyl group were designed to interfere with the carbocationic 
catalytic mechanism of terpene synthases. The lone electronic pairs of the hydroxyl group can 
quench a carbocation on the alpha carbon to generate an epoxide, and, in this way, the 
carbocationic intermediate will be frozen in epoxide form. With this objective in mind, novel 
8OH-FDP (141) and 14OH-FDP (142) FDP analogues were synthesised to explore the 
mechanism of DCS (Scheme 30).  
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Scheme 30. FDP analogues targeted for synthesis in this study. 
 
2.1 Synthesis of 14Me-FDP (137) 
The synthesis of 14Me-farnesol (165, Scheme 33 vide infra) was first reported by Sen et al., 
who used it as an authentic standard for aiding characterisation in the study of alternative 
substrates for prenyl transferases involved in the synthesis of juvenile hormone (JH).
196
 Three 
different types of JH have been isolated from Lepidoptera (butterflies and moths), JHI (143), 
JHII (144) and JHIII (145) (Scheme 31). The most common JH 
197
 is the JHIII derived from 
FDP and it has been proved to be an important factor for growth and development in plants 
and invertebrates.
198
  
Scheme 31. Juvenile hormones characterised from Lepidoptera. 
 
The synthetic methodology used by Sen et al. relied on the use of vinyl stannanes and 
involved eight synthetic steps to afford the geraniol derivative (160, Scheme 33).
196
 Improved 
methodology was developed by Rawat et al,
199
 for the synthesis of 14Me-FDP (137). This 
method adds successive isoprene units with a procedure that allows the introduction of 
different alkyl groups through displacement of a vinylic triflate intermediate with dialkyl 
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cuprate. This methodology was also applied in this work for the preparation of 15Me-FDP 
(138) and 14,15Me-FDP (127). 
Retrosynthetic analysis: A generic farnesyl diphosphate 146 is prepared from the 
corresponding alcohol 147 that is prepared from ester 148. The disconnection of the alkyl 
group (R2) of 148 led to synthons 149 and 150 that correspond to dialkylcuprate 151 and 
triflate 152 respectively. Compound 152 may be prepared from -keto ester 153 and the -
keto ester is disconnected to give synthones 154 and 155 that correspond to dienolate 156 and 
bromide 157. Bromide 157 was prepared from alcohol 158 (Scheme 32). The second isoprene 
unit is disconnected in an analogous way.  
  
 
Scheme 32. Retrosynthetic analysis of a generic alkyl substituted FDP analogue, where R1 
and R2 is any alkyl group. 
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This synthetic plan was used for the preparation of 14Me-FDP (137) with some modifications 
(Scheme 33). -keto ester 133 was prepared from dimethylallyl bromide (131) following a 
procedure described by Rawat.
199 
However, the vinyl triflate (159) was best prepared by a 
procedure described by Specklin et al.
200
 Whereas an ethyl group was introduced by Cu (I) 
assisted displacement of the triflate with ethyl magnesium bromide (Et)2CuLi in 73% yield 
from -keto ester 133. Methyl group in the second isoprene unit was introduced by reaction 
with the corresponding phosphonate and (Me)2CuLi in 65% yield, as described by Jin et al.
201
 
The reduction of esters 134 and 164 was carried out by the reaction with DIBAL-H at low 
temperature. Then, the transformation of corresponding alcohols 160 and 165 into suitable 
leaving group was performed by mesylation and subsequent displacement of mesyl group by 
bromine or chlorine (Scheme 33).   
 
Reagents and conditions: (i) Ethyl acetoacetate, NaH, BuLi, THF, 0 ºC; (ii) Et3N, lithium trifluoromethane 
sulfonate, trifluoromethanesulfonic anhydride, DCM 0 ºC; (iii) CuI, EtMgBr, THF, -78 ºC ; (iv) DIBAL-H, 
toluene, -78 ºC, (v) Et3N, MsCl, LiBr, THF, -45 ºC to 0 ºC; (vi) ethyl acetoacetate, NaH, BuLi, THF, 0 ºC; (vii) 
NaH, diethylchlorophosphate, Et2O, 0 ºC; (viii) Me2CuLi, Et2O, -78 ºC; (ix) DIBAL-H, toluene, -78 ºC; x) S-
collidine, MsCl, LiBr, DMF 0 ºC; (Bu4N)3HP2O7, CH3CN, then DOWEX 40 W (NH4
+
 form) cation exchange. 
Scheme 33. Synthesis of 14Me-FDP (137)
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2.1.1 Preparation of -keto ester 133 
 
Scheme 34. Preparation of -keto ester (133) from dimethyl allyl bromide (131). 
 
The formation of the lithium dienolate 132 from ethyl acetoacetate (166) and the reaction of 
this intermediate with different alkylating agents has been previously reported by Weiler.
202
 
The dienolate 132 was formed by deprotonation with sodium hydride, followed by further 
deprotonation with a stronger base, such as butyllithium (Scheme 35). The alkylation was 
tested by Weiler with different alkylating agents and, in all cases, takes place exclusively at 
the  carbon atom of 166.202 
 
Scheme 35. Mechanism of formation of 133. 
 
An incomplete reaction was observed when the bromide 131 reacted with 1.2 equivalents of 
dienolate 132 with yields varying from 37 to 61% (Table 1, entry 1). Increasing the number 
of equivalents of 132 led to a moderate improvement in the yield of the reaction 60-68% 
(Table 1, entry 2). Reaction times over 1 hour led to an increase in the by-products observed 
by TLC; therefore, reductions of reaction time to 1 hour improve the yield to 72-80% (Table 
1, entry 3). Jin et al.
203
 made similar observations. 
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Entry Temperature 
ºC 
Molar 
equivalents 
of 132
* 
Molar 
equivalents  
of nBuLi 
and NaH*  
Reaction 
time (h) 
Yield 
(%) 
1 0 1.2 2 4 37-61 
2 0 3 3.3 4 60-68 
3 0 3 3.3 1 72-80 
*Molar equivalents in relation to 131 
Table 1. Different conditions used for the preparation of 133. 
 
2.1.2 Preparation of ester 134 
 
Scheme 36. Preparation of ester 134 via triflate 159. 
 
The ester 134 was prepared from vinylic triflate 159 (Scheme 36). The synthesis of this 
vinylic triflate has been performed efficiently using a pyridine amine bistriflate (2-(5-
chloropyridyl) N(SO2CF3)2) by Rawat.
199
 However, this work concluded that the amine salts 
were difficult to remove, making necessary the purification of the rather unstable vinylic 
triflate 159 by column chromatography. However, an alternative methodology for selective 
synthesis of vinylic triflates from -keto esters has been described by Specklin et al.204 This 
method uses a mild base, such as EtN(Pr
i
)2 in the presence of LiOTf salt, which fixes the 
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geometry of the enolate double bond via metalation, thus achieving exclusively the Z isomer 
of the product. Premixing the lithium salt and the base with the -keto ester 133 for at least 
10 minutes before adding the triflic anhydride, was especially important for fixing the 
stereochemistry of the enolate 168 (Scheme 37). Near simultaneous addition of all reagents 
led to isolation of a mixture of geometrical isomers. The solvent used in the formation of the 
enolate influences the geometry of the double bond, giving the Z isomer exclusively when 
dichloromethane was used, while in contrast, mixtures of geometrical isomers are obtained 
when other solvents, such as diethyl ether, are used.
204
  
 
Scheme 37. Stereoselective formation of enol triflate 159.  
 
Vinyl triflate 159 was synthesised in 83% yield. Although it was possible to purify 159 by 
flash chromatography column, affording yellow oil, the colour slowly turned to black upon 
storage for few hours in the fridge, thus highlighting the unstable nature of this compound. 
The unpurified triflate 159 was considered by 
1
H NMR spectroscopy to be sufficiently pure 
for its use without purification in all subsequent reactions and that is the reason why it was 
used immediately before and after its decomposition. 
Although initial attempts to perform the displacement of the vinyl triflate 159 with 
Et2CuMgBr (prepared in situ by reaction of EtMgBr and CuI) resulted in low yield of ~50%, 
the reaction outcome observed by TLC indicated that the reaction was complete and clean. 
The procedure of quenching involves the addition of saturated aqueous NH4Cl solution and 
the subsequent extraction with diethyl ether, which results in the precipitation of the copper 
salts. The presence of copper salts made the extraction procedure difficult. The procedure 
developed by Jin et al.
203
 overcomes this problem by diluting the reaction mixture with 
diethyl ether and addition of concentrated NH4OH to the quenched solution. The biphasic 
mixture was stirred for 2 hours. In this latter case, the procedure led to the complete 
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dissolution of the copper salts and the obtention of a clear biphasic mixture. The workup 
proceeded without further complication obtaining ester 134 in 88% yield.   
 
2.1.3 Preparation of alcohol 160 
 
Scheme 38. Preparation of alcohol 160 from ester 134. 
   
The diisobutylaluminium hydride (DIBAL-H) was chosen to reduce allylic esters to their 
corresponding alcohols, thus avoiding isomerisation of the vicinal double bond. A 
preliminary test reaction afforded the allylic alcohol 160 in low yield of 59% (Table 2, entry 
1). The original work-up using a saturated aqueous solution of sodium potassium tartrate to 
chelate aluminium was substituted by a basic quench of the reaction (NaOHaq, 2M), but no 
improvement of the yield was observed (Table 2 entry 2). In subsequent experiments basic 
(NaOHaq, 2M) or acid (HCl, 1M) for extended periods was investigated. The complete 
dissolution of the aluminium aggregates and consequent improvement in the work-up and 
yield was achieved by this method (Table 2, entries 3 and 4). 
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Entry Equivalents of 
DIBAL-H 
Quenching method Yield (%) 
1 2.5 K
+ 
Na
+ 
tartrate for 10 min 59 (impure) 
2 3 2 M NaOH for 10 min 61 
3 3 1 M HCl + DCM stirring for 2 h 85 
4 3 2 M NaOH + DCM, stirring for 16 h 93 
 
Table 2. Reaction yields obtained from the various conditions used for quench and 
subsequent work up of the reaction used for formation of 160. 
 
2.1.4 Preparation of alcohol 165 
 
Scheme 39. Preparation of alcohol 165 from alcohol 160. 
 
The first step for the addition of an isoprene unit to alcohol 160 was the transformation of the 
alcohol into a suitable electrophile that can undergo alkylation with dienolate 132. The 
transformation of alcohol 160 into bromide 161 with the method used by Jin et al.,
203 
which 
involves the transformation of the alcohol via a mesylate intermediate and subsequent 
displacement of the mesylate with LiBr in a one-pot reaction, was tested and resulted in a 
clean reaction. Alkylation of dienolate 132 was performed immediately and without further 
58 
 
purification of bromide 161. The required -keto ester 162 was obtained in 78% yield 
(Scheme 33). 
The transformation of -keto ester 162 with diethylchlorophosphate and NaH afforded the 
vinylic phosphonate 163 in 86% yield. This procedure afforded exclusively the Z isomer 
through sodium chelation of the intermediate enolate and subsequent O-phosphorylation with 
diethyl chlorophosphate.
203
 Alternatively, the E isomer can be obtained using tertiary amines, 
such as Et3N in HMPA as bases.
205
  
Phosphate 163 reacted with dimethyl lithium cuprate to afford ester 164. Ester 164 was 
analysed by TLC after purification by chromatography and judged pure as only one spot was 
observed in the TLC plate. Subsequent reduction of ester 164 with DIBAL-H afforded the 
corresponding alcohol 165. The purification of alcohol 165 by flash chromatography afforded 
one pure product as determined by TLC. However, 
1
H NMR spectroscopic analysis displayed 
additional signals that were not expected giving the apparent purity of the product (Figure 
9B). GC-MS analysis revealed the presence of a second product that display a molecular ion 
with m/z = 204 (Figure 9A). The by-product was identified as (2E, 6E)-7-ethyl-11-
methyldodeca-2,6,10-trien-1-ol, (Figure 9B, 169) originating from direct reduction of the 
phosphonate 163. The by-product 169 accounts for the 29% of the total product judging from 
relative integrals on signals centred at 4.07 and 4.03 ppm that correspond to protons marked 
as Hb in the 
1
H NMR spectrum (Figure 9B, 169). The formation of the by-product 169 was 
previously observed by Jin
201
 in the dimethyl cuprate displacement reaction of 163. Its 
formation was overcome by the addition of methyl iodide followed by its stirring for 2 hours 
at -45 ºC, before quenching the reaction.  
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Figure 9. A) Gas chromatogram of the mixture of product 169 and 163 B) 
1
H NMR spectrum 
of the mixture of products (in the range δH 4 - 6 ppm).   
 
Following the procedure of Jin,
201
 the displacement of phosphate 163 resulted in the complete 
disappearance of 163. Ester 164 was obtained in 65% yield and the subsequent reduction 
afforded the alcohol 165 in 60% yield.     
  
2.1.5 Preparation of diphosphate 137 
The first step in the preparation of the diphosphate 137 is the preparation of tris(tetra-n-
butylammonium) hydrogendiphosphate salt (171). Diphosphoric acid is first generated from 
disodium dihydrogen diphosphate (170) by exchange of the sodium ions for protons on a 
cation exchange column, followed by immediate titration to pH 7.3 with 40% (w/w) aqueous 
tetra-n-butylammonium hydroxide (Scheme 40). 
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Scheme 40. Formation of tris(tetra-n-butylammonium) hydrogen diphosphate (171). 
 
The alcohol 165 was converted into the chloride 172 using the procedure described by 
Collington and Meyers.
206
 This procedure starts with the conversion of the alcohol into a 
mesylate group by reaction with methanesulphonyl chloride and Et3N and subsequent 
displacement of mesylate by chlorine. The mentioned chloride 172 was immediately used in 
the next reaction. Direct displacement of the allylic chloride 172 by the diphosphate salt 171 
afforded the diphosphate salt 173. This salt was passed through a cation exchange column 
(Dowex50W-X8, ammonium form) to obtain the tris ammonium salt of diphosphate 173. 
Ammonium salts are easier to purify by HPLC and are solid, which make them easy to 
handle (Scheme 41).  
 
Scheme 41. Preparation of the FDP analogue 137.  
 
Crude salt was purified by two different methods. Methanol trituration of the solid obtained 
from the lyophilised fractions from the ion exchange column has been shown to be a good 
method to quickly obtain an impure FDP analogue (5-10% impurity of PPi by as judged 
31
P-
NMR).
207
 Purification of the remaining residue after methanol trituration by reverse-phase 
HPLC afforded pure diphosphate salt 137 in 39% yield.  
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2.1.6 Conclusions 
The methodology developed by Rawat et al.
199
 was optimised and modified using the 
procedures reported by Specklin
204 
regarding selective enolate formation and by Jin
203 
regarding the displacement of vinyl triflates with lithium dialkyl cuprates. 14Me-FDP (137) 
was obtained in 6% yield over twelve steps by combining these two methods.  
 
2.2 Synthesis of 15Me-FDP (138) 
The first report related to the preparation of 15Me-FDP (138) was published by Ogura et 
al.,
208
 who prepared the isopentenyl diphosphate derivative 174 as an inhibitor of farnesyl 
diphosphate synthase. However, incubation of analogue 174 and diphosphate 175 with 
farnesyl diphosphate synthase gave as a product the chemoenzymatic prepared 15Me-FDP 
(138, Scheme 42).  
 
Scheme 42. Chemoenzymatic preparation of 15Me-FDP (138).  
 
Later on, a synthetic method was published by Montellano et al. according to Horner-
Wadsworth-Emmons’ olefination of geranyl acetone with diethyl carboethoxyethyl 
phophonate, affording a mixture of isomers.
209
 A synthetic methodology used to modify the 
hydrocarbon chain involving a coupling with vinylic triflate was first reported by Dawe.
210
 
15Me-FDP (138) was prepared following the isoprene chain elongation developed by Weiler 
and Sum.
162
 Thus, alkylation of geranyl bromide (176) with dienolate 132 yielded the -keto 
ester 177. A second reaction via triflate 178 according to Rawat
199
 allowed coupling with 
EtMgBr, generating ester 179. Subsequent reduction of the ester 179 and diphosphorylation 
of alcohol 180 afforded 15Me-FDP (138, Scheme 43). 
62 
 
 
Regents and conditions: i) ethyl acetoacetonate, NaH, BuLi, 0 ºC; ii) Et3N, lithium triflate, triflic anhydride, 0 
ºC; iii) CuI, EtMgBr -78 ºC; iv) DIBAL-H -78 ºC v) S-collidine, MsCl, LiBr, DMF, 0 ºC and then 
(Bu4N)3HP2O7, CH3CN, then DOWEX 40 W (NH4
+
 form) cation exchange. 
Scheme 43. Synthesis of 15Me-FDP (138). 
 
2.2.1 Preparation of diphosphate 138 
The addition of bromide 176 to a solution of dienolate 132 gave the -keto ester 177 in 81% 
yield. 
Although the preparation of enol triflate 178 proceeded as usual, judging by TLC, the 
analysis of the crude mixture by 
1
H NMR spectroscopy did not show the expected signal for 
the alkene proton of 178 at 5.75 ppm. The signals corresponding to the OCCH2CO protons of 
the ester 177 observed at 5.1 ppm disappeared and only one absorption is observed in the 
olefinic region at 5.8 ppm integrating for one proton. The absorptions corresponding to the 
ethyl ester could still be observed. Hence, it is proposed a cyclisation triggered by acid, 
possibly coming from hydrolysis of triflic anhydride to triflic acid (pKa = -12).
211
 The 
proposed mechanism for the formation of cyclic product 183 starts with the protonation of the 
expected product 178 to generate tertiary carbocation 181. This intermediate undergoes a 
cyclisation by attacking the middle double bond to generate cyclic carbocation 182. 
Deprotonation of this intermediate affords the proposed product 183 (scheme 44). 
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Scheme 44. Possible mechanism for the formation of the proposed cyclic product 183. 
 
Vinylic triflate 178 was finally obtained by adding an excess of Et3N to the reaction. The 
base quenched the acid coming from the triflic anhydride and the reaction proceeded without 
further complication. Triflate 178 was used in the next step without further purification. 
The ethyl group was introduced by reaction with Et2CuLi of the vinylic triflate 178. Further 
analysis of the reaction by GC-MS did not show any by-product from the direct reduction of 
the vinylic triflate, therefore, the addition of ethyl iodide was not necessary in this case. Ester 
179 was synthesised in 41% yield over two steps. Alcohol 180 was obtained in 69% yield by 
the reduction of ester 179 with DIBAL-H. Methanol trituration of the crude 
diphosphorylation reaction afforded a first fraction of the 15Me-FDP (138) in 18% yield (5% 
impure). The purification of the remaining crude solid after trituration with methanol by 
HPLC afforded a second fraction of pure colourless solid in 36% yield.  
 
2.2.2 Conclusions 
Methodology developed for the synthesis of 14Me-FDP (137) was successfully applied to the 
synthesis of 15Me-FDP (138). Cyclisation of vinyl triflate 178 triggered by acid was 
overcome by adding an excess of base and the final diphosphate 138 was obtained in 8% 
yield over six steps. 
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2.3 Synthesis of 14, 15 diMe-FDP (139) 
The synthesis of alcohol 187 via vinyl cuprate coupling has been previously reported.
212
 An 
alternative synthesis was performed by allyl barium coupling of chloride 184 and bromide 
185. In both cases, the synthesis suffers from poor step economy with 17 steps to afford 
alcohol 187 and poor yield. Alcohol 187 was used in the study of the insect juvenile 
hormone.
196  
 
Scheme 45. Synthesis of alcohol 187. 
 
2.3.1 Preparation of diphosphate 139 
The synthesis of 14,15-diMeFDP (139) was performed from-keto ester 162 (Scheme 33). 
Ester 189 was obtained in 52% yield from -keto ester 162. The reduction of the ester gave 
alcohol 187 in 73% yield. The diphosphorylation of 187 afforded a colourless solid after 
lyophilisation of fractions obtained from ion exchange column. The methanol trituration of 
the solid afforded a first fraction of diphosphate 139 as colourless solid in 36% yield. The 
purification of the remaining solid by HPLC afforded a second fraction of 139 in 19% yield 
(Scheme 46). 
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Reagents and conditions i) Et3N, lithium triflate, triflic anhydride, 0 ºC; ii) CuI/EtMgBr (1:2) -78 ºC; iii) 
DIBAL-H -78 ºC iv) S-collidine, MsCl, LiBr, DMF 0 ºC and then (Bu4N)3HP2O7, CH3CN, then DOWEX 40 W 
(NH4
+
 form) cation exchange. 
Scheme 46. Synthesis of 14,15diMe-FDP (139). 
 
2.3.2 Conclusions 
14,15Me-FDP (139) was prepared for the first time using a methodology developed for the 
synthesis of 14Me-FDP (137). Whereas this methodology achieved diphosphate 139 in 5% 
yield over twelve steps, a previous methodology reported by Ewing et al.
196 
involved 
seventeen steps to afford alcohol 187 in 3% yield. 
 
2.4 Synthesis 12Me-FDP (136) 
Literature review revealed that 12Me-FDP (136) had never been synthesised prior to this 
study. However, in 1970, Corey performed a synthesis of ether 193 with analogous 
hydrocarbon chain as 12Me-FDP (136). This compound was prepared as an intermediate in 
the synthesis of an analogue of JHII (132, Scheme 31). The synthesis involved a modified 
Wittig olefination between triphenyl phosphonium salt 190 and aldehyde 191, deprotonation 
of resulting betaine with sec-butyl lithium and addition of paraformaldehyde to afford alcohol 
192 which is reduced to 193 (Scheme 47).
213
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Scheme 47. Previous published synthesis of modified FDP hydrocarbon chain in C12. 
 
Later on, Mori
214
 described an improved synthesis of the hydrocarbon chain of 12Me-
farnesol (209, Scheme 50) from farnesyl acetate (194). The synthesis starts with the oxidation 
of farnesyl acetate (194) with selenium dioxide to afford the allylic alcohol 195. The alcohol 
195 was further oxidised to -unsaturated aldehyde 196 by reaction with MnO2. This 
aldehyde is converted into diene 197 by Wittig olefination. Finally, a selective diimide 
reduction of the terminal double bond afforded the final product 198 (scheme 448).
214
 
However, this synthesis presented several problems, including the isomerisation of the double 
bond on C2 when the terminal double bond was reduced.
215
 
 
Scheme 48. Synthesis of the hydrocarbon chain of 12Me-FDP (136) by Mori. 
 
Retrosynthetic analysis: Diphosphate 136 was prepared from the corresponding alcohol that 
was obtained from hydrolysis of THP ether 199. The disconnection of methyl group on C12 
of 199 gave synthons 200 and 201, which correspond to dimethyl cuprate lithium 202 and 
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bromide 203 respectively. Bromide 203 is obtained from alcohol 204 that derivates from 205 
(Scheme 49).  
 
Scheme 49. Retrosynthetic analysis of 12Me-FDP (136).  
 
The synthesis starts with the THP protection of trans, trans-farnesol (206). The THP 
protected farnesol 207 was then oxidised with selenium dioxide in CH2Cl2 and t-BuOOH as a 
co-oxidant to afford the allylic alcohol 204 in 21% yield.
216
  The exclusive E stereochemistry 
of the allylic oxidation with SeO2 is well established.
217
 The transformation of the resulting 
hydroxyl group to a leaving group allowed displacement with lithium dimethyl cuprate to 
afford THP ether 205 in 81% yield. Subsequent deprotection of the THP ether 205 and 
diphosphorylation of alcohol 209 afforded 12Me-FDP in 29% yield over two steps (136) 
(Scheme 50).  
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Reagents and conditions (i) PPTS, DHP, RT; (ii) SeO2, t-BuOOH (70% in H2O) (iii) Et3N, MsCl, LBr THF, -
45ºC to RT ; (iv) Me2CuLi, Et2O, -78 ºC; (v) PPTs in MeOH (vi) S-collidine, MsCl, LiBr, DMF  0 ºC; (vii) 
(Bu4N)3HP2O7, CH3CN, then DOWEX 40 W (NH4
+
 form) cation exchange. 
Scheme 50. Synthesis of 12Me-FDP (136). 
 
2.4.1 Preparation of alcohol 204 
The THP protection of farnesol (206) was performed using pyridinium para-toluenesulfonate 
(PPTS) and dihydropiran (DHP). This clean reaction afforded 207, after purification, as 
colourless oil in 86% yield. The selenium dioxide oxidation of the THP ether 207 gave the 
expected primary alcohol 204 along with some contamination of the secondary alcohol 208, 
as previously reported by Labadie et al.
216
 These two alcohols were separated by flash 
chromatography on silica using a mixture of hexane and ethyl acetate as eluent. The primary 
alcohol 204 was obtained in 21% yield.  
 
2.4.2 Preparation of 12Me-FDP (136) 
As it has been previously described for alcohol 160 (Scheme 33), the conversion of the allylic 
alcohol 204 into bromide 203 was performed. Alcohol 204 was then converted into a 
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mesylate by reaction with methanesulfonyl chloride and Et3N, the mesylate group was then 
displaced with LiBr in a one-pot reaction. However, the displacement of the mesylate at 0 ºC 
led in this case to a slow reaction that was incomplete after 3 hours. The reaction was 
repeated, warming from -45 ºC to room temperature after LiBr addition. A colour changed 
from white milky to a yellow solution was observed. The reaction was completed in 1.5 hour 
as judged by TLC. The slow reaction was attributed to the hindered position of the allylic 
alcohol. The proximity to the methyl group to the alcohol can hinder the attack of the 
bromide, increasing the difficulty of the substitution. The allylic bromide was used in the next 
step without further purification. 
The preliminary reaction of bromide 203 with MeLi at 0 ºC afforded a complex mixture of 
products as indicated by TLC, suggesting that this reactive bromide (203) was clearly not 
stable under the conditions used. The reaction was repeated at -78 ºC using dimethyl lithium 
cuprate as a nucleophile, and the purification of the crude obtained after 30 minutes of 
reaction afforded a yellow oil in 53% yield over two steps. Although 
1
H NMR spectroscopy 
indicates the presence of some impurities, the sample was judged sufficiently pure for 
carrying on to the next step.  
Stirring the THP ether 205 in MeOH with PPTS overnight afforded the alcohol 209 in 81% 
yield. However, a close examination of the 
1
H NMR spectrum of alcohol 209 revealed that 
the impurity persisted. However, repeated attempts to purify the sample were unsuccessful 
(Figure 10, impurities were marked as *, +). 
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Figure 10. 
1
H NMR spectrum (250 MHz, CDCl3) of alcohol 209 with the signals 
corresponding to the impurity marked with *, +. 
 
The proposed mechanism for the formation of the inseparable impurity starts with the 
displacement of bromine 203 by Me2CuLi. The organocuprate intermediate 210 undergoes 
addition of methyl group and elimination of CuMe to afford THP ether 211. The similarities 
between the structures of the two products obtained explain the inability to purify the 
compound. In addition, the broad doublet observed at 4.67 ppm matches with the signals 
expected for the two protons of the terminal double bond of 211 and a small signal 
overlapping with the singlets at 1.6 ppm could be a doublet corresponding to the allylic 
methyl group of 211. The integration of the signals allowed calculation of the grade of the 
impurity was less than 10% (Scheme 51). 
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Scheme 51. Proposed mechanism for the formation of the inseparable by-product 211. 
 
Despite the presence of the impurity, the product was judged sufficiently pure to continue the 
synthesis. Therefore, alcohol 209 was converted in the corresponding diphosphate salt. 
Methanol trituration of the crude fraction collected from the ion exchange column gave 
12Me-FDP (136) as a colourless solid in 36% yield.  
 
2.4.3 Conclusions 
New methodology for synthesis was developed for preparation of the novel FDP analogue 
12Me-FDP (136). This new approach avoided the isomerisation on C2 reported in procedure 
developed by Mori. Consequently, Mori achieved synthesis of alcohol 209
 
in 3% yield,
214
 
whereas methodology reported here achieved alcohol 209 in 8% yield. The preparation of the 
novel FDP analogue named 12Me-FDP (136) was achieved in 3% yield over five steps. 
 
2.5 Synthesis of 8nor-FDP (140) 
FDP analogues with increasing or decreasing number of carbon atoms between double bonds 
were denominated frame shifted by Gibbs.
218
 Frame shifted FDP analogues were synthesised 
for the first time by Gibbs during inhibition studies of mammalian FTase. Gibbs successfully 
applied Wenkert’s methodology219 for the transformation of carbon-oxygen sigma-bonds into 
carbon-carbon sigma-bonds to the synthesis of 8nor-FDP (140). The key synthetic step of this 
route is the addition of lithium dihydrofuran (212) to the allylic bromide 131, and subsequent 
stereospecific nickel-catalysed ring opening reaction by methyl magnesium bromide 
affording the trisubstituted alkene 213. Alcohol 213 was then converted into iodide 214 and 
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the isoprene chain elongation was achieved by means of a Negishi’s cross-coupling220 
reaction between the iodide 214 and the vinylic iodide 215 to afford the alcohol 216 (Scheme 
52).
221
 A different synthetic route was developed in this study for the preparation of 8nor-
FDP (140). 
 
Scheme 52. Synthesis of 8-nor-farnesol (216) proposed by Gibbs. 
 
Retrosynthetic analysis: Diphosphate is prepared from the corresponding alcohol 216 that is 
obtained from the deprotection of THP ether 217. The first disconnection is the dimethylvinyl 
tail of 217 to give synthones 218 and 219. Synthones 218 and 219 correspond with bis-
dimethylvinyl cuprate 220 and bromide 221 respectively. 221 Is prepared from the 
corresponding alcohol 222 (Scheme 53).  
 
Scheme 53. Retrosynthesis of 8nor-FDP (140). 
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The synthesis starts with the THP protection of commercially available trans-geraniol (224), 
followed by allylic oxidation with selenium dioxide to afford allylic alcohol 222. The 
hydroxyl group is converted to bromide to afford 221. Then, the bromide 221 is treated with 
dialkyl copper 220 to afford THP ether 217. The deprotection of the THP ether will afford 
alcohol 216 and the final diphosphorylation will afford the target compound 140 (Scheme 
54).  
 
Reagents and conditions:  i) DHP, PPTS, DCM, RT. ii) SeO2, t-BuOOH, salicylic acid, DCM 0 ºC iii) MsCl, 
Et3N, LiBr, THF, -45 ºC to RT iv) PPTS, MeOH, RT v) S-collidine, MsCl, LiBr, DMF 0 ºC and then 
(Bu4N)3HP2O7, CH3CN, then DOWEX 40 W (NH4
+
 form) cation exchange. 
Scheme 54. Synthesis of 8nor-FDP (140). 
 
2.5.1 Preparation of alcohol 222 
Protection of geraniol was achieved in 89% yield by acid catalysed reaction with 
dihydropyran. The oxidation of THP ether 223 afforded the allylic alcohol 222 in 60% yield. 
In this case, salicylic acid was added to the reaction mixture to minimise over oxidation of 
alcohol 222 to the corresponding aldehyde 225 (Scheme 54).
222
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2.5.2 Preparation of THP ether 217 
Alcohol 222 was converted into allyl bromide 221 by conversion to mesylate and 
displacement with LiBr, as described for alcohol 160 (Scheme 33). After 1 hour, the reaction 
was complete as judged by TLC. The crude product was used in the next step without further 
purification. Displacement of the allylic bromide 221 with the cuprate 220 gave the THP 
ether 217 as major product in 87% yield. However, the 
1
H NMR spectrum of 217 displays 
small signals that suggest that the sample is contaminated with an inseparable compound 
(Figure 11, *, #).  
 
 Figure 11. 
1
H NMR spectrum (400 MHz, CDCl3) of the THP ether 217 impurity is marked 
with * and #. 
 
The product is presumably formed through an SN2’ mechanism through intermediate 
organocuprate 226 that undergoes a [1, 3] sigmatropic rearrangement to afford 227 (Scheme 
52). According to this structure, the broad doublet observed at 4.98 ppm corresponds to the 
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two protons on the terminal double bond of 227 marked with a * and the quadruplet at 2.28 
ppm marked with #, corresponds to the double allylic proton of 227. The integrals for these 
protons show that ether 217 is contaminated with 14% of 227 (Figure 11). 
 
Scheme 55. Proposed mechanism for the formation of the inseparable by product 227. 
 
The impurity persisted after several attempts when purifying 217 by column chromatography 
on silica. The synthesis was continued with this unidentified impurity.  
 
2.5.3 Preparation of 8nor-FDP (140) 
PPTS mediated deprotection of THP ether 217 afforded alcohol 216 in 68% yield. The 
diphosphorylation of alcohol 216 and purification by ion exchange column and reverse phase 
HPLC afforded diphosphate 140 as a white solid in 57% yield (Scheme 54). 
 
2.5.4 Preparation of a mixture of 8-nor-farnesenes: (E) E-8-nor--farnesene (228), (E)-
8-nor--farnesene (229), (Z)-8-nor--farnesene (230). 
The mixture of (E)-7,10-dimethyl-3-methyleneundeca-1,6,9-triene (228), (3E,6E)-3,7,10-
trimethylundeca-1,3,6,9-tetraene (229) and (3Z,6E)-3,7,10-trimethylundeca-1,3,6,9-tetraene 
(230) was prepared by dehydration with PPTS in dichloroethane (Scheme 56). The farnesene 
mixture was purified using a pipette charged with small amount of silica, and analysed by 
GC-MS (section 4.2.6, Figure 40).  
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Scheme 56. Preparation of 8nor-farnesene mixture. 
 
2.5.5 Conclusions 
8Nor-FDP was prepared through a new synthetic route that relies on the addition of dialkyl 
cuprate 220 to allylic bromide 221 as a key step. By using this methodology, the synthesis of 
this novel FDP analogue was achieved in 18% yield over 6 steps.  
  
2.6 Synthesis of 8OH-FDP (141) 
No report of the synthesis of FDP analogues containing a hydroxyl group has ever been 
published. A retrosynthesis designed to plan the synthesis of 8OH-FDP (141) with an 
addition of Grignard reagent as a key step is described here. 
Retrosynthetic analysis: Diphosphate 141 is prepared from the acetyl alcohol 231 that is 
disconnected on C8 to give synthones 232 and 233 that correspond to Grignard reagent 234 
and aldehyde 235 that is prepared through oxidation of  236 (Scheme 57). 
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Scheme 57. Retrosynthetic analysis of 8OH-FDP (141). 
 
Aldehyde 235 was prepared by selenium dioxide oxidation of commercially available geranyl 
acetate 236 and subsequent oxidation of the resulting alcohol 237 with PDC to afford 
aldehyde 235. The Grignard reagent 234 should be made from the commercially available 
bromide 131 by reaction with Mg. The diphosphorylation will be performed by selective 
tosylation of the primary alcohol via the usual diphosphorylation reaction to afford the 8OH-
FDP 141 (Scheme 58). 
 
Reagents and conditions: i) SeO2, t-BuOOH, salicylic acid, 0 ºC ii) PDC, molecular sieves 3Å, 0 ºC iii) TsCl, 
Py, RT iv) (Bu4N)3HP2O7, CH3CN, then DOWEX 40 W (NH4
+
 form) cation exchange. 
Scheme 58. Synthesis of 8OH-FDP (141). 
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2.6.1 Preparation of aldehyde 235 
As it has been explained above, the oxidation of geranyl acetate 236 with selenium dioxide 
was performed for ether 223 (Scheme 54) achieving 237 in 44% yield. Oxidation with PDC 
led initially to the required aldehyde in poor yield. This reaction yield was improved by the 
addition of molecular sieves (3 Å) to the reaction mixture, and further filtration of the 
reaction mixture through celite
®
, which notably facilitated the workup of this transformation. 
The aldehyde 235 was ultimately obtained in 67% yield. 
 
2.6.2 Preparation of the diol 238 
The addition of the Grignard reagent 234 to the aldehyde 235 was performed with a large 
excess of 234 to trigger simultaneous deprotection of the acetal group. The Grignard reagent 
was initially formed by reaction of magnesium tunings (previously activated in an oven at 
200 ºC) with the bromide 131 in freshly distilled diethyl ether, and the reaction was started by 
addition of a small crystal of I2. However, no reaction was observed, and only starting 
material was recovered from the reaction mixture. 
In a 2
nd
 attempt, the reaction was carried out according to the modified procedure of Barbier. 
This protocol is similar to Grignard’s procedure, but the major difference is that Barbier 
reaction is performed in one pot.
223, 224
 Under Barbier’s conditions, consumption of all 
starting material led to a new product with the expected TLC polarity. However, the 
1
H NMR 
spectrum of the product did not show the expected absorptions of the required product 238. 
Integration of the characteristic triplets at 5.32 and 5.24 ppm reveals that the new product 
contains only two double bonds. Two additional double doublets centred at 5.84 ppm and 
4.97 ppm were suggestive of the presence of a terminal double bond. The Barbier product 
was finally characterised as diol 240, which could be formed following the SN2’ like 
mechanism depicted in Scheme 59.   
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Scheme 59. Proposed reaction mechanism explaining formation of diol 240. 
 
A literature search revealed that the SN2’ like reaction described in Scheme 59 had been 
previously reported using similar Mg, Co or Zn based reagents with bromide 131.
225
 
Alternatively, alcohol 238 was obtained in low yield through the oxidation of farnesyl acetate 
194.
216
 Thus, oxidation of farnesyl acetate afforded a mixture of primary alcohol and 
secondary alcohol that could be separated by chromatography column. The reaction gave the 
secondary alcohol 241 in 13% yield. Hydrolysis of the acetate afforded the diol 238 in 87% 
yield (Scheme 60). 
 
Scheme 60. New synthetic route for the synthesis of 238. 
 
2.6.3 Preparation of 8OH-FDP (141) 
A p-toluenesulfonyl (tosyl) group was selected as the leaving group to carry out the 
diphosphorylation reaction given that it is expected that the tosyl chloride would selectively 
react with the primary alcohol group of diol 238 due to its bulk. After 24 hours, TLC analysis 
revealed a product that was not UV active. The compound was isolated by flash 
chromatography on silica gel and analysed by 
1
H NMR spectroscopy. The signal at H = 4.14 
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ppm corresponding to the CH2OH protons had slightly shifted to 4.15 ppm. Mass 
spectrometry identified the product as the allylic chloride 242. This chloride resulted from 
displacement of the initially formed tosylate (Scheme 61). The final diphosphate 8OH-FDP 
(141) was formed from 242 using the standard phosphorylation conditions, resulting in 
decomposition of the compound. Finally, diphosphate was prepared by Dr Juan A. Faraldos 
using a procedure described by Giner et al., which involves protection of the secondary 
alcohol with an acetate group and deprotection with NH3 (aq) after diphosphorilation.
226
  
 
Scheme 61. Preparation of 242. 
 
2.6.4 Conclusions 
The synthetic route initially proposed proved to be unsuitable for the preparation of 8OH-
FDP (141) due to the unexpected reactivity of the Grignard reagent 234. Alternative synthesis 
by means of an allylic oxidation of farnesyl acetate (194) is a low yield, but direct route to 
prepare diol 238. Selective phosphorylation of diol 238 was difficult and a tedious sequence 
of protection/deprotection was required to prepare 8OH-FDP (141, Scheme 62).
226 
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Reagents and conditions: i) SeO2, t-BuOOH, salicylic acid, 0 ºC ii) Ac2O, py, RT iii) MeOH, PPTS, RT iv) S-
collidine, MsCl, LiBr, DMF  0 ºC v) (Bu4N)3HP2O7, CH3CN, then DOWEX 40 W (NH4
+
 form) cation exchange 
vi) NH3 (aq)                                                                                                                                                                                                                                             
Scheme 62. Preparation of 8OH-FDP (141). 
 
2.7 Synthesis of 14OH-FDP (142) 
Literature review revealed that the 14OH-FDP has never been synthesised before. However, 
Tago has reported the synthesis of plaunotol (248),
227
 which is the homologous C20 hydroxy 
derivative of geranylgeranyl diphosphate. The proposed synthesis was performed by means 
of Wittig olefination between the phosphonium 247 and ketone 246 (Scheme 63).  Plaunotol 
has been reported to have an antibiotic activity against Helicobacter pylori, which is the 
bacterium responsible for gastritis,
228
 gastric ulcers
229
 and duodenal ulcers.
230
 In addition, H. 
pylori has been classified by the World Health Organisation as a potential cancer-causing 
agent.
231
 
 
Scheme 63. Key step of the synthesis developed by Tago. R = Et, Cy or Pr
i
, R’ = Me. 
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It was therefore decided to prepare compound 142 via an analogous Wittig olefination 
reaction with ketone 250, which was to be prepared by Rubottom oxidation of 267 (Scheme 
64). Phosphonium salt 251 was to be prepared as described by Tago, via degradation of THP-
protected geraniol.
227 
 
Scheme 64. Retrosynthetic analysis of 14OH-FDP (142). 
 
2.7.1 Preparation of phosphonium salt 251 
The synthesis of the phosphonium salt 251 was made by degradation of THP protected 
geraniol 223 (Scheme 66). Correct selection of the protecting group in this case was crucial 
given that the conditions for deprotection should not cleave acetate group to allow the final 
diphosphorylation reaction. Whereas THP is removed under acidic conditions, acetate needs 
basic conditions, Therefore, THP should be a compatible group for the conditions used in this 
synthesis. Chemoselective oxidation of the distal double of THP ether 223 afforded the 
epoxide 252 in 69% yield. Although the 
13
C NMR spectrum of 252 could not be interpreted 
due to the high level of complexity of the spectrum, the product was characterised by 
1
H 
NMR spectroscopy and mass spectrometry. This complexity can be explained by the 
formation of diastereoisomers due to the following circumstances: 1) the presence of the 
chiral and racemic THP protecting group, and 2) the resulting mixture of isomers upon 
epoxidation that produce a mixture of two pairs of enantiomers (252a / 252b and 2.55c / 
252d) and two pairs of diastereoisomers (252b / 252d and 252a / 252c) (Scheme 65).  
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Scheme 65. Different stereoisomers obtained from epoxidation of 223. 
 
Cleavage of the epoxide 252 with a mixture of H5IO6 / NaIO4 afforded aldehyde 253 in 
moderate yield (28%). Subsequent sodium borohydride reduction of 253 afforded the 
corresponding alcohol 254 in 83% yield. Iodide 255 was prepared from alcohol 254 by 
tosylation of the alcohol and displacement of this leaving group with NaI. Phosphonium salt 
251 was obtained as a white solid in 67% yield by refluxing iodide 255 and PPh3 in freshly 
distilled diethyl ether for 48 h (Scheme 66). 
 
Reagents and conditions: i) mCPBA, DCM 0 ºC ii) H5IO6 / NaIO4, H2O/THF 0 ºC iii) NaBH4 EtOH 0 ºC iv) 
TsCl, Py, DCM and then NaI in anhydrous acetone v)  PPh3, Et2O. 
Scheme 66. Synthetic route for the preparation of the phosphonium salt 251. 
 
2.7.2  Preparation of ketone 250 
The key step in the formation of acetyl -hydroxy ketone 250 via silyl enol ether 257 relies 
on its successful Rubottom oxidation (Scheme 67).
232
 Ketone 256 was treated with LDA in 
THF at -78 ºC and subsequently with TMSCl to afford 257 in 90% yield. Silyl enol ether 257 
proved to be stable upon storage in the fridge for months under anhydrous conditions. 
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Scheme 67. Synthetic route to the ketone 250. 
 
The epoxidation of enol ethers with peroxy acids (Rubottom oxidation) results in -hydroxy 
ketones after the epoxide ring opening. The reaction starts with the attack of the peroxy acid 
to the enol 259 to afford a highly unstable epoxide 260. Epoxide ring opening is then affected 
by the surrounding acid to afford initially a carbocation 262, which is quenched by additional 
acid to afford ester 263. Attack of the hydroxyl group to the ester releases the silyl ether to 
generate hydroxyl carbonate 264, which is subsequently hydrolysed to the final -hydroxy 
ketone 265 (Scheme 68). Although a selective Rubottom oxidation at low temperatures has 
been used successfully in an alternative synthesis of plaunotol as described by Kikumasa,
233
 
no procedure for the key oxidation was reported.   
 
Scheme 68. Mechanism for the Rubottom oxidation.
234
  
 
The Rubottom oxidation of enol ether 257 was carried out by adding dropwise a solution of 
mCPBA to a solution of 257, both in DCM, and stirring for 3 h at -78 ºC. Acid hydrolysis 
with aqueous HCl followed by basic hydrolysis with KCO3 While this procedure afforded the 
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desired product 258 only in small traces, large amounts of ketone 256 were recovered 
(Scheme 67). 
TLC analysis on silica using previously deactivated plates (by dipping the plate in 10% Et3N 
solution in ether and allowed to dry)  indicates that the reaction mixture after 3 h at -78 ºC 
contains a large amount of silyl enol ether 257 and ketone 256. The initial hydrolysis of the 
starting material can be explained by the presence of benzoic acid in the commercial mCPBA 
used. Thus, the mCPBA was purified by washing an ethereal solution of mCPBA with an 
aqueous phosphate buffer at pH = 7.5.
235
 Reaction of silyl enol ether 257 with the freshly 
purified mCPBA, followed by acid / basic hydrolysis afforded the expected hydroxy ketone 
258 in 4% yield. Intriguingly, TLC monitoring of the reaction did not show any evidences of 
ketone 256 and large amount of the starting material enol ether 257 was recovered after work 
up.  
In a further attempt at this reaction, both temperature and reaction time were increased (-45 
ºC for 4 h). Under these conditions, a hydroxy ketone 258 was obtained in 29% yield. All 
attempts to scale up this reaction resulted in complex mixtures of products, from which the 
required product could not be isolated by purification.  
During the synthesis of 2S-hydroxymutilin, Wang et al. developed a modification of the 
original Rubottom procedure to allow selective oxidation (mCPBA) of silyl enol ethers in the 
presence of additional (terminal) double bonds under buffered (pyridine/acetic acid) 
conditions at -20 ºC.
236
 Following these conditions (-20 or -45 ºC), similar untreatable 
mixtures of products were again observed upon hydrolysis. The consistently low yields and 
poor reproducibility of the Rubottom oxidation of 257 prevented a successful synthesis of 
250 following this seemingly successful protocol in previous cases. 
  
2.7.3 Preparation of ketone 269 
As an alternative, - keto acetal 269 was then prepared as depicted in Scheme 69 to attempt a 
novel synthesis of 14OH-FDP (142) following the same olefination strategy previously 
described (see Scheme 64).  
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Reagents and conditions: i) CuI, MeMgBr, THF, 0 ºC and then 266, -78 ºC ii) 4Å MS, cyclohexylamine, DCM, 
RT. 
Scheme 69. Synthesis of 269. 
 
The first attempts to prepare 267 via direct addition of one equivalent of MeMgBr were 
unsuccessful, resulting in the formation of the corresponding alcohol (41% yield) from 
double addition of methyl magnesium bromide to ester 266. The literature search revealed 
that most of the reported Grignard additions to ethyl esters resulting in alkyl ketone formation 
have been made by reaction of the corresponding chlorinated Grignard reagent.
237
 
Alternatively, R2CuLi reagent can also been successfully employed.
238
 The reaction of 
compound 266 at -78 ºC in THF with Me2CuLi gave ketone 267 in 62% yield. The 
subsequent formation of the enamine 268 was performed by direct reaction of 
cyclohexylamine in the presence of molecular sieves 4 Å affording the target compound in 
98% yield. 
The treatment of enamine 268 with LDA at 0 ºC followed by the addition of bromide 131 did 
not afford the expected ketone 269. The 
1
H NMR spectrum of the major product isolated 
from crude reaction displays two singlets at 4.67 and 4.27 ppm, accounting for one proton 
each. These two signals correspond to two different tertiary carbons of two different acetals. 
The spectrum also displays two doublets at 3.04 and 2.58 ppm, which integrate for one proton 
each. The chemical shift of these signals and multiplicity (AB system) suggest that they 
belong to two diastereotopic CH2 protons located in the proximity of two quaternary centres, 
one being chiral/prochiral. Multiplets centred at 3.77 and 3.62 ppm integrating for 2 and 6 
correspond to the ethyl group of two acetals. Additionally, the multiplet centred at 1.21 ppm 
integrates for 15 protons, which correspond to four methyl groups of the acetals and one 
additional methyl group (Figure 12). 
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Figure 12. 
1
H NMR spectrum of product obtained from the treatment of compound 271 with 
LDA. 
 
Based on this data, it can be concluded that a dimer of 267 is formed by condensation of 270 
giving 271 (Scheme 70). 
 
Scheme 70. Mechanism of aldol reaction of 267.  
 
A new synthetic approach was proposed for the synthesis of ketone 269. -Keto ester 272 
was prepared by Claisen condensation between ester 266 with ethyl acetate.
239
 After solvent 
removal (4 h) by high vacuum, the sample was relatively clean as judged by 
1
H NMR 
spectrum. However, attempts to further purify the crude product by chromatography on silica 
resulted in the loss of the acetal group. Therefore, the compound was used without further 
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purification. The crude weight accounts for 81% yield. Compound 273 was produced by 
deprotonation of -keto ester 272 and alkylation with bromide 131. The 1H NMR spectrum of 
the crude displays the expected signals for compound 273 and hence, it was used in the next 
step without further purification expecting that the by-products could be removed by simple 
evaporation. After base catalysed decarboxylation of 273, careful neutralisation of the basic 
reaction media, extraction of the product and removal of the solvent and volatile impurities 
under high vacuum afforded 269 in 30% yield over two steps (Scheme 71).     
Reagents and conditions: i) NaH, EtOAc, THF, reflux ii) NaH, 131, THF 0 ºC iii) NaOH, H2O, EtOH, reflux.  
Scheme 71. Successful synthetic route to acetal 269.  
 
2.7.4 Wittig olefination 
Scheme 72. Wittig reaction. 
 
The addition of 269 to a solution of the ylide of 251, which is prepared using n-BuLi at -78 
ºC for 30 minutes, and subsequent stirring (5 h) at -45 ºC (Scheme 72), afforded aldehyde 
276 (Scheme 74) as a mixture of isomers instead of the expected acetal 274. This was 
indicated by signals at 10.09 and 9.35 ppm in 
1
H NMR spectrum. The spectrum displayed 
two signals at 10.09 and 9.35 ppm indicating the formation of a 1:3 isomeric mixture of 
aldehydes, which were reduced to alcohols 277 with NaBH4 (Scheme 74). NOE experiments 
were performed to identify each isomer. The 
1
H NMR spectrum of alcohol 277 displays two 
singles at 4.62 and 4.52 ppm, corresponding to the protons on C14 for each isomer. Analysis 
of the integrals indicated approximately the same isomeric distribution as in the aldehyde 
precursors 276, 1:3 respectively. Whereas the irradiation of signal at 4.62 ppm (minor 
isomer) results in no appreciable NOE enhancements, the irradiation of signal at 4.52 ppm 
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(major isomer) led to 1% NOE enhancement of the triplet (5.47 ppm), corresponding to the 
proton on C6. Unfortunately, this observation identified the major isomer as E isomer 275 
(Scheme 73). 
 
Scheme 73. NOE effect was used to identify the major isomer of 275 as E-configured. 
 
The reaction of ketone 269 with phosphonium salt 251 was expected to afford the cis isomer 
given that a similar reaction with an analogue of ketone 246 containing one more isoprene 
unit tested by Tago et al. has proven to give a selectivity (Z : E) between 4:1 and 61:1 
depending on the conditions.
227 
 
Wittig reaction was carried out and proportion of Z isomer was increased by stirring the 
crude product in a mixture of THF/acetic acid (3:2) affording 276 as mixture of isomers Z/E 
(6:4) in 30% yield after chromatography column on silica (Scheme 74). 
 
Reagents and conditions: i) NaBH4, EtOH 0 ºC ii) Py, acetic anhydride, DCM, RT iii) PPTS, MeOH, RT.  
Scheme 74. Preparation of alcohol 249. 
 
Aldehyde 276 was reduced to alcohol 277 by reaction with NaBH4. The two isomers of the 
alcohol 277 were separated by vacuum chromatography on silica,
240
 and the desired trans-
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isomer was isolated as pure isomer in 36% yield. The acetate protection of alcohol 277 was 
achieved in 71% yield. THP deprotection of 278 yielded acetate 249 in 68%. 
The quantities generated by this approach were not enough to carry out the planned 
diphosphorylation/deacetylation sequence needed for enzymatic evaluation. The extremely 
low yield (˂1%), clearly discounted this approach for the preparation of 14OH-FDP (142).  
 
2.7.5 Conclusions 
As previously described by Tago,
227 
phosphonium salt 251 was prepared instead by the 
synthesis of ketone 250, through a Rubottom oxidation that seemed to be an inefficient 
method due to its poor reproducibility. In addition, the reaction suffered from low yield when 
scaling up was performed. Alternatively, keton 269 was prepared through a sequence of 
Claisen oxidation and decarboxylation. Wittig reaction between ketone 269 and salt 251 has 
poor selectivity, thus Z isomer was obtained in low yield. As a result, the overall yield was 
low. Therefore, this methodology is discounted to accomplish the synthesis of diphosphate 
142.  
Perhaps in the current case, the modification of the Wittig olefination used by Corey
213
 could 
significantly reduce the number of steps leading to the desired alcohol (Scheme 75). 
Unfortunately, this new proposal was not tested due to time restrictions. 
 
Scheme 75. New proposed synthesis for the preparation of 14OH-FDP (142). 
 
2.8 Overall conclusions  
The methodology developed by Rawat et al.
199
 for the synthesis of alkyl modified FDP 
analogues was optimised and applied to the synthesis of 14Me-FDP (137), 15Me-FDP (138) 
and 14,15Me-FDP (139). Whereas 14Me-FDP (137) was obtained in 6% yield over twelve 
steps, previously reported synthesis of 14Me-FDP (137) was achieved in 5% yield.
199
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Whereas 15Me-FDP (138) was prepared in six steps in 8% yield, previously reported 
synthesis by Montellano et al. afforded 15Me-FDP (138) in less than 2% yield.
209
 Therefore, 
these two examples show the improvement achieved by the method reported herein. 
14,15Me-FDP (139) was synthesised for the first time using this method in 5% yield. 
A new methodology for the preparation of FDP analogues by the addition of dialkyl cuprate 
to an electrophile was developed and applied to the synthesis of 12Me-FDP (136) and 8Nor-
FDP (140). 12Me-FDP (136) was synthesised for the first time in 3% yield. Whereas 8nor-
FDP (140) was previously synthesised by Rawat et al. in 13%,
218
 the methodology presented 
herein achieved 8Nor-FDP (140) in 18% yield. However, this method is limited by the 
formation of by-products, which difficults the purification of the final product.    
The synthesis of a new 8OH-FDP (141) was performed through an allylic oxidation of 
farnesyl acetate. Dihydroxy farnesol 238 was achieved in low yield. The initial plan for 
selective phosphorylation of 238 was discarded due to the decomposition of chlorine 242 
under phosphorilation conditions. Tedious sequence of protection/deprotection was designed 
to prepare 8OH-FDP (141, Scheme 62).
  
The synthesis of 14OH-FDP (142) was performed by means of Wittig olefination. As 
previously described by Tago,
227 
phosphonium salt 251 and keton 269 were prepared through 
a sequence of Claisen oxidation and decarboxylation. Wittig reaction between ketone 269 and 
salt 251 afforded aldehyde 276 in poor yield and selectivity. Alcohol 249 was achieved in 
poor overall yield and therefore this methodology was discounted to accomplish the synthesis 
of diphosphate 14OH-FDP (142). 
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  CHAPTER 3 
Innovative methodologies for the enzymatic 
production of valuable semiochemicals 
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3. Introduction 
The study of the procedures reported in the literature reveals a great variation in experimental 
conditions and in the reported yields and/or conversions of incubations with terpene 
synthases. These variations explain the poor reproducibility of enzymatic yields and problems 
encountered in obtaining terpenes in sufficient quantity to be fully characterised.
241
  
The reactions of terpene synthases with their substrates are usually performed in aqueous 
solutions that contain substrate, enzyme, MgCl2 and buffer. This mixture is overlaid with an 
organic solvent to extract terpenes from the aqueous media. In a typical incubation procedure, 
this biphasic mixture is incubated for 24 h and then vortexed to extract organic compounds 
from the aqueous media to the organic solvent. The organic solvent is analysed after phase 
separation (Figure 13).   
 
Figure 13. Standard set-up for incubations with sesquiterpene synthases. 
 
In this chapter, efforts aimed at the development of a rationally optimised procedure for the in 
vitro production of valuable sesquiterpenes by optimising reaction conditions and minimising 
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the product losses of volatile products upon workup are described. Toward this end, a set of 
experiments to determine the optimal concentration of Mg
2+
, substrate and enzyme with the 
four sesquiterpene synthases (DCS, AS, GDS and GAS) used in this project were performed. 
In addition, different extraction methods, organic solvents and work-up procedures were 
tested to simplify the current, and often-inefficient work-up steps during the sesquiterpene 
synthase mediated reactions. Additionally, flow chemistry methodology to improve the 
performance of sesquiterpene synthases was explored.   
 
3.1 Optimal magnesium concentration  
3.1.1 --Cadinene synthase (DCS) from Gossypium arboreum  
The optimal Mg
2+
 concentration for DCS was determined by measuring the enzymatic 
conversions using a GC-FID apparatus and -humulene as internal standard. The GC-FID 
methodology was later validated by comparison with the well-established radiochemical-
assay employed for GAS and GDS. 
Incubations of DCS and FDP (Chapter 1, Scheme 21) in buffer (25 mM HEPES, 5 mM DTT, 
12 µM DCS, pH 7.5) with concentration of MgCl2 ranging from 3 to 12 mM were performed 
in a final volume of 500 µL. Preparations were overlaid with 1 mL pentane containing the 
internal standard -humulene (35 μM). The mixture was incubated for 30 minutes. 
Hydrocarbons were extracted by 30 s vortex and organic extracts were analysed by GC-FID. 
The optimal concentration of MgCl2 was 6 mM as judged by the decreasing conversion 
observed at higher concentration, as shown in Figure 14. 
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Figure 14. Plot of conversion of FDP against Mg
2+
 for DCS displays decreasing conversion 
at concentrations higher than 6 mM. 
 
The optimal concentration obtained by GC-FID assay was compared with the value obtained 
by radio-assay with [1-
3
H]-FDP, which was performed as described above for aristolochene 
synthase.
242
 Assays (final volume 250 µL) were initiated by addition of an enzyme solution 
(50 μM, 25 µL) to 100 μM [1-3H]-FDP (240000 dpm/nmol) in buffer (25 mM HEPES, 5 mM 
DTT, pH 7.5) with a concentration of MgCl2 ranging from 1 to 9 mM. After incubation for 12 
min, reactions were stopped by addition of 100 mM EDTA and overlaid with pentane (1 mL). 
Once the samples had been vortexed for 10 s, the pentane was removed and the sample 
extracted with pentane in the same way (2 x 1 mL). The pooled pentane extracts were filtered 
through approximately 50 mg of silica, then emulsified with Ecoscint O (15 mL) and finally 
analysed by scintillation counting. The optimal concentration of MgCl2, as shown in Figure 
15, was 6 mM. This value is in agreement with the value obtained with GC-FID assay, which 
means that both methods were considered suitable for optimising sesquiterpene synthase 
incubations for product conversion. 
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Figure 15. Experiment under kinetic conditions using 
3
H-FDP. CPMA: counts per minute to 
detemine optimal Mg
2+
 with DCS. 
 
3.1.2 Aristolochene synthase from Penicillium roqueforti (AS) 
The incubations of AS and FDP (Chapter 1, Scheme 13) in buffer (20 mM Tris, 5 mM 2-
mercaptoethanol, 15% glycerol, 12 µM AS, pH 7.5) with concentration of MgCl2 ranging 
from 3 to 12 mM were performed as described above for DCS (vide supra). The conversion 
was measured by GC-FID analysis. As shown in Figure 16, optimal concentration was 3 mM. 
This value is in agreement with the data published by Hohn.
176 
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Figure 16. Study performed by GC-FID to determine optimal Mg
2+
 concentration with AS. 
 
3.1.3 (-)-Germacrene D and (+)-germacrene A synthases from Solidago canadensis 
(GDS and GAS, respectively)  
By using radio-labelled FDP, the optimal metal requirements of GAS (Chapter 1, Scheme 9) 
and GDS (Chapter 1, Scheme 16) were estimated previously as 3 mM and 10 mM, 
respectively.
243
  
 
3.2 Optimal substrate concentration 
At concentration above ≈ 0.5 mM of FDP, a white precipitate was observed immediately after 
dissolving FDP in a buffer containing Mg
2+
 at 10 mM. The precipitate was only poorly 
soluble in protic (MeOH/CHCl3) or aprotic polar solvent, such as DMSO, thus hampering the 
full characterisation by NMR spectroscopy. The low solubility, HRMS/LRMS (m/z = 505) 
and 
31
P NMR spectroscopy (δP 3 ppm in CDCl3) data were, however, in agreement with the 
values previously reported for difarnesyl phosphate (282, Scheme 76).
 244
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Scheme 76. Proposed mechanism for the Mg
2+
 triggered conversion of FDP (17) into 282. 
 
In order to estimate the concentration of FDP just below the critical concentration for 
formation of 282, different buffer solutions ([Mg
2+
] = 10 mM) containing FDP in the 
concentration range (0.1 to 0.5 mM) were prepared. Then, the precipitate was removed by 
filtration. The samples were analysed by reverse phase HPLC (same conditions as specified 
in section 6.3.4 for purification of 137) and the area of the peak of remaining and soluble 
FDP was plotted against the initial concentration of FDP (Figure 17).   
 
Figure 17. [FDP]
initial
 vs Area of the peak in the HPLC corresponding to remaining soluble 
FDP.  
 
The HPLC peak area corresponding to FDP represents the amount of FDP that did not 
undergo conversion into 282 (i.e. [FDP]final) and remains in solution. As shown in Figure 17, 
a [FDP]intial plateau is reached at ca. FDP = 0.4 mM, which corresponds  to the maximum  
FDP concentration before the beginning of the conversion into 282 and is the highest 
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concentration that it is possible to reach in buffer solution and, therefore, the maximum 
concentration available for enzymatic reaction.  
The reaction outlined in Scheme 76 only occurs at a concentration above 0.4 mM. A possible 
explanation for this observation will be the formation of micelles at this concentration. FDP 
has a polar head and a hydrophobic tail, which makes this compound a surfactant. Surfactants 
group themselves in aqueous solution into micelles putting together all the polar head and 
tails. The formation of micelles occurs above a critical surfactant concentration called critical 
micelle concentration (CMC).
245
 This disposition can trigger the conversion of FDP into 282 
by increasing the proximity of polar heads in the micelle.   
 
3.3 Optimal enzyme concentration 
3.3.1 (-)-Germacrene D synthase 
A series of analytical incubations (24 h) were performed with GDS in concentrations ranging 
from 4 to 12  at fixed optimal concentrations of FDP (0.35 mM) and Mg2+ (10 mM) 
(section 3.2 and 3.1.3, respectively). Conversion was measured by GC-FID by comparison of 
the peak areas of the pentane extractable products and -humulene (35 μM) that was used as 
an internal standard. Figure 18 shows that the conversion of the reaction starts to decline at 6 
μM enzyme concentration. Higher concentrations most likely lead to enzyme aggregation, 
which explains the decrease in enzymatic activity. The highest conversion under these 
conditions was 43%.  
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Figure 18. Conversion of FDP with varying GDS concentrations. 
 
The enzymatic aggregation process can be partially prevented by addition of a detergent to 
the buffer that can avoid interactions between enzyme units. The four following detergents: 
CHAPS, TRITON X100, TWEEN 20, TWEEN 80, all at 1%, were tested in buffers 
containing a fixed concentration of enzyme (12 μM) (Table 3, entries 2-5) in 24-hours 
incubation. In all cases, a substantial improvement in the enzymatic conversion was 
observed. 
Entry Detergent Conversion % 
1 - 43 
2 TRITON X100 (285) 94 
3 TWEEN 20 (283) 92 
4 TWEEN 80 (284) 85 
5 CHAPS (286) 76 
 
Table 3. Conversions with GDS when detergent is added to the incubation buffer. 
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Although for synthetic purposes the best conversion was obtained with Triton X100 (Table 3, 
entry 2, 285 Scheme 77), due to the insolubility of the amphoteric detergent CHAPS (Scheme 
77, 286) in organic solvents, such as CDCl3 or C6D6 (Table 3, entry 5), this detergent was 
preferred for characterisation purposes over the others because signals of the other detergents 
can be seen in the 
1
H NMR spectrum.  
 
Scheme 77. Structure of TEEWN 20 (283), TEEWN 80 (284), triton 100X (285), CHAPS 
(286). 
 
3.3.2 (+)--Cadinene synthase 
The same experiment was performed with increasing concentration of DCS ranging from 6 to 
18  at fixed optimal concentrations of FDP (0.35 mM) and Mg2+ (6 mM) (sections 3.2 and 
3.1.1 respectively). Here too, the slope of the curve obtained decreases at high concentration 
of the enzyme (Figure 19). The result suggests enzymatic aggregation; similarly to previous 
experiments, the conversion was increased by inclusion of 1% CHAPS (286) protein 
detergent to achieve 45% conversion at 12 of DCS, which is a 3-fold improvement over 
incubation carried out without detergent. 
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Figure 19. Conversion of FDP to -cadinene with varying DCS concentrations. 
 
3.3.3 (+)-Germacrene A and aristolochene synthases  
Following similar protocols, the optimal concentration of both GAS and AS was studied. 
Analytical incubations (24 h) were performed with enzyme concentration ranging from 6 to 
18  at fixed optimal concentrations of FDP (0.35 mM) and Mg2+ (3 mM) (Section 3.2, 
3.1.3 and 3.1.2) for both enzymes. In contrast to the previous experiments with GDS and 
DCS, the experiments with AS and GAS do not suggest that enzymatic aggregation occurs 
for these enzymes at high concentration judged by the absence of a plateau in the conversion 
vs enzyme concentration curves obtained (Figures 20 and 21). 
 
Figure 20. Conversion of FDP to aristolochene with varying AS concentrations. 
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Figure 21. Conversion of FDP to (+)-germacrene A with varying GAS concentration. 
 
Linear correlation between concentration of enzymes (GAS and AS) and conversion suggest 
that quantitative conversion can be achieved by increasing the enzyme concentration. 
However, a concentration higher than 18 in a large volume of buffer would require a 
large quantity of enzyme. Therefore, incubations (in mg scale) for enzymatic product 
characterisation purpose can be performed with 18 This enzyme concentration value is 
considered a good balance between enzyme economy and relatively high conversion. 
Not surprisingly, since GAS and AS do not aggregate at higher enzyme concentration no 
improvement in conversion was observed in the presence of 1% detergent (e.g. CHAPS).  
 
3.3.4 Conclusions 
Interestingly, enzymes that performed best at higher concentration of Mg
2+ 
(GDS and DCS 
10 mM and 6 mM respectively) aggregate at high concentration of enzyme and, therefore, 
benefit from inclusion of detergents, whereas enzymes that performed best at low 
concentration of Mg
2+
 (GAS and AS 3 mM), do not undergo aggregation and, therefore, do 
not benefit from inclusion of detergents. This observation suggests that Mg
2+ 
plays a role in 
the aggregation process possibly by chelating with amino acids present on the surface of the 
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different enzyme units acting as a nexus between them and, therefore, triggering aggregation. 
Detergents can avoid aggregation by surrounding enzyme molecules, thus preventing 
interaction between them. 
The reaction conditions for the enzymatic production of (+)-germacrene A and (-)-
germacrene D, -cadinene and aristolochene were optimised for Mg2+, enzyme and substrate 
concentrations. Under the optimised conditions, the sesquiterpenes were obtained in moderate 
to excellent 45-94% yields. In both cases (GDS and DCS), the enzymatic conversion can be 
enhanced (3-5-fold) by the addition of detergents (1%). Although for characterisation 
purposes CHAPS is the preferred detergent, from a synthetic point of view, 1% TRITON 
X100 allows near quantitative conversions (94% with GDS), and hence appears to be 
superior.  
 
3.4 Novel, improved methodologies for incubation of sesquiterpene 
synthases 
Methods for the enzymatic production of terpenes in sufficient amount to be characterised 
have been described previously.
246
 However, classic incubation procedures are often 
inefficient, and, in some cases, not even described in sufficient detail to allow reproduction. 
Furthermore, the overall yields are, in general low, and hence, of no apparent synthetic 
utility. Against this backdrop, and as part of this project, substantial efforts were dedicated to 
the design and development of a new protocol capable of maximising the conversion and 
isolated yields of the reactions catalysed by sesquiterpene synthases. At the design stage, one 
of the most important questions, which needed to be addressed, was whether conversions 
could be enhanced by minimising the amount of organic solvent used for product extraction. 
In this manner, the isolation of volatiles could be efficiently optimised by reducing the 
product losses encountered during the evaporation of the solvent. The new methodology was 
initially developed for semi-preparative scale (mg scale) preparations of (-)-germacrene D 
using optimised conditions [30 ºC, GDS (12 M), FDP (0.4 mM), Mg2+ (10 mM)] in biphasic 
systems with deuterated organic solvents, which allows the quick and easy identification of 
products by NMR spectroscopy. This methodology was further extended to other natural 
compounds, such as (+)-germacrene A and -cadinene, and their analogues using alternative 
FDP substrate surrogates. The optimisation of this new route to valuable terpenes included a 
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study of different reaction chambers and deuterated solvents. After some experimentation, it 
was found that the best vessel to carry out semi-prep incubations with GDS, was an ACE 
pressure tube. The longitudinal geometry of this reaction device minimised the contact 
between the organic and aqueous phases, thus avoiding denaturation of the biocatalyst at the 
interface. As a plus, incubations following this novel set-up also benefit from the pressure 
proof seal of the reaction vessel itself, which effectively minimised losses of volatile 
products. Furthermore, after some analytical trials, it became evident that d6-benzene (or d8-
toluene) was prohibited due to the formation of an enzyme precipitate on the interface. The 
best extracting solvent turned out to be CDCl3; extraction being performed using an 
automated rotor operating at 4 ºC for the continuous extraction of volatiles over a 12 h period. 
After extraction, the organic phase was separated using a Biotage phase separator, whereby 
the organic lower layer passed through the filter and the aqueous layer remained in the tube. 
The CDCl3 solution was directly collected and transferred into a standard NMR tube for the 
subsequent spectroscopic analysis of products.  
  
3.4.1 Semi-preparative enzymatic production of sesquiterpenes.  
The following general procedure highlights the suitability of the novel approach for the direct 
examination of products by NMR spectroscopy. Reactions were performed in sealed ACE 
tubes containing incubation buffer (15 mL), FDP (or analogue, 0.35 mM), CHAPS (150 mg, 
1% for GDS and DCS), enzyme (e.g. GDS 12 μM) and CDCl3 (2 mL, deactivated over basic 
alumina). Each incubation solution was gently agitated for 24 h at 30 ºC. Extraction of 
enzymatic products into the organic layer was best effected by rotation at 4 ºC for 12 h. After 
extraction, the aqueous layer (a milky suspension) and the organic layer were separated using 
a Biotage phase separator. The resulting CDCl3 solution was dried by filtration through a 
Pasteur pipette containing anhydrous Na2SO4. The pooled CDCl3 extracts were concentrated 
to ~ 0.4 mL under a gentle stream of nitrogen and analyzed by NMR methods.  
Four different modifications and improvements of the general procedure (A) were made to 
meet specific needs. In order to facilitate and speed up the phase separation step, in some 
cases, the addition of methanol was necessary to break emulsions formed in the extraction 
process. This emulsion, that contains a trapped product, remained in the phase separator 
along with aqueous phase (procedure B). The separation was best achieved by subjecting the 
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reaction vessel and contents to freeze/thawing cycles in liquid nitrogen. This process allowed 
a cleaner phase separation without the spectroscopic interference of the methanol (procedure 
C). The purification and structural identification of the enzymatic products was facilitated by 
excluding -mercaptoethanol (spectroscopic interference) from the aqueous reaction buffer 
and by filtering the CDCl3 extracts through basic alumina and dry Na2SO4 (procedure D).  
Figure 22 illustrates the progressive improvement (A to D) of the extractive procedure and 
increased purity of the enzymatic product in D. 
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Figure 22. 1H NMR spectra of the products arising from preparative incubation. The concentrations of GDS and FDP were fixed and enzymatic reaction was 
tested under different conditions. A) General procedure, B) addition of MeOH, C) Freeze/thawing cycles D) Freeze/thawing cycles without -
mercaptoethanol after filtration through basic alumina and Na2SO4. 
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In order to quantify the improvement observed with different protocols, each sample was 
taken to the same final volume by evaporation, as already described. The integration of the 
solvent signal and the clear signal at 5.78 ppm (normalised to 1) allowed comparison between 
procedures. As shown in Table 4, the solvent/product ratio was progressively enhanced by a 
simple modification of general method A (entry 1), reaching a substantial 10-fold increase in 
product extracted following D conditions (compare entries 1 and 4). 
Entry Procedure Integral of CHCl3 
at 7.26 ppm 
Integral of signal at 
5.78 ppm 
1 A 53.3 1 
2 B 10.9 1 
3 C 6.1 1 
4 D 5.3 1 
 
Table 4. Relative integrals for solvent peak obtained with each procedure. 
 
3.4.2 Conclusions 
Optimal FDP, enzyme and Mg
2+
 concentration values were used in this section to develop a 
protocol for the incubations of terpene synthases. Optimisation of this protocol was achieved 
by reducing product loss during evaporation and work-up (elimination of emulsions).  
Breaking the emulsion formed during work up was found to be of paramount importance for 
optimising product extraction from aqueous phase, as shown in Figure 22. In addition, 
reduction of product loss by evaporation was achieved by using ACE sealed tubes as reaction 
vessel and using deuterated solvent that allowed direct analysis by NMR spectroscopy, 
avoiding evaporation of large amount of solvents. All these improvements are combined in 
standard procedure D. Procedure D was successfully used for preparative scale preparation 
(and characterisation) of sesquiterpenes derivatives (see Chapter 4) obtained from the 
incubation of unnatural FDP analogues with sesquiterpene synthases, as described in Chapter 
2.  
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3.5  In vitro production of natural and unnatural sesquiterpenes by 
continuous extraction in flow 
In previous works, our group has demonstrated the synthetic utility of terpene enzymes in the 
production of -pinene/verbenone and (+)-germacrene A  and D analogues.247 However, the 
slow reactions rates characteristic of terpene synthases, together with the moderate yields 
obtained simply by scaling up the analytical incubation conditions, led to consideration of 
flow chemistry as a potentially attractive and alternative route to valuable terpenoids.  
The high current interest in continuous-flow processes performed in microfluidic systems
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is driven by their advantages over classical batch approaches. Miniaturisation of flow devices 
allows an enhanced mass and heat transfer owing to a very large surface-to-volume ratio. 
Apart from organic synthetic protocols, biocatalytic reactions have been facilitated by 
biphasic flow. Esterifications in ionic liquid/heptane mixtures,
249
 hydrolysis of esters in 
water/decane solvents
250
 and reductions of carbon–carbon double bonds251 or aldehydes252 are 
accelerated in biphasic flow systems because of the efficient product removal from the 
aqueous phase. Microwave- and ultrasound-facilitated biphasic reactions have already been 
reported.
253
  
Pre-steady-state kinetic studies of terpene synthases have revealed that the overall rate of 
terpene catalysed reactions is limited by product release to the aqueous media (i.e. mass 
transfer ratio between the non-aqueous enzymatic active site and the aqueous media-
buffer).
254
 The solubility of terpenes in water is remarkably low (10-30 mgL
-1
)
255
 and 
saturation of the aqueous buffer is expected to occur quickly, which further slows down the 
catalytic process. For fast removal of terpenes from aqueous media, flow reactors offers an 
increase the contact area between aqueous and organic phases by reducing the diffusion 
distance. This can lead to higher reaction rates by enhancement of mass transfer.
256
  
Based on this extractive advantage of flow chemistry, efforts were made to accelerate the 
naturally slow catalytic cycle of terpene synthases by quick removal of their water-insoluble 
terpene products; a continuous extraction protocol was devised. The method was initially 
developed for native terpenes, but easily adapted to generate non-natural sesquiterpenoids.  
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3.5.1 Flow reactor design 
The flow reactor was designed with a T-shape inlet, as depicted in Figure 23, to ensure 
segmented flow. This kind of flow is characterised by a series of regular segments of 
different phases. Each segment is vortexed by its interaction with the wall of the tube causing 
a continuous refresh of the interface; this convective effect is called the Taylor flow.
257
 
Segmented flow has proved to increase the efficiency of the mass transfer between two 
different phases and, consequently, the yield of the process.
258
 
 
Figure 23. T-shape inlet to create a segmented flow. 
 
In initial trials, solutions of substrate FDP, GDS, and pentane (with internal standard for 
measuring conversion by CG-FID, see section 3.1) were individually injected into the flow 
reactor (Figure 24). Alternatively, flow reactor using solutions of premixed enzyme-substrate 
and pentane were also tested (Figure 25). Under these conditions, both experiments displayed 
an identical conversion value. These results indicated that in the set-up outlined in Figure 25 
the enzyme is reversibly inhibited before contact with organic solvent by saturation of the 
aqueous solution with the product. Therefore, the reaction rate could be controlled by product 
extraction in the presence of an organic solvent. In addition, the initial reaction before contact 
with organic solvent is negligible in comparison with the overall reaction. These inferences 
were further corroborated by the identical conversion value obtained from a continuous 
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quenching experiment using EDTA in the collector chamber (Figure 25). This experiment 
indicates that the batch (slow reaction happening in the collector) contribution to the total 
conversion is negligible, and hence illustrates the extraction advantages and reaction rate 
enhancements of the design. The apparatus depicted in Figure 25 was used for all subsequent 
experiments at fixed substrate concentration of 0.35 mM using pentane as the organic solvent 
for extraction. 
 
Figure 24. Flow reactor set-up with separate addition of enzyme and FDP. 
 
 
Figure 25. Flow reactor set-up with premixing of the FDP and enzyme. 
 
3.5.2 Preliminary studies of GDS in a flow reactor 
The first set of reactions was performed at constant GDS concentration of 9 µM and 30 min 
residence time (see Table 7 for conditions vide infra). The first experiment using a flow 
reactor with a small internal diameter (0.175 mm) generated a white precipitate upon mixing, 
suggesting enzyme inactivation by aggregation or denaturation of the protein (Table 5, entry 
1). This observation indicated that the vortex generated inside the reactor was too intense, and 
112 
 
milder conditions must be use to avoid enzyme inactivation. Thus, the experiment was 
repeated with a 0.45 mm internal reactor diameter and this proceeded without precipitation, 
achieving 17% conversion (Table 5, entry 2).  
It has been demonstrated that a combination of a flow reactor with ultrasound is a powerful 
combination to increase mass transfer in a biphasic system. This improvement arises from the 
cavitation collapse of bubbles in a sonicated liquid. The bubbles formed in the interface of the 
biphasic mixture increase the contact area between phases.
259
 For instance, Jolhe et al. 
reported a dramatical reduction in the reaction time (less than ten minutes compared to batch 
reactor) for the preparation of peracetic acid in an ultrasound irradiated flow reactor, 
compared to analogous reaction in batch.
260
 Hence, for further improving the mass transfer 
between the organic and aqueous phase, the tube of the reactor was immersed in a sonication 
bath. Bubbles were observed inside the tube, which confirms that cavitation is occurring 
inside the tube. Consequently, the conversion of the reaction increased to 48% (Table 5, entry 
3). A control experiment in batch under the same reaction conditions (temperature, time, 
reaction volume, organic solvent, etc) led to conversions of about 24% (Table 5, entry 4). The 
control experiment show that the conversion of incubations can be increased a 100% by 
performing the experiment in a flow reactor under sonication. 
Entry Internal reactor 
diameter [mm] 
Sonication Conversion [%] 
1 0.175 NO <1 
2 0.45 NO 17 
3 0.45 YES 48 
4 Batch 
(Control) 
YES 24 
 
Table 5. GDS ([GDS] = 9 µM) preliminary studies with different internal reactor diameters 
(0.175 and 0.45 mm) with and without sonication for comparison of conversion in batch and 
in a flow reactor. 
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3.5.3 Test of enzymatic aggregation in flow 
Experiments in batch have demonstrated that enzyme aggregation severely impairs the 
conversion rate when enzyme concentration was increased (see Sections 3.3.1 and 3.3.2). In 
order to investigate enzymatic aggregation in flow reactors and see if this problem can be 
overcome by the use of a flow reactor, three different concentrations of GDS (6, 9 and 12 
mM) were tested in flow with optimised conditions (0.45 internal reactor diameter, under 
sonication). Enzymatic aggregation is best evidenced by the non-linear increase in conversion 
values upon progressive enzyme concentration increments (Table 6, entries 1, 2 and 3).  
Entry [GDS] µM Conversion [%] 
1 6 27 
2 9 48 
3 12 52 
 
Table 6. Conversion vs GDS concentration studies in flow (0.45 mm internal reactor 
diameter with sonication). 
 
Previous experiments have demonstrated that enzymatic aggregation can be overcome by 
adding detergent to the incubation buffer. Additionally, Jensen et al. demonstrate that the 
formation of emulsions derived from the addition of detergents in a flow reactor can increase 
the contact surface between phases with a consequent increase in the conversion.
261
 This 
possibility was explored by inclusion of 1% CHAPS in the buffer to prevent aggregation but, 
unfortunately, this experiment led to the blockage of the reactor due to the formation of 
emulsions, thus demonstrating that this detergent is incompatible with the design and the 
enzymatic aggregation can not be overcome with this method. 
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3.5.4 Reaction time optimisation 
The optimal reaction time in the flow reactor under sonication conditions was also evaluated 
by decreasing the flow rate while keeping both the enzyme concentration (9 µM) and the 
internal reactor diameter (0.45 mm) constant. Surprisingly, increasing the reaction time up to 
1 h led to a substantial (ca 5-fold) decrease in conversion. More puzzling, a control 
experiment in batch (1 h) led to a modest 1.6-fold increase in conversion. The decrease in the 
turbulences generated inside the tube resulting from the decrease in the flow rate worsened 
the extraction of the product, thus explaining the greatly diminished conversion of the 1 h 
run. 
 
3.5.5 Internal reactor diameter optimisation 
Convective forces inside the flow reactor can be modulated by changing the internal reactor 
diameter while retention time is kept constant by adjusting the flow rate and tube length. A 
smaller internal reactor diameter increases the interactions of the fluid with the wall, thus 
increasing the mixing between organic and aqueous phase. On the other hand, bigger internal 
reactor diameters decrease the vortex effect generating milder mixing conditions.
262
 This 
effect was tested by Claus et al. in the multiphase hydrogenation of , -unsaturated 
aldehydes. In this experiment, the catalyst was dissolved in aqueous solution and the 
aldehyde was dissolved in organic solvent. The biphasic mixture was then treated with 
hydrogen gas to carry on the hydrogenation. Using these conditions, Claus et al. found that a 
change from 1000 m to 500 m internal reactor diameter had a dramatic effect, increasing 
the reaction rate over 260%.
263
 Bearing in mind this previous example of optimisation, a 
second set of reactions was performed to optimise the diameter of the tube used in the flow 
reactor.  The internal reactor diameter was changed while the tube length and the flow rate 
were adjusted to 30 min reaction time, as shown in Table 7.  
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Internal reactor 
diameter [mm] 
Length 
[m] 
Flow reactor 
volume [mL] 
Flow rate 
[µLmin
–1
] 
Residence time 
[min] 
0.175 5 0.12 4 30 
0.45 5 0.8 26 30 
0.8 4 2 66 30 
1.6 1 2 66 30 
 
Table 7. Different flow rates used with different internal reactor diameters to obtain a 30 min 
residence time. 
 
Initial experiment with a 0.175 mm diameter was repeated using optimised conditions 
([GDS] = 12 µM, sonication), resulting in a 12% conversion (Table 8, entry 1). As expected, 
the increase in diameter of 0.45 mm led to a larger conversion (51%) (Table 8, entry 2). 
However, a further increase of the diameter (0.8 mm) did not result in a further increase in 
conversion (47%) (Table 8, entry 3). Moreover, an increase of the diameter to 1.6 mm 
resulted in a less efficient extraction and only a modest conversion of 22% (Table 8, entry 4) 
was observed. This demonstrate that internal reactor diameter bigger than 0.8 mm create too 
mild vortex mixing thus decrease in conversion is observed. 
Entry Internal reactor diameter 
[mm] 
Conversion [%] 
1 0.175 12 
2 0.45 51 
3 0.8 47 
4 1.6 22 
 
Table 8. Optimisation of the internal reactor diameter. This set of experiments were 
performed at [GDS] = 12 µM under sonication. 
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3.5.6 Conclusion 
Incubations of GDS in a flow reactor were best performed in a internal reactor diameter of 
0.45 mm under sonication at an enzyme concentration of 12 µM for 30 min reaction time. 
Under these conditions, a control experiment in batch revealed that incubations in the flow 
reactor doubled the conversion achieved. Enzyme aggregation was observed upon increasing 
enzyme concentration. In contrast with previous experiments in batch, this problem could not 
be overcome by addition of detergents due to the formation of emulsion that blocks the flow 
reactor. 
 
3.5.7 General application flow reactors with AS and DCS 
The general applicability of this methodology was demonstrated by extending the study to 
DCS and AS. These two enzymes were tested at different concentrations in the flow reactor 
and batch for 30 min reaction time. All experiments were performed first without sonication 
for their comparison between batch and flow reactions. As with GDS, the conversion of FDP 
into the corresponding products by AS and DCS was improved under flow reactor conditions. 
Furthermore, experiments performed with sonication in a flow reactor resulted in better 
conversion for both enzymes. 
Conversions obtained in batch indicated that AS does not aggregate at concentrations of up to 
12 µM, judging by the linear increase of the conversion with enzyme concentration (Table 9, 
entries 1-3). Comparison of the conversion values obtained in batch and in flow without 
sonication, revealed a rather modest increment in conversion at any enzyme concentration 
(Table 9, entries 1-3). Further experiments were performed at an enzyme concentration of 12 
M with different internal reactor diameters under sonication. In this case, an internal reactor 
diameter of 0.45-0.8 mm increased the conversion to 66-88%, respectively. In contrast, 
otherwise identical batch experiments under sonication achieved a conversion of 43% (Table 
9, entries 4 and 5). Remarkably, sonication seems to have negligible effect in batch reactions 
(Table 9, entries 3 and 4-5). 
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Entry [Enz] 
µM 
Internal reactor 
diameter [mm] 
Sonication Conversion in 
flow [%] 
Conversion in 
batch [%] 
1 6  0.45 NO 21 15 
2 9  0.45 NO 34 27 
3 12  0.45 NO 49 43 
4 12 0.45 YES 66  
43 
5 12 0.8 YES 88 
 
Table 9. Flow and batch experiments with AS performed with and without sonication in 0.8 
and 0.45 mm internal flow reactor diameter (30 min). 
 
Unfortunately, an increase of the reaction temperature (40 ºC) with the conditions shown in 
Table 9 entry 5 resulted in the denaturation of the protein and a decrease in the conversion 
(21%). 
Values obtained in batch experiments indicated that DCS does not aggregate at 
concentrations of up to 12 µM (30 min reaction), judging by the linear increase of the 
conversion with enzyme concentration (Table 10, entries 1-3). In contrast, with previous 
experiments in batch, where aggregation was observed during the 24 h incubation period, 
enzymatic aggregation seems to take place only during prolonged incubations periods. By 
comparing the corresponding batch with flow experiments (Table 10, entries 1-3), the 
production of (+)--cadinene in continuous extraction in flow was double the efficiency of 
the equivalent batch process. Further experiments at 12 µM enzyme concentration, with 
sonication and internal reactor diameter of 0.45 mm, gave the highest conversion of 56% 
(Table 10, entry 4). In contrast with AS, experiments with DCS in an internal reactor 
diameter of 0.8 mm led to a decrease in the conversion (27%, Table 10, entry 5).    
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Entry [Enz] 
µM 
Internal reactor 
diameter [mm] 
Sonication Conversion in 
flow [%] 
Conversion in 
batch [%] 
1 6  0.45 NO 14 6 
2 9  0.45 NO 26 11 
3 12  0.45 NO 42 15 
4 12 0.45 YES 56  
30 
5 12 0.8 YES 27 
 
Table 10. Flow and batch experiments with DCS performed with and without sonication in 
0.8 and 0.45 mm internal flow reactor diameter (30 min). 
 
These experiments outline that incubations with DCS benefit from incubation in a flow 
system, even without sonication. Nevertheless, the best results were obtained with sonication 
achieving double conversion in comparison with batch experiments. 
  
3.5.8 Conclusion 
The conversions obtained with both AS and DCS were increased in both cases over a 100% 
by performing reactions in flow reactor under sonication, but using different tubing diameter 
for each case. These results demonstrate that this methodology can be applied to other 
sesquiterpene synthesis. However, an optimisation of the conditions used in each case needs 
to be performed. 
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3.5.9 Enzyme recycling study 
The vortex process used to extract the enzymatic products from batch experiments, results in 
enzyme inactivation. However, continuous extraction in a flow system is performed in milder 
mechanical conditions that can keep the enzyme active after the incubation period. In order to 
test this possibility, the aqueous phase was recovered for a previous run with AS (61%) and 
assayed twice for residual activity by exposure to additional  FDP (1 eq) under identical flow 
conditions. The conversion dropped to 16% (2
nd
 cycle) and 6% (3
rd
 cycle).  
These experiments show that the enzyme is losing activity in each catalytic cycle and after 
the third use, the enzyme is almost inactive.   
 
3.5.10 Production of unnatural terpenes 
Metabolic engineering and synthetic biology protocols have recently shown innovative and 
more sustainable large-scale production of valuable terpenes. However, these approaches 
cannot yet be used for the generation of modified-FDP and, therefore, for the production of 
unnatural terpenoids.
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In vitro experiments have shown that some unnatural FDP analogues acted as substrates of 
terpene synthases, generating a range of unnatural terpenes (Chapter 4). Three alkyl 
analogues of FDP (12Me-FDP (136), 14Me-FDP (137), and 15Me-FDP (138)) were used 
under flow conditions generating a set of potentially bioactive unnatural compounds. By 
using the reaction conditions identified above, DCS and AS were used to transform these 
three FDP analogues into their corresponding sesquiterpene derivatives.  
The incubation of AS in flow with analogues showed a clear improvement of the reactions 
performed in flow in comparison with the corresponding reactions in batch (Table 11, entry 
1-3), achieving 1.6 to 2.9 fold higher conversion. In addition, two sesquiterpene derivatives 
that has been characterised in Chapter 4 were obtained: 14Me-germacrene A (287) and 
15Me-aristolochene (288) (Figure 26, Table 11, entries 2-3, see Chapter 4, Section 4.2.3 and 
4.2.5 respectively for their characterisation). 
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Figure 26. Structures of products obtained from the incubation of 14Me-FDP (137) and 
15MeFDP (288) with AS. 
 
The incubation of DCS in flow also shows an improvement in the conversion, in this case, 
between 3.5 to 1.5 times higher than the analogous reaction performed in batch (Table 11, 
entry 4-6). 
Entry Enzyme Analogue Product Conversion 
(batch) 
Conversion
(flow) 
1 AS  12Me-FDP 
(136) 
Mixture 22 63 
2 AS 14Me-FDP 
(137) 
14Me-germacrene A 
(287) 
6 11 
3 AS 15Me-FDP 
(138) 
15Me-aristolochene 
(288) 
9 15 
4 DCS 12Me-FDP 
(136) 
Mixture 2.5 5 
5 DCS 14Me-FDP 
(137) 
Unknown 9 14 
6 DCS 15Me-FDP 
(138) 
Mixture 1 3.5 
 
Table 11. Result from the incubation FDP analogues and AS or DCS. AS was incubated with 
FDP analogues in a 0.45 mm internal reactor diameter under sonication. DCS was incubated 
with FDP analogues in a 0.8 mm internal reactor diameter under sonication. 
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The results show that the methodology is also applicable to the conversion of FDP analogues 
into aristolochene and -cadinene derivatives. The difficulty with such FDP analogues in 
batch reactions is largely overcome given that the reactions are about two to three times more 
efficient when performed in flow.  
 
3.5.11  Conclusion 
These experiments demonstrate that the use of a biphasic continuous flow system increases 
the enzymatic conversion of terpene synthases through the improved extraction of the 
hydrophobic cyclic reaction products. This effect is not limited to a specific enzyme and is 
especially useful when the overall conversion is low, as in the case of substrate analogues. In 
general, all the enzymes examinated in this chapter performing the incubations in a flow 
reactor improved conversion at least 100%, in comparison with the reactions performed in 
batch. In the future, efforts can be focused in combined flow reactors with immobilised 
enzymes to improve enzyme stability to allow several catalytic cycles.    
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CHAPTER 4 
Enzymatic production and NMR characterisation 
of unnatural sesquiterpenoids  
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4. Introduction  
The FDP analogues used in this study can be classified into four classes: alkyl substituted, 
frame shifted, fluorinated analogues and hydroxyl substituted analogues. All farnesyl 
diphosphate (FDP) analogues described in Chapter 2 and some other previously synthesised 
within our group were tested with (+)-germacrene A (GAS), aristolochene (AS), (-)-
germacrene D (GDS) and -cadinene (DCS) synthases.  
FDP analogues with alkyl modifications of the universal C15 farnesyl chain such as 12Me-
FDP (136), 14Me-FDP (137), 15Me-FDP (138) or 14,15diMe-FDP (139) have been prepared 
before and shown to be substrates of protein-farnesyltransferases.
265
 However, to the best of 
our knowledge, these CH3-alkylated variants had never been tested with terpene cyclases 
prior to this study.  
Frame-shifted FDP analogues are generally defined as those possessing either one extra or 
one less [eg. 8nor-FDP (140)] CH2 units (or spacer) between the double bonds of native FDP. 
The removal of one spacer will modify the interaction of the FDPs with the enzyme, likely 
changing the interactions between the key amino acids of the active site and the analogue. 
These interactions are responsible for the stabilisation of reaction intermediates. Previous 
studies have demonstrated that some of these analogues are substrates of mammalian 
FTase
266
 but no report has ever been published describing reactions with terpene cyclases.  
Historically, fluorinated FDP analogues have been used in mechanistic investigations of 
sesquiterpene synthases because the electronegativity of the fluorine atom can interfere with 
the carbocationic intermediates, whereas changes in the binding to the active site of the 
enzyme are minimised due to the small size of the fluorine atom.
267
 More often, fluorinated 
analogues have been used as inhibitors of these enzymes, but in some instances, they have 
been shown to act as substrates surrogates of terpene synthases
268
 producing valuable novel 
fluoro-containing terpenoids. The fluorinated FDP analogues chosen for the present study 
were 6F-FDP (289) (analogue provided by Dr. D. J. Miller), 10F-FDP (290) (10F-farnesol 
provided by Dr. J. A. Faraldos) and 14F-FDP (291) (analogue provided by Dr. V. Gonzalez).     
Hydroxyl FDP analogues have not been tested with terpene synthases. The electron -
donating properties of the hydroxyl group are expected to stabilise -cationic species, 
however the strong electronegativity of oxygen can destabilised positively charged 
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intermediates place at -positions. Hydroxyl group can quench the intermediate carbocation 
and consequently, this can result in the formation of either a ketone or an aldehyde. 
Therefore, these novel mechanistic probes are expected to act as carbocationic traps. To 
investigate this possibility, 8OH-FDP (141) was prepared (Dr. J. A. Faraldos) and tested with 
(+)--cadinene synthase.  
 
Scheme 78. FDP analogues used in this study. 
 
4.1 (+)-Germacrene A synthase from Solidago canadensis 
4.1.1 Incubation of FDP (17) with GAS 
The incubation of FDP (17) with GAS gave one major pentane extractable product as judged 
by GC-MS analysis. The GC chromatogram displays a broad peak at lower retention time 
(Figure 27). The signal has been noticed before for all-trans configured germacrenoids and it 
is believed to represent the thermally-induced Cope rearrangement of (+)-germacrene A  to 
the corresponding -elemene (Chapter 1, Scheme 10) isomers, hence suggesting a (+)-
germacrene A  analogue. Its mass spectrum displayed a peak at m/z = 162, which could 
indicate the loss of an isopropenyl group as reported for the parent (+)-germacrene A.
269
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Figure 27. Gas chromatogram of the pentane extractable products obtained from incubation 
of FDP (17) and GAS. Inset, mass spectrum (+)-germacrene A (50) eluting at 25.134 min. 
 
The Cope rearrangement of (+)-germacrene A (50) into (-)--elemene (51) is a [3,3] 
sigmatropic reaction that takes place with retention of configuration at C10 (Chapter 1, 
Scheme 10).
270
 The Cope rearrangement has been used for the identification of (+)-
germacrene A (50). The simple increase of the temperature injection port of the GC-MS is 
enough to increase the amount of -elemene (51) (lower tr) and consequently decrease of the 
amount of (+)-germacrene A (50).
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4.1.2 Incubation of 14Me-FDP (137) with GAS 
The GC-MS analysis of the pentane extractable products obtained from the incubation of 
14Me-FDP (137) with GAS revealed the presence of one major product, which GC trace 
displays the characteristic broad peak previously observed for (+)-germacrene A (Figure 
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28A). The presence of the broad peak suggests that the product obtained is a (+)-germacrene 
A derivative containing an extra methyl group on C14 (292, Scheme 79). Confirmation of the 
identity of the compound was obtained by increasing the temperature of the injector port to 
250 ºC. The new chromatogram obtained shows that the peak previously centred at 28.5 min 
has shifted to 25.7 min. This observation is in good agreement with the formation of the 
14Me--elemene (297, Scheme 79) (Figure 28B). 
 
Figure 28. A) Gas chromatogram of the pentane extractable products obtained from 
incubation of 14Me-FDP (137) and GAS using an injector port temperature of 50 ºC B) Gas 
chromatogram of the pentane extractable products obtained from incubation of 14Me-FDP 
(137) and GAS using an injector port temperature of 250 ºC 
 
In addition, the chromatogram shows small peaks that persist when the Cope rearrangement 
is induced by increasing the temperature injection port of the GC-MS. The peaks are 
attributed to the presence of acid in the GC column coming from previous samples. The acid 
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transformation of (+)-germacrene A into bicyclic selenines (294, 295 and 296) has been 
previously observed (Scheme 79).
272
  
 
Scheme 79. Acid catalysed formation of selenines and thermal rearrangement of 14Me-
germacrene A. 
 
Variable temperature 
1
H NMR spectroscopy (from RT to -50 ºC) with this new product 
revealed the temperature dependent 
1
H NMR spectrum shape that is characteristic of the 
interconversion of different conformers of germacrene A. This evidence confirms that the 
obtained product from the incubation of 14Me-FDP with GAS is 14Me-germacrene A (292). 
For a more detailed interpretation of 
1
H NMR spectrum see section 6.19, table 15. 
Additionally, the spectrum mass spectrum obtained of 292 resembles mass spectrum obtained 
for the parent (+)-germacrene A (50, Figure 27). 
 
4.1.3 Incubation of 15Me-FDP (138) with GAS 
In contrast to 14Me-FDP (137), 15Me-FDP (138) was inactive with GAS as judged by the 
absence of products in the pentane extracts. The extra methyl group in this case seems to 
prevent the initial 1,10-cyclisation normally mediated by GAS. Hence, this observation 
suggests the formation of nerolidyl diphosphate (NDP, 95) during the native cyclisation with 
FDP (Chapter 1, Scheme 20). This isomerisation is impeded in the in the case of 15Me-FDP 
(138) due to the size of the extra methyl group (Scheme 80). 
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Scheme 80. Isomerisation of 15Me-FDP (138) to 15Me-NDP (298). 
 
4.1.4 Incubation of 10F-FDP (290) with GAS 
The fluorine substituent in 10F-FDP (290) should prevent the 1,10-cyclisation of GAS, due to 
the relatively reduced electron density at C10 caused by F-substitution. In addition, the 
destabilising effect of the fluorine atom should suppress the formation of the germacrenyl 
cation 301 and hence behave as an inhibitor for GAS. However, GC-MS analysis revealed the 
presence of a product that display a molecular ion with m/z = 222 eluting at 25.6 min, which 
appears to confirm the unexpected formation of a fluoro-containing sesquiterpenoid. 
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Figure 29. Gas chromatogram of the pentane extractable products obtained from incubation 
of 10F-FDP (290) and GAS. Inset, mass spectrum of the compound eluting at 25.612 min. 
 
Fluorinated germacrene A (302, Scheme 81) obtained from a 1,10-cyclisation is expected to 
undergo thermally induced Cope rearrangement to obtain the corresponding fluorinated,  -
elemene. However, sesquiterpenoid obtained failed to undergo facile thermal Cope 
rearrangement, thus ruling out unambiguously a fluoro-germacrene as the putative enzymatic 
product. 
Other possible products are the linear farnesenes obtained after the elimination of 
diphosphate. Co-elution and spiking experiments using GC-MS with an authentic sample of a 
mixture of linear 10F-farnesenes (303, 304 and 305 Scheme 81)
273
 did not show any 
similarity in the retention time nor mass spectrum with the obtained sesquiterpene. Farnesene 
products were ruled out thus indicating that the new sesquiterpene was most likely cyclic. 
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GAS is known to produce small amounts of -humulene (2%) with the native substrate 
FDP.
274
 The new fluorinated sesquiterpene obtained was most likely a 1,11-cyclisied 
humulene product. The reaction is driven by the change in the reactivity of the double bond 
that favour this 1,11-cyclisation pathway by fluorine donation of -electrons to the distal 
10,11-double bond of FDP (Scheme 81).  
 
Scheme 81. Reaction mechanism accounting for the formation of 10F--humulene (300), and 
excluding formation of other possible products. 
 
Alternatively, it has been proposed in a mechanistic study recently published by Faraldos et 
al. that GAS can transform FDP into (+)-germacrene A through a cyclopropyl carbocationic 
intermediate.
75
 In this alternative mechanism, the formation of 10F--humelene (300) is 
explained by the formation of the intermediate 307. In this scenario, path a is very slow 
because the energetic barrier for the formation of 301 is high whereas path b is more 
favourable because the lonely pairs of the F can give extra stabilisation to carbocation 299 
reducing the energetic barrier for this transformation (Scheme 82).   
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Scheme 82. Alternative mechanism for the formation of 10F--humulene (300). 
 
1
H and 
19
F NMR spectroscopy analyses supported the formation of 300 by the observation of 
a downfield doublet of triplets signal (JH−F = 40.4 Hz and JH−H = 8.1 Hz) at 4.89 ppm, which 
strongly resembles the characteristic doublet of triplets absorbance at 5.38 ppm (JH−H = 15.8. 
Hz, and JH−H = 7.3 Hz) assigned to the H-9 olefinic proton of α-humulene. The relative 
upfield H-9 shift (ca. 0.5 ppm) observed for 300 is consistent with the γ-shielding effect of 
the vinylic fluoro substituent. Moreover, 
19
F NMR spectrum of the reaction product generated 
displayed a doublet (JH−F = 41.6. Hz) centred at −109.9 ppm, which further supports the 
identification of this enzymatic hydrocarbon as 10F-α-humulene (300).136  
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Figure 30. A) doublet of triplets of 10F--humulene (300). B) Doublet of triplets of -
humulene. C) 
19
F NMR spectrum of 10F--humulene (300). 
 
4.1.5 Incubation of 8nor-FDP (140) with GAS 
The incubation of 8nor-FDP (140) gave one major compound eluting at 17.8 min (Figure 31) 
as judged by GC-MS. The comparison of the GC-MS trace of a non-enzymatic preparation of 
8-nor-farnesene derivatives, prepared by the dehydration of the corresponding alcohol using 
the procedure reported by Coates,
275
 rules out any of three 8-nor-farnesene derivatives (228, 
229, 230) as a possible product.  
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Figure 31. Gas chromatogram of the pentane extractable products obtained from incubation 
of 8nor-FDP (140) and GAS. Inset, mass spectrum of the compound eluting at 17.790 min.  
 
 
Scheme 83. Mixture of 8nor-farnesenes.  
 
If 8nor-FDP (140) followed the natural reaction mechanism catalysed by GAS, it should 
afford a nine member ring carbocation 306, which could then undergo either a proton 
removal to yield 308, or a hydride shift from C1 to C11 to give the allylic carbocation 307 
and then  309 (Scheme 84) after proton loss from C15.    
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Another possible scenario of the incubation with 8nor-FDP (140) involves an inverse attack 
of the distal double bond at C10 on C1 to afford 310. The enzyme performs an inverse attack 
of the distal double bond with the native substrate to give a small amount of -humelene. 
Stable allylic carbocation 312 is achieved form 310 by hydride shift and subsequent 
deprotonation yields in this case 313 resembling -humulene 314. Alternatively, 311 can be 
formed from carbocation 310 by deprotonation (Scheme 84). 
 
Scheme 84. Mechanisms of formation and possible products of the incubation of 8nor-FDP 
and GAS.  
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Comparison of the published mass spectrum of -humulene (314)276 with the one obtained in 
the incubation of the 8nor-FDP (140) revealed a very similar fragmentation pattern. The 
overall shape of the spectrum is comparable with the one published. The mechanism 
proposed for the formation of 313 is very similar to the mechanism proposed for the 
conversion of FDP into (-)-germacrene D by GDS and remarkably GDS produce the same 
product as GAS when incubated with 8nor-FDP (140) (vide infra). GAS and GDS enzymes 
can operate using an inverse attack of the distal double bond, when incubated with some FDP 
analogues.
243
 This evidence points to 313 as the product of the incubation but unfortunately, 
all the efforts to confirm the proposed structure using 
1
H NMR spectroscopy were 
unsuccessful. The preparative scale incubations did not afford sufficient material for full 
characterisation by NMR spectroscopy. Therefore, this proposal could not be confirmed 
during this study. 
 
4.1.6 Quantification of enzymatic products of GAS 
In order to estimate how good each FDP analogue performs as substrate surrogates, 
incubations harbouring an internal standard (-humulene) of known concentration were 
repeated for each FDP analogue under optimal conditions (Chapter 3). These experiments 
were performed in an analytical scale for 24 h and conversion was measured using a GC-FID 
apparatus.   
As shown in Table 12, FDP analogues were in all cases worse substrates than FDP (17, Table 
12, entry 1). 6F-FDP (298, Table 12, entry 2) was the substrate that displayed the highest 
activity and 10F-FDP (290, Table 12, entry 3) displayed lower substrate activity. This result 
explains the poor quality of the NMR spectrum obtained in the incubation of 10F-FDP. 
14Me-FDP (137, Table 12, entry 4) has a moderate substrate activity retaining around 60% of 
activity compared with FDP (17, Table 12, entry 1).  
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Entry Substrate Conversion (%) Conversion relative to 
FDP (%)
a 
1 FDP (17) 40 100 
2 6F-FDP(289)
b 
30 74 
3 10F-FDP (290) 12 29 
4 14Me-FDP (137) 23 57 
5 15Me-FDP (138) - - 
a) Conversion normalised to 100% conversion with FDP. b) Product identified as 6F-germacrene A.
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Table 12. Conversions of FDP (17) and FDP analogues with GAS. 
 
4.1.7 Conclusions 
As expected, the incubation of 14Me-FDP (137) with GAS gave 14Me-germacrene A (292) 
as the only pentane extractable product, whereas 15Me-FDP (138) has no substrate activity. 
This observation can be explained by the formation of NDP in the mechanism of GAS. The 
isomerisation of 15Me-FDP (138) to 15Me-NDP (298) is prevented by the steric impediment 
of the methyl group on C15 (Scheme 80).  
The product obtained from the incubation of 10F-FDP (290) was identified as 10F--
humulene (300). This product is obtained from an unexpected 1,11-cyclisation and provides 
evidence that GAS retains a certain character of -humulene synthase.  
The same unexpected 1,11-cyclisation was proposed for the formation of the 8nor--
humulene (313) from the incubation of 8nor-FDP (140). This result again showed the dual 
ability of the enzyme to operate two different pathways (1,11-and 1,10-cyclisation).  
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4.2 Aristolochene synthase from Penicillium roqueforti 
4.2.1 Incubation of FDP (17) with AS 
The incubation of FDP (17) with AS gave one major product as judged by GC-MS, with a 
product peak at 25.8 min and other two minor products were observed at 26.2 and 26.5 min 
(Figure 32). The two minor products were previously identified as valencene and (-)-
germacrene A, respectively.
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Figure 32. Gas chromatogram of the pentane extractable products obtained from incubation 
of FDP (17) and AS. Inset, mass spectrum of (+)-Aristolochene (56) eluting at 25.849 min. 
 
A preparative scale incubation afforded enough aristolochene for characterisation by 
1
H 
NMR and 
13
C NMR spectroscopy. The data obtained from the 
1
H NMR and 
13
C NMR spectra 
are in agreement with the structure of the expected product (56, Scheme 85). The 
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spectroscopic data are in agreement with the NMR spectrum published for the synthetically 
prepared (-)-aristolochene (56, Scheme 13) (see section 6.20.1 for full interpretation).
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Scheme 85. (+)-Aristolochene (56). 
 
4.2.2 Incubation of 12Me-FDP (136) with AS 
The incubation of 12Me-FDP (136) with AS gave four different compounds in the pentane 
extracts as indicated by GC-MS analysis. By increasing the injection temperature port to 250 
ºC a new peak at 19.6 min appeared while the intensity of the peaks at 29.6 and 29.4 min 
decreased (Figure 33). This behaviour is indicative of an all-trans germacrene analogue.   
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Figure 33. Gas chromatogram of the pentane extractable products obtained from incubation 
of 12Me-FDP (136) and AS using an injector port temperature of 50 ºC B) Gas 
chromatogram of the pentane extractable products obtained from incubation of 12Me-FDP 
(136) and AS using an injector port temperature of 250 ºC (peak at 21.6 min is an impurity 
that does not display sesquiterpene molecular ion mass). 
 
The mass spectrum of the products eluting at 29.0 and 29.1 min display a molecular ion with 
m/z = 218. The shape and the fragmentation pattern of both compounds (Figure 34) strongly 
resemble the mass spectrum of aristolochene (Figure 32). The two compounds could be 
isomers of aristolochene achieved by deprotonation at C12 from the intermediate 12Me-
germacradienyl cation (315). The intermediate 12Me-germacrene A (316 or 318) can undergo 
the same reaction as the natural intermediate (+)-germacrene A to afford the final mixture of 
products 317 and 319 (Scheme 86).  
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Scheme 86. Possible mechanism of product formation.  
 
Both mass spectrums indicate formation of a fragment with m/z = 203 that correspond to the 
loss of a methyl group. The difference in abundance of this peak in each spectrum (96% in 
Figure 34A and 25% in Figure 34B) may be due to the different geometry of double bond 
between C11 and C12 of 317 and 319 (Scheme 86). Different geometry of the double bond 
makes methyl group of one isomer easier to fragment than the methyl group of the other 
isomer and therefore a difference in abundance is observed in the mass spectrum. 
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Figure 34. A) mass spectrum of the product eluting at 29.1 min from Figure 33A B) mass 
spectrum of the product eluting at 29.0 min from Figure 33A. 
 
4.2.3 Incubation of 14Me-FDP (137) with AS 
The incubation of 14Me-FDP (137) with AS gave a mixture of at least 7 different products 
with the expected molecular ion with m/z = 218 as indicated by GC-MS. This complex 
mixture of compounds can be produced by the acidic decomposition of 14Me-germacrene A, 
as shown in the case of GAS. The major compound eluting at 28.5 min has the characteristic 
broad peak attributed to the Cope rearrangement that occurs in the injection port (Figure 
35A). Indeed, the elevation of the injection port temperature to 250 ºC resulted in a shift to 
shorter retention time of the major peak, and a much clearer chromatogram (Figure 35B) was 
obtained. The new peak is the -elemene derivative (Scheme 87, 321) obtained as the product 
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of the Cope rearrangement: therefore, the most probable major product of the incubation of 
14Me-FDP (137) with AS is 14Me-germacrene A (Scheme 87, 320). 
 
Scheme 87. Cope rearrangement of 14Me-FDP (137). 
 
 
Figure 35. Gas chromatogram of the pentane extractable products obtained from incubation 
of 14Me-FDP (137) and AS using an injector port temperature of 50 ºC B) Gas 
chromatogram of the pentane extractable products obtained from incubation of 14Me-FDP 
(137) and AS using an injector port temperature of 250 ºC.  
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(E, E)-germacrenes are known to exist as a mixture of slowly interconverting conformers at 
ambient temperatures. The population of these different conformers in bulk solution has been 
extensively studied. For instance, the cyclodecadiene ring of hedycaryol can theoretically 
adopt four different conformations that are denoted as UD (322), DU (323), DD (324) and 
UU (325). This denomination is referred to up (U) or down (D) orientation of the methyl 
groups in C2 and C6 of the cyclodecadiene ring (Scheme 88). The two double bonds in the 
cyclodecadiene ring, in the conformations denoted as UU (325) and DD (324), have a crossed 
disposition between them whereas double bonds in the conformations denoted as DU (323) 
and UD (322) have a parallel disposition in the cyclodecadiene ring. In all the conformers, 
the substituent on C7 is preferable in equatorial position or pseudoequatorial.
279
 Studies of 
hedycaryol using 
1
H NMR spectroscopy have concluded that in solution, hedycaryol exists 
only as two parallel UD (322) and DU (323) and one crossed conformation UU (325) 
(scheme 88).
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Scheme 88. Four possible conformations of hedycaryol. 
 
In solution, the fast interconversion of the three different conformers (DU, UD and UU) of 
germacrene A in equilibrium gives the appearance of the 
1
H NMR spectrum a strong 
temperature dependence.
281
 As a result, the 
1
H NMR spectrum signals are broad at room 
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temperature, but they get sharper at lower temperatures at slower interconversion rates and 
the different conformers can be separately characterised.
282
  
Some examples are found in literature where NOE experiments in combination with variable 
temperature NMR spectroscopy are used to determine the most stable conformation of simple 
all trans-germacrenes such as germacrene A.
283
 The relative populations of each conformer 
of germacrene A were difficult to determine due to the small amounts of impure germacrene 
A isolated from plants. Purification was also difficult due to the thermal and photo-lability of 
germacrene A.
284
 Recently, the Coates group was able to obtain large amounts of pure (+)-
germacrene A (50), using genetically-engineered yeast for high level production of farnesyl 
phosphate
285
 combined with DNA encoding (+)-germacrene A (50) synthase. Full 
characterisation was performed. NOE experiments at variable temperature allowed the 
assignment of each 
1
H NMR signal to the corresponding proton in each conformation. The 
conformer population was calculated from the integrals of the individual olefinic protons.  
The conformer of (+)-germacrene A (50) named as UU (crossed, 328) was the major 
conformation the population of this conformer accounts for 52%. The signals corresponding 
to the two olefinic protons were identified as a doublet of doublets at 4.78 ppm (H1) and 
doublet at 4.51 ppm (H5) as previously suggested for one conformer of hedycaryol and 
dihydropregeijerene.
286
 Additionally, the two protons at C12 were assigned to singlets at 4.65 
and 4.54 ppm overlapping with the same protons from the conformation 326 and 327. The 
assignments of the methyl groups were established by Sathe et al.
287
 by comparison with data 
obtained from deuterated dihydropregeijerenes which identified the olefinic methyl singlets 
of 328 at 1.37 (H14) and 1.52 (H15) ppm. In addition, the saturation of the frequency 
corresponding to H1 (4.78 ppm) of 328 produced a small NOE enhancement (1%) of signal at 
4.51 (H5, 328) ppm, thus, corroborating the syn relationship of the vinylic hydrogens of 328. 
The saturation of this frequency was transferred to the signals at H 5.01 (326) and 4.94 ppm 
(327) by an exchange process verifying the H1 chemical shift position of the less populated 
conformers 326 and 327. 
The conformer of (+)-germacrene A (50) named as UD (parallel, 326), accounts for 29%. The 
signals corresponding to the two olefinic protons were identified as a triplet at 5.01 ppm (H1) 
and doublet of doublets at 5.07 ppm (H5). Additionally the two protons of double bond on 
C12 were assigned to singlets at 4.65 ppm, overlapping with the same protons from the 
conformation UU (328) and 4.54 ppm. NOE enhancement (3%) obtained from vinylic methyl 
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signals at 1.46 (H15) and 1.54 (H14) ppm when signals of vinyl protons at 5.01 (H1) and 
5.07 (H5) ppm are irradiated, corroborate the anti conformation and assignation of the methyl 
groups 
The population of the conformer of (+)-germacrene A (50) named as DU (parallel, 327) 
accounts for 19% of the population of the three conformers. The signals corresponding to the 
two olefinic protons were identified as a doublet at 4.94 ppm (proton on C1) and triplet at 
5.21 ppm (proton on C5). Additionally, the two protons of double bond on C12 were assigned 
to singlets at 4.65 ppm, overlapping with the same protons from the conformations UD (326) 
and UU (328), and 4.51 ppm. NOE enhancement (2%) obtained from vinylic methyl signals 
at 1.48 (H15) and 1.68 (H14) ppm when signal of vinyl protons at 4.94 (H1) and 5.21 (H5) 
ppm are irradiated, corroborate the anti conformation and assignment of the methyl groups.
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Scheme 89. Conformers of (+)-germacrene A (50). 
 
The population of the corresponding conformations of 14Me-germacrene A (320) are 
different to the parent germacrene A (50) due to the bulky methyl group. The additional 
methyl group in the structure can increase the steric interactions between the pendant methyl 
groups, increasing the energy of the conformation that places the bulkiest groups close 
together, in this case the UU conformation (320a, Figure 36). As a result, the population of 
146 
 
this conformer is expected to be reduced with a consequential increase in the populations of 
the UD (320b, Figure 36) and DU (320c, Figure 36).  
Preparative incubation of 14Me-FDP (137) with AS afforded 14Me-germacrene A (320) in 
sufficient quantity (6 mg) to be studied by 
1
H NMR spectroscopy. Direct comparison of the 
1
H NMR spectrum of 320 with that of the parent (+)-germacrene A and analysis according to 
Faraldos et al.
288
 allowed the assignment of signals to each individual conformation of 14-Me 
germacrene A (320).
 
 
Although the UU conformer of 14Me-germacrene A (320a, Figure 36) was still dominant, its 
relative population dropped to 39% when compared to the 52% observed for UU conformer 
of the parent (+)-germacrene A. In the 
1
H NMR spectrum, the doublet of doublets 
corresponding to proton on C1 is shifted upfield to 4.71 ppm. The doublet at 4.51 ppm 
observed for the parent (+)-germacrene A (50) corresponding to the proton on C5 is shifted 
downfield at 4.53 ppm and overlaps with the signal of the protons on C12. The signal for one 
of the protons on C12 is approximately constant for the three conformers at 4.64 ppm and so 
appears as a broad singlet. 
Interestingly, the population of the UD conformer of 14Me-germacrene A (320b, Figure 36), 
accounts for 29%, as it was observed for the parent (+)-germacrene A (50). The triplet at 5.01 
ppm for (+)-germacrene A has shifted to 4.91 ppm (proton on C1) and now overlaps with the 
signal of the conformation DU (320c, Figure 36) (proton on C1), making the signal appear as 
an asymmetric doublet of doublets. The doublet of doublets at 5.07 ppm, in 14Me-
germacrene A (320), is shifted to 5.01 ppm (proton on C5). Additionally the two protons of 
double bond on C12 were assigned to singlets at 4.64 ppm and overlaps with the same 
protons from the conformations UU (320a, Figure 36) and DU (320c, Figure 36), and 4.60 
ppm.  
The DU conformer (320c, Figure 36), increased its population to 33% of the total population 
of conformers. The triplet at 5.21 ppm for (+)-germacrene A (50) is shifted to 5.22 ppm in 
14Me-germacrene A (320) (proton on C2).  
The signals for the CH3 of the ethyl group corresponding to each conformation are three 
triplets overlap and are centred at 0.9 ppm (Figure 36). For a more detailed analysis of 
1
H 
NMR signals, see Chapter 6, Section 6.20.2, Table 16.   
147 
 
As for the parent (+)-germacrene A the most abundant conformation is UU (320a, Figure 36), 
in contrast, the other two conformations DU (320c, Figure 36) and UD (320b, Figure 36) 
dominate over the UU (320a, Figure 36) conformation. The increasing bulkiness reduces the 
energy gaps between different conformations.  
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Figure 36. Variable temperature 
1
H NMR (500 MHz, CDCl3) spectra of 14Me-germacrene A (320) and conformational study.  
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4.2.4 Incubation of 14,15diMe-FDP (139) with AS 
The incubation of 14,15diMe-FDP (139) with AS gave a complex mixture of compounds in 
the pentane extracts. However, the big broad peak present in the chromatogram (Figure 37A) 
suggested that the major product could be 14,15diMe-germacrene A (329, Scheme 90). 
Increasing the injector port temperature to 250 ºC led to a cleaner chromatogram displaying 
only one major product at 26.29 min (Figure 37B). The experiment strongly implies that the 
compound was 14,15diMe-germacrene A (329) and the product of the Cope rearrangement as 
the -elemene derivative 330. 
 
Scheme 90. Cope rearrangement of 14,15diMe-germacrene A (329) into 330. 
 
150 
 
 
Figure 37. Gas chromatogram of the pentane extractable products obtained from incubation 
of 14,15diMe-FDP (139) and AS using an injector port temperature of 50 ºC B) Gas 
chromatogram of the pentane extractable products obtained from incubation of 14,15diMe-
FDP (139) and AS using an injector port temperature of 250 ºC. 
 
Preparative incubations were performed in order to determine the relative population of each 
conformation of 14,15diMe-germacrene A (329) by NMR spectroscopy. The increasing 
bulkiness of an additional methyl group would be expected to increase the energy of the UU 
(329a, Figure 38) conformation, and, therefore, a reduction on its population in favour of the 
UD conformation (329b, Figure 38) was expected. 
The 
1
H NMR spectrum displayed the diagnostic temperature dependence of flexible 
germacrenes. The signal pattern was very similar to the one shown by 14Me-germacrene A 
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(320). The complexity of the multiplet at 0.85 ppm is indicative of the presence of the 
additional methyl group. Chapter 6, Section 6.20.3, Table 17. 
Surprisingly, the conformational distribution was found to be identical to the conformational 
distribution observed for 14Methyl germacrene A (320, Figure 36). This result suggests that 
the bulkiness of the substituents on C15 had no incremental effect on the relative energy of 
each conformer over and above that exerted by the C14 methyl group and hence on the 
population of the conformations.  
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Figure 38. Variable temperature 
1
H NMR (500 MHz, CDCl3) spectra of 14,15diMe-germacrene A (329).
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4.2.5 Incubation of 15Me-FDP (138) with AS 
The incubation of 15Me-FDP (138) with AS gave only one compound in the pentane extracts 
with m/z = 218 eluting at 28.5 min. The remarkable similarity of its mass spectrum with 
aristolochene (Figure 32) strongly suggested that the product was the 15Me-aristolochene 
(331) (Figure 39). 
 
Scheme 91. Product of the incubation of 15Me-FDP (138) with AS. 
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Figure 39. Gas chromatogram of the pentane extractable products obtained from incubation 
of 15Me-FDP (138) and AS. Inset, mass spectrum of the compound eluting at 28.493 min. 
 
4.2.6 Incubation of 8nor-FDP (140) with AS 
The incubation of 8nor-FDP (140) with AS gave a complex mixture of compounds in the 
pentane extracts as indicated by GC-MS analysis with a major peak at 21.5 min (Figure 40A). 
The sample was compared with an authentic sample of 8-nor-farnesene prepared by 
dehydration of 8-nor-farnesol (Figure 40B).
289
 The comparison of the chromatograms 
revealed that the major product of the incubation was 8-nor-farnesene (Scheme 83, 228) 
and the peak eluting at 22.8 min was the mixture of (E)-farnesene (Scheme 83, 229) and 
(Z)-farnesene (Scheme 83, 230) (Figure 40).  
AS was not able to produce cyclic products with 8nor-FDP (140). However, the diphosphate 
analogue appears to be bound to the active site and the ionisation of the diphosphate 
generates a mixture of 8-nor-farnesenes (Scheme 83).  
155 
 
 
Figure 40. A) Gas chromatogram of the pentane extractable products obtained from 
incubation of 8nor-FDP (140) and AS. B) Gas chromatogram of mixture of 8nor-farnesenes 
generated by dehydration of 8-nor-farnesol.  
 
4.2.7 Conclusions 
The incubation of 12Me-FDP (136) with AS gave a mixture of different geometrical isomers 
of 12Me-germacrene A (316 and 318, Scheme 86) and 12-Me-aristolochene (317 and 319, 
Scheme 86) derivatives. The complex mixture of compounds is due to the presence of 
geometrical isomers formed during the reaction.  
The incubation of 14Me-FDP (137) and 14,15diMe-FDP (139) afforded in both cases the 
corresponding germacrene A derivative and remarkably, both germacrene A derivatives 
displayed the same conformer distribution (Figures 36 and 38). These results suggest that the 
increasing steric impediment has a limited impact on the population of conformers.  
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In contrast to GAS, AS appears not to have the ability of triggering 1,11-cyclisations, judging 
by the incubation of 8nor-FDP (140) with AS that resulted in a mixture of 8-nor-farnesenes. 
  
4.3 (-)-Germacrene D synthase from Solidago canadensis 
4.3.1 Incubation of FDP (17) with GDS 
The incubation of (-)-germacrene D synthase with FDP gave, as expected a single, product 
eluting at 25.77 min that has a molecular ion with m/z = 204. The major fragment at m/z = 
161 corresponds to a loss of 43 units of mass, which corresponds with the loss of an isopropyl 
group (Figure 41). Previously published mass spectral data for (-)-germacrene D (78) were 
found to be identical to those obtained in this case.
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Scheme 92. Structure of (-)-germacrene D (78). 
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Figure 41. Gas chromatogram of the pentane extractable products obtained from incubation 
of FDP (17) and GDS. Inset, mass spectrum of (-)-germacrene D (78) eluting at 25.770 min.  
 
For characterisation purposes, a preparative incubation was performed using optimised 
conditions (Chapter 3). The sample obtained from FDP (17) was sufficient (1.7 mg) to allow 
full characterisation. The 
1
H NMR spectrum displays characteristic signals that agree with 
previously published NMR spectroscopy data for (-)-germacrene D.
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 The doublet at 5.78 
ppm is assigned to the protons Hb (Figure 42). The coupling constant of the doublet at 5.78 (J 
= 16 Hz) matches the minor coupling constant of the doublet of doublets centred at 5.25 ppm 
which supports the assignation of the signal to Hc (Figure 42). The two remaining doublet of 
doublets were assigned through their integration: therefore, the doublet of doublets centred at 
5.13 ppm is assigned to Ha (Figure 42) and 4.76 ppm is assigned to Hd (Figure 42). Another 
pair of characteristic signals are the two upfield doublets at 0.86 and 0.81 ppm corresponding 
to the methyl groups from the pendant isopropyl group (Figure 42). 
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Figure 42. 
1
H NMR (400 MHz, CDCl3) spectrum of (-)-germacrene D (78). 
 
This sample was sufficiently concentrated to record a 
13
C NMR spectrum that further 
confirmed the identity of (-)-germacrene D (78).  
 
Figure 43. 
13
C NMR (126 MHz, CDCl3) spectrum of (-)-germacrene D (78). 
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4.3.2 Incubation of 12Me-FDP (136) with GDS 
The additional methyl group on 12Me-FDP (136) was not expected to interfere in the reaction 
mechanism of GDS. Hence, a (-)-germacrene D derivative was expected from the incubations 
with GDS. Nevertheless, a new chiral centre at C11 will be created due to the presence of the 
additional methyl group that will desymmetrise the isopropyl group of native (-)-germacrene 
D. The hydride shift from C1 to C11 should not be impeded by the bulkiness of the additional 
methyl group and the stereochemistry of the shift should not be affected. In the case of FDP, 
the rotation of the isopropyl group has no effect on the stereochemistry of the final product 
because of the symmetry of the isopropyl group. However, in the case of the 12Me-FDP 
(136), the stereochemistry of the final product is determined by the relative position of the 
ethyl group when the hydride shift takes place (332 or 333). Free rotation of carbocation 332 
would lead to two diastereoisomers (337 and 335, Scheme 93). 
 
Scheme 93. Possible products formation of the incubation of 12Me-FDP (136) and GDS.  
 
The incubation of 12Me-FDP (136) with GDS led to the formation of two main and four 
minor products as judged by GC-MS (Figure 44). Comparison of the mass spectrum of the 
two new enzymatic sesquiterpenoids eluting at 27.4 and 28.9 min and spectrum of (-)-
germacrene D (78, Figure 41) revealed that these products were not the expected 12-Me 
derivatives of 78. Nevertheless, these two compounds share an almost identical mass 
spectrum, suggesting that they are most likely diastereoisomers. On the other hand, the mass 
spectrum of one of the minor products eluting at 29.3 min displays the distinctive (-)-
germacrene D peak at m/z = 161 and the overall fragmentation pattern that strongly resembles 
(-)-germacrene D (78, Scheme 32).    
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Figure 44. A) Gas chromatogram of the pentane extractable products obtained from 
incubation of 12Me-FDP (136) and GDS. B) Mass spectrum of the peak eluting at 27.4 min. 
C) Mass spectrum of the peak eluting at 28.9 min D) Mass spectrum of the peak eluting at 
29.3 min. 
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The mixture of compounds made difficult the identification of the two main products by 
1
H 
NMR spectroscopy. The sample obtained from a preparative incubation was not a sufficient 
amount to obtain a clear 
13
C NMR spectrum. The 
1
H NMR spectrum of the crude displays a 
doublet of doublets centred at 4.72 ppm (Figure 45) that resembles the doublet of doublets 
observed for (-)-germacrene D (78, Figure 42) corresponding to the protons on C15. The 
assignment is supported by the HSQC correlation of each of the doublets with the same 
carbon signal. The measured coupling constant for this doublet of doublets is much higher 
than the values of the ones observed for (-)-germacrene D. However, the signals have the 
same chemical shift as olefinic protons on C1 and C6 for (-)-germacrene D. The doublet at 
5.78 ppm is almost identical to the signal observed in (-)-germacrene D (Figure 42). Despite 
of these similarities, the identity of these two compounds could not be established and is still 
unknown. 
 
Figure 45. 
1
H NMR (600 MHz, CDCl3) spectrum of the products from the incubation of 
12Me-FDP (136) and GDS.  
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4.3.3 Incubation of 14Me-FDP (137) with GDS 
The methyl group in C14 is separated from any carbon that is involved in the reaction 
mechanism of GDS. Therefore, 14Me-FDP was expected to produce 14Me-germacrene D 
(338) upon incubation with GDS. While the mass spectrum displays a single m/z = 218 peak, 
the mass spectrum displays a mass and the base peak at m/z = 175 indicating a loss of an 
isopropyl group which is a diagnostic peak for (-)-germacrene D. The mass spectrum of the 
new compound has a fragmentation pattern almost identical to (-)-germacrene D (Figure 46). 
 
Scheme 94. Structure of 14Me-germacrene D (338). 
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 Figure 46. Gas chromatogram of the pentane extractable products obtained from incubation 
of 14Me-FDP (137) and GDS. Inset, mass spectrum of 14Me-germacrene D (338) eluting at 
22.092 min.  
 
Preparative incubation allowed 
1
H NMR and 
13
C NMR spectroscopic analysis. The 
comparison with previously obtained NMR spectrum of (-)-germacrene D (Figure 47) 
revealed the expected differences that confirm the identity of 14Me-germacrene D (338). 
Indeed, the region in the 
1
H NMR spectrum between 5.1-4.7 ppm was identical for both 
compounds. In the downfield region, a new triplet is observed at 0.87 ppm with a coupling 
constant of J = 7.5 Hz which is assigned to the presence of the ethyl group. On the other 
hand, the singlet observed at 1.51 ppm for germacrene D (Figure 42) has now disappeared 
which is consistent with the expected product. The signal for the new methylene group at C14 
was identified at 2.30 ppm as doublet of triplets and assigned to this carbon through its 
coupling constant of J = 7.5 Hz indicating that these protons are coupled with the triplet 
observed at 0.87 ppm (Figure 47). 
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Figure 47. 
1
H NMR (500 MHz, CDCl3) spectrum of 14Me-germacrene D (338). 
 
13
C NMR spectrum revealing the presence of an additional signal upfield at 21.4 ppm, which 
confirms the presence of an additional methyl group (Figure 48). 
 
Figure 48. 
13
C NMR (126 MHz, CDCl3) spectrum of 14Me-germacrene D (338). 
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4.3.4 Incubation of 14,15 diMe-FDP (139) with GDS 
The GC-MS analysis revealed the presence of at least nine different products with m/z = 232 
(Figure 49). The products eluting at 29.5 min (Figure 49A) and 33.2 min (Figure 49B) were 
the two major fractions. The mass of the product A was similar to the mass spectrum of the 
compound obtained from the incubation of 15Me-FDP (138) with GDS (vide infra). The 
mass spectrum for the peak B (Figure 49B) was very similar to the mass spectrum of (-)-
germacrene D, displaying the characteristic peak at m/z = 189 corresponding to the loss of an 
isopropyl group. The mass spectrum (Figure 49B) suggests 14,15 diMe-germacrene D (339) 
as possible product.  
 
Scheme 95. Structure of 14,15diMe germacrene D (339). 
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Figure 49. Gas chromatogram of the pentane extractable products obtained from incubation 
of 14,15diMe-FDP (139) and GDS. A) Mass spectrum of the peak eluting at 29.491 min. B) 
Mass spectrum of the peak eluting at 33.180 min.  
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Unfortunately, all the attempts to perform a preparative scale incubation of 14,15diMe-FDP 
(139) with GDS to confirm the identity of the product B and solve the structure of A were 
unsuccessful. The inability to obtain a 
1
H NMR spectrum is probably due to the low 
conversion rate with 14,15diMe-FDP (139) and the mixture of products obtained.  
 
4.3.5 Incubation of 15Me-FDP (138) with GDS 
The GC-MS analysis revealed the presence of at least six different products with the expected 
m/z = 218 (Figure 50). The mass spectrum of the product eluting at 26.9 min (Figure 50A) 
has remarkable similarities with the product obtained in the incubation of 14,15- diMe-FDP 
(139) (vide supra), but the identity of both products remains unknown. The mass spectrum of 
the product eluting at 29.8 min displays great similarities with the mass spectrum of (-)-
germacrene D (Figure 41) including the diagnostic loss of the isopropyl group. Therefore, the 
identity of this product can be assigned to the corresponding germacrene D derivative. The 
identity of the product eluting at 29.1 min is unknown.  
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Figure 50. Gas chromatogram of the pentane extractable products obtained from incubation 
of 15Me-FDP (138) and GDS. A) Mass spectrum of the peak eluting at 26.894 min. B) Mass 
spectrum of the peak eluting at 29.776 min.   
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Again, in this case, it was not possible to obtain a clear 
1
H NMR spectrum from the 
preparative incubation of 15Me-FDP (138) with GDS due to a mixture of compounds 
obtained and the low yield of the enzymatic conversion (vide infra). 
 
4.3.6 Incubation of 8nor-FDP (140) with GDS 
GC-MS analysis products obtained from the incubation of 8nor-FDP (140) and GDS revealed 
the presence of at least eight products in trace quantities and one major product eluting at 
17.8 min. The retention time and the mass spectrum (Figure 42) are identical to the ones 
obtained for the major product of the incubation of 8nor-FDP (140) and GAS (Figure 31). 
The identity of this product was discussed in section 4.1.5 and 313 (Scheme 84) was 
suggested as product. In addition the mechanism previously proposed for the formation of 
this product is similar to the mechanism of formation of (-)-germacrene D (vide supra). 
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Figure 51. Gas chromatogram of the pentane extractable products obtained from incubation 
of 8nor-FDP (140) and GDS. Inset, mass spectrum of product eluting at 17.789 min.   
 
4.3.7 Incubation of 6F-FDP (289) with GDS 
The double bond between C5 and C6 (FDP, 17) is not playing any role in the catalysis of 
GDS. Therefore, the fluorine atom at C6 should not interfere in the GDS mechanism and 6F-
germacrene D is the expected product of the enzymatic reaction. 
The GC-MS analysis revealed that GDS was indeed able to turn over 6F-FPP (289) to give 
one single fluorine containing sesquiterpenoid. The mass spectrum of the product has a signal 
at m/z = 222, which is in agreement with the presence of a fluorinated sesquiterpene. In 
addition, a peak at m/z = 179 indicates the characteristic loss of an isopropyl group. The 
molecular ion at m/z = 159 is generated by further fragmentation of the peak at m/z = 179 by 
losing the fluorine atom (Figure 52).  
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Scheme 96. Structure of 6F-germacrene D (340). 
 
 
Figure 52. Gas chromatogram of the pentane extractable products obtained from incubation 
of 6F-FDP (289) and GDS. Inset, mass spectrum of product eluting at 21.415 min.    
 
Preparative scale incubation allowed the characterisation by 
1
H NMR spectroscopy of 6F-
germacrene D (340). The downfield region of the spectrum displayed a similar pattern of 
signals as (-)-germacrene D. Although in this case one of the signals is missing, this is due to 
substitution of one of the olefinic protons with a fluorine atom. In addition, all the signals at 
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5.8 and 5.25 have shifted downfield to 6.15 and 5.83, respectively, due to the presence of the 
shielding effect of the fluorine atom in the molecule. In the upfield region, the characteristic 
doublets at 0.8 ppm confirm the presence of the isopropyl group. The rest of the signals are 
unfolded in a different manner from (-)-germacrene D due to the presence of the fluorine 
atom. The 
19
F NMR spectrum displays an apparent broad doublet at -106.0 ppm. The signal 
can be a doublet of doublets form by the separate coupling of the fluorine atom with each of 
the protons of the neighbouring methylene moiety (Figure 53).      
 
 
Figure 53. 
1
H NMR and 
19
F NMR (565 MHz, CDCl3) spectrum of 6F-germacrene D (340). 
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4.3.8 Incubation of 14F-FDP (291) with GDS 
Three different products were obtained from the incubation of 14F-FDP (291) with GDS as 
indicated by the GC-MS analysis. However, previous studies have shown that with short 
incubation periods only two products were observed.
292
 This observation can be attributed to 
the instability of the resulting product that is slowly decomposing. Another eight secondary 
products in trace amounts are observed in the chromatogram (Figure 54). 
 
 
Figure 54. Gas chromatogram of the pentane extractable products obtained from incubation 
of 14F-FDP (291) and GDS.  
 
The mass spectrum of the peak eluting at 25.5 min (Figure 54C) displays a signal at m/z = 
220 (Figure 55C), the mass matches the presence of fluorinated dehydrogermacrene D. It has 
been suggested that the formation of the new double bond occurs during the ionisation of the 
sample in the chamber of the mass spectrometer.
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 The molecular ion is m/z = 159 and  
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corresponds to the loss of the isopropyl group and the loss of HF at the same time. The 
overall shape of the mass spectrum resembles the shape of (-)-germacrene D hence most 
probable product is 14F-germacrene D (341). The mass spectrum of the two peaks eluting at 
21.8 min and 23.5 min is very similar and both display a molecular mass of m/z = 202, this 
molecular mass denotes loss of HF (Figures 55A and 55B).    
 
 
Scheme 97. Structure of 14F-germacrene D (341). 
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Figure 55. A) Mass spectrum of the product eluting at 21.8 min. B) Mass spectrum of the 
product eluting at 23.5 min. C) Mass spectrum of the product eluting at 25.5 min. 
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Preparative incubation allowed analysis by 
1
H NMR and 
19
F NMR spectroscopy of the 
products. The 
19
F NMR spectrum displays three absorptions at -73.45 (t, J = 9.5 Hz), -178.9 
(d, J = 48.5 Hz) and -183.3 (d, J = 49.7 Hz) ppm. The three absorptions observed by 
19
F 
NMR spectroscopy confirm that the three products obtained from the incubation contain a 
fluorine atom and the loss of HF observed in the mass spectrum happened in the mass 
spectrometer.  
Unfortunately, the three major products of the incubation could not be separated and the 
complexity of the spectrum made the full identification of each product difficult. However, 
the comparison of this spectrum with 
1
H NMR spectrum of pure (-)-germacrene D (78, 
Figure 41) revealed two set of signals that could correspond to the expected germacrene D 
derivative. The doublet at 5.80 ppm (d, J = 15.6 Hz, Hb’) appears at the same chemical shift 
as in the (-)-germacrene D spectrum (Figures 41 and 56). The doublet at 5.43 ppm (Ha, Figure 
56) is the equivalent to the doublet of doublet that is found at 5.15 ppm for (-)-germacrene D 
(Figure 41), the signal has been shifted downfield due to the presence of the fluorine atom, 
which also broadens the signals and the final shape is an apparent doublet. The doublet of 
doublets at 5.26 ppm (dd, J = 16.0, 9.9 Hz, Hc, Figure 56) has also a similar chemical shift as 
for (-)-germacrene D. Another set of signals that can be attributed to 14F-germacrene D is 
displayed as a doublet at 5.90 ppm (d, J = 31.8 Hz, Hb), doublet of doublets at 4.80 ppm (dd, 
J = 38.6, 20.0 Hz, Hc) and doublet at 4.58 ppm (d, J = 17.3 Hz Hd) (Figure 56). 
In addition, two signals are observed that correspond to the CH2F, appearing as singlets at 
2.20 and 1.56 ppm. Both signals are shifted down field in comparison with the parent (-)-
germacrene D, which is in agreement with the presence of the fluorine (Figure 56). 
 
177 
 
 
Figure 56. 
1
H NMR (600 MHz, CDCl3) spectrum obtained from the preparative incubation 
of 14F-FDP (291) and GDS. 
 
4.3.9 Quantification of enzymatic products of GDS 
As it has been mentioned for GAS, all products obtained from the incubation of GDS and 
FDP analogues were quantified using GC-FID by comparison with internal standards (-
humelene). These experiments allowed an estimation of the enzymatic conversion and allow 
comparison with FDP (17). 
6F-FDP (289, Table 13, entry 2) and 14Me-FDP (137, Table 13, entry 3) present 
approximately half of the conversion in comparison with FDP (17, Table 13, entry 1). These 
two analogues present the highest capability as substrates, which is linked to the fact that they 
are the only two analogues, which give a single product. 14F-FDP (291, Table 13, entry 4) 
displays high conversion but lower than 6F-FDP (289, Table 13, entry 2) and 14Me-FDP 
because of the instability of the obtained product. 15Me-FDP (138, Table 13, entry 6) and 
14,15diMe-FDP (139, Table 13, entry 7) gave complex mixtures of compounds and in 
consequence the efficiency of the enzyme is low, which explains why was not possible to 
obtain the NMR spectrum. 
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Entry Substrate Conversion (%) Conversion relative 
to FDP (%)
a 
1 FDP (17) 76 100 
2 6F-FDP (289) 38 50 
3 14Me-FDP (137) 45 59 
4 14F-FDP (291) 33 43 
5 14,15-diMe-FDP 
(139) 
2.3 3 
6 15Me-FDP (138) 2.4 3.2 
a) Conversion normalised to 100% conversion with FDP.  
Table 13. Conversions of FDP (17) and FDP analogues with GDS. 
 
4.3.10 Conclusions 
The GDS incubation of 14Me-FDP (137) and 6F-FDP (289) gave single products 
characterised as 14Me-germacrene D (338, Scheme 94) and 6F-germacrene D (340, Scheme 
97), respectively. As in the case of GAS, these two analogues 14Me-FDP (137) and 6F-FDP 
(289) display the highest substrate activities. 
12Me-FDP (136) gave two major products: one of them was identified as a 12Me-
germacrene D (335, Scheme 93) by its mass spectrum (Figure 44) and the identity of the 
second major product is unknown but it is suggested as a possible isomer of 12Me-
germacrene D. The minor products are still unidentified. 
14,15-DiMe-FDP (139) and 15Me-FDP (138) gave in both cases one product that can be 
identified by its mass spectrum as a 14,15-diMe-germacrene D (339, Scheme 95) and 15Me-
germacrene D, respectively, and secondary products display with very similar mass spectrum 
between the two analogues (Figures 49 and 50). The identity of the secondary products is still 
unknown. 
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14F-FDP (291) gave a mixture of three compounds: one of them has been previously 
identified as a decomposition product. The major product was identified as the 14F-
germacrene D (341, Scheme 97).  
8nor-FDP (140) proved the ability of GDS to induce 1,11 cyclisation giving the same product 
as GAS when incubated with 8nor-FDP (140). 
 
4.4 (+)--Cadinene synthase from Gossypium arboreum 
4.4.1 Incubation of 10F-FDP (290) with DCS 
The single product obtained from the incubation of 10F-FDP (290) and DCS was the same 
product previously characterised from the incubation of GAS with 10F-FDP (290) namely 
10F--humelene (300). 10F--humulene (300) arose from a 1,11-macrocyclisation triggered 
by the presence of the fluorine atom. The fact that the DCS generates the same product as 
GAS (enzyme that operates through 1,10-cyclisation) supports the proposed 1,10-cyclisation 
catalytic mechanism for this enzyme. 
 
4.4.2 Incubation with 8nor-FDP (140) with DCS 
The GC-MS analysis of the pentane extractable products of the incubation of 8nor-FDP (140) 
with DCS indicated a complex mixture of products, with the major product eluting at 19.8 
min. The rest of the products were found in trace amounts and their identity is unknown 
(Figure 57). The comparison of the gas chromatogram with the corresponding gas 
chromatogram of the authentic sample of 8-nor-farnesene (Figure 40B) ruled out any of the 
8-nor-farnesenes.   
The mass spectrum of the major product shows similarities with the mass spectrum obtained 
from the incubation of GAS and GDS (Figure 31 and 51) with 8nor-FDP (140). Indeed, the 
fragmentation pattern is identical and the only difference observed is the intensity of some 
peaks (Figure 57). The different retention time and the similarities in the mass spectrum 
could indicate a isomeric relationship between the products.    
 
180 
 
 
Figure 57. Gas chromatogram of the pentane extractable products obtained from incubation 
of 8nor-FDP (140) and GDS. Inset, mass spectrum of product eluting at 19.832 min.    
 
The first steps of the mechanism proposed for DCS (involving a 1,10-cyclisation) led to 
germacradienyl cation (Chapter 1, Scheme 21, 97). The same intermediate has been proposed 
for the formation of (+)-germacrene A and (-)-germacrene D by GAS and GDS respectively 
(Chapter 1, Scheme 9 and 16, 49 and 76). However, the germacradienyl cation generated by 
DCS is proposed to have a cis conformation of the C2,C3-double bond due to a previous 
isomerisation of the FDP (17) into NDP (Scheme 20, 95).
293
 The isomerisation of 8nor-FDP 
(140) will give the intermediate 8nor-NDP (342), the 1,10-attack of the distal double bond 
will afford the unstable intermediate 343. Subsequent hydride shift affords the stable 
carbocation 344. Quenching of this carbocation by the loss of the proton on C13 will yield 
the transoid 8nor--humulene (345) which is in agreement with the observed mass spectrum 
and the retention time. 
181 
 
 
Scheme 98. Mechanism for the formation of the proposed product for the incubation of 8nor-
FDP (140) and DCS. 
 
The formation of product 345, which arises from a macrocyclisation of the distal double bond 
and is similar to the products obtained with enzymes that operates using the 1,10 cyclisation, 
agrees with the proposed mechanism involving a 1,10 cyclisation for DCS (Chapter 1, 
Scheme 21).   
 
4.4.3 Incubation of 8OH-FDP (141) with DCS 
The incubation of the 8OH-FDP (141) led to one major compound with signal at m/z = 218.9, 
and minor compounds with same m/z. Two different compounds were isolated from the 
mixture by preparative TLC and chemical structures that were in agreement with the NMR 
spectroscopic studies for each compound were proposed. 
The less polar compound (major product) was analysed by 
1
H NMR and 
13
C NMR 
spectroscopy. The 
13
C NMR spectrum displays a signal at 214.5 ppm, which strongly 
suggests that the hydroxyl group has been transform to a ketone. The structure proposed for 
this compound is the keto -cadinene derivative (346). 2D NMR spectroscopic studies were 
performed to confirm this hypothesis (Table 14). 
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Scheme 99. Structure of the main product obtained from the incubation of DCS with 8OH-
FDP (141). 
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1
H NMR 
13
H NMR 
(HSQC, DEPT-
135) 
HMBC 
(Correlation) 
COSY 
(Correlations) 
Assignment / C-
number (346) 
- 214.5 - - 1 
- 134.8 7, 8 or/and 14
* 
- 6 
5.54 (bd, J = 4.0 
Hz, 1H) 
123.2 8 or/and 14
*
  4, 7 (weak) and 
14 
5 
2.75 (dq, J1 = J2 = 
6.5 Hz, 1H) 
48.0 2 and 15  9 and 15 10 
2.31 (m, 1H) 39.2 - 3 4 
2.22 – 2.12 (m, 
2H) 
40.2 (CH2) / 43.9 4, 3, 10 (all weak) 
/ 10 and 15 
3 / 8 and 10 2 (1H) / 9 
2.09 (t, J = 13.0 
Hz, 1H) 
40.2 (CH2) 3, 4(weak), 10, 
11(weak) 
3 2 (1H) 
2.03 (qd, J = 7.0 
3.0 Hz, 1H) 
27.2 12 and 13 12 and 13 11 
1.99 – 1.94 (bd, 
2H, J = 6.5 Hz) 
31.0 (CH2) 5 (weak), 8
 
 8 and 14 (weak) 7 
1.83 – 1.75 (m, 
1H) 
47.5 2, 12 and 13 2, 4 3 
1.66 (s, 4H) 23.8 / 18.9 (CH2) 5 / 10 4 and 7  / 7 and 9  14 / 8 (1H) 
1.19 – 1.10 (m, 
1H) 
18.9 (CH2) 10 7, 8 and 9 8 (1H) 
1.01 (d, J = 7.0 
Hz, 3H) 
11.5 10 10 15 
0.89 (d, J = 7.0 
Hz, 3H) 
15.1 12 11 13 
0.86 (d, J = 7.0 
Hz, 3H) 
21.4 13 11 12 
Table 14. Correlation of 
1
H NMR and 
13
C NMR spectrum signals observed by HSQC, 
HMBC and COSY and the assignment of each signal to proton and carbon atoms, 
respectively.  
*The two signals overlap, therefore, it is not possible to distinguish between the effect in one signal from the 
other. 
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The isopropyl group is easily recognised from the two doublets up field at 0.86 and 0.89 ppm 
respectively, also, the same coupling constant suggests that they are coupled to the same 
proton, which is confirmed by the presence of correlations in the HMBC spectrum. However, 
the correlation between these two methyl groups and the neighbouring proton on C11 was not 
observed in the HMBC experiment, it was clearly observed in the COSY. Signal of proton on 
C3 was assigned through its correlations observed in the HMBC with signals of protons on 
C12, C13 and COSY correlation with protons on C4 and C2. The resonance in the 
1
H NMR 
spectrum of the protons on C2 is splitted in two different signals due to the proximity of the 
chiral isopropyl group. The signal up field has a strong HMBC correlation with signals of the 
protons on C3 and C10. In addition, it displays a modest correlation with protons on C11 and 
C4. This assignation was also confirmed by the single COSY correlation with proton on C3. 
Only one interaction in the COSY was observed in the case of proton on C4, the strong 
correlation of this proton with proton on C3 allowed the assignation. The doublet assigned to 
protons on C15 displays a correlation in both experiments with proton on C10. Signal of 
proton on C10 correlates in the HMBC with protons on C2 and C15 and in addition COSY 
correlation with protons on C9 and C15 supports the assignation. Assignation of the proton 
on C9 was confirmed by HMBC correlation with protons on C10 and C15 COSY correlation 
with protons on C8 and C10 gives further support for the assignation. The signal in the 
1
H 
NMR spectrum of methyl group 14 is easily recognised as being a singlet at 1.66 ppm. The 
integration of this signal and interactions in the HSQC suggest that another signal is 
overlapping on in this signal. Protons on C8 are splited in two different signals due to the 
proximity to the chiral proton on C9. One of these two protons is overlapping with protons on 
C14. The COSY correlation with protons on C7 and C9 unequivocally supports the 
assignation. The HMBC correlation of the CH2 signal of protons on C7 with the methyl group 
14 and COSY correlation with protons on C8 supports the assignation.  
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Figure 58. Expansion of the HMBC spectrum of compound 346 between 2.9 and 0.8 ppm 
(
1
H axis) and between 65 and 10 ppm (
13
C axis). 
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Figure 59. COSY spectrum of compound 346. Expansion of the COSY spectrum of 
compound 346 between 2.9 and 0.7 ppm (
1
H axis) and between 3.0 and 0.8 ppm (
1
H axis). 
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The relative stereochemistry of ketone 346 was determined by NOE measurements. The 
saturation of the signal at δH = 1.01 ppm, corresponding to the methyl group on C15, led to a 
modest enhancement on signal at δH = 1.83-1.75 ppm corresponding to proton on C3. In 
addition, the lack of any NOE interaction between the proton on C3 and the methyl on C15, 
suggest a syn geometric relation between these two functional groups. The saturation of the 
signal at δH = 2.12 ppm, corresponding to the proton on C9, led to an enhancement on signals 
δH = 0.89 ppm (4%) and δH = 5.54 ppm (1%) corresponding to protons on C12 and C5, 
respectively. In addition, the saturation of signal at δH = 2.31 ppm led to NOE enhancement 
of signal at δH = 0.9 ppm (2%), corresponding to protons on C12. Similarly to the previous 
case, these interactions indicate the syn relation between protons on C9 and C4 of the 
isopropyl group. Hence, the protons on C9 and C4 as well as the isopropyl group have a syn 
relation, therefore, they have an anti geometrical relation with the methyl group on C15. 
Hence, there are two different possibilities for the absolute configuration of ketone 346. 
 
Scheme 100. NOE saturation effect observed and possible stereoisomers. 
 
The stereochemistry of -cadinene has been studied and is well established.294 Assuming that 
the stereochemistry of the protons on C3 and C4 is the same that the enzyme induces when 
incubated with FDP, the most probable stereochemical configuration for the product is 
represented in 346.   
The more polar compound, which is the minor product of the incubation, was isolated in 
small amounts that were insufficient to study by 
13
C NMR. The polarity of the product 
suggests that it could be the corresponding 8-hydroxyl -cadinene (349) derivative.  
188 
 
 
Scheme 101. Secondary product of the incubation of 8OH-FDP (141) with DCS. 
 
The product was identified by comparing the recorded spectrum with the previously 
published 
1
H NMR spectrum of -cadinene.295, 296 Resonances present in the 1H NMR 
spectrum of the unknown compound at 5.45, 2.62, 2.46, 2.09, 2.03, 1.68, 0.98 and 0.79 ppm 
were similar to the corresponding resonances observed for -cadinene. In addition, previously 
published NMR spectroscopic data of a -cadinene triol derivative, display a chemical shift 
of 4.05 ppm for the analogous proton on C1, while a chemical shift of 3.97 ppm was 
observed in compound 349.
297
 Unfortunately, the signal corresponding to the neighbour CH2 
was not found in the spectrum probably because the signal is overlapped with some of the 
impurities present in the spectrum. The resonance at 5.30 ppm was the expected signal for the 
proton on the hydroxyl group of 349.   
In the case of ketone 346, the proximity of the hydroxyl group to one of the carbocations 
formed during the catalysis of DCS disrupted the mechanism in the last step by giving a 
lower energy path through the tertiary carbocation (351, Scheme 102) to 346. However, not 
all the substrate has been transformed into ketone 346 and part of the compound has been 
transformed into the corresponding cadinene hydroxyl derivative 349. A closer look to the 
1
H 
NMR spectrum of the ketone 346 reveals that in the aliphatic region signals for the isopropyl 
have small duplicate signals. This suggests that the two enantiomers of the 8OH-FDP (141) 
are not converted at the same rate, producing different ratios of two diastereoisomers.  The 
hydride shift necessary for the transformation of the hydroxyl group into a ketone (Scheme 
102, 351, path a) can be slow enough for one of the isomers to give time for the removal of 
the hydrogen to take place (Scheme 102, 349, path b). This elimination led to the formation 
of a small amount of the hydroxyl derivative 349 (Scheme 102).  
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Scheme 102. Proposed mechanism for the formation of the ketone 446 and alcohol 449. 
 
Although the products obtained do not provide any information to distinguish between the 
two different mechanism proposed (1,10 or 1,11 cyclisation, Scheme 21) for DCS, it reveals 
the previously unknown stereochemistry of the proton on C9. The stereochemistry of the 
proton in this position could not be determined because the proton is removed during 
catalysis and there are no tools to observe the carbocationic intermediate formed within the 
enzyme. Therefore, the FDP hydroxyl derivative provided us with a new tool to trap these 
intermediates in the form of carboxyl derivatives, thus allowing us to determine the 
stereochemistry of the intermediate. Remarkably, this is the first example in which a terpene 
cyclase is able to convert an alcohol into a ketone, this new ability opens new possibilities for 
the use of terpene synthases as synthetic tools. 
 
4.4.4 Conclusions 
10F-FDP(290), 8nor-FDP (140) and 8OH-FDP (141) were designed to distinguish between 
the two different mechanisms proposed in the literature for DCS one involving a 1,6 
cyclisation and other involving a 1,10 cyclisation mechanism (Chapter 1, Scheme 21).
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The incubation of 10F-FDP (290) gave 10F--humelene (300) as single product, as it was 
obtained when incubated with GAS. The ability of this enzyme to induce a 1,11-cyclisation 
has been observed before only in enzymes that operate with a 1,10-cyclisation mechanism. 
190 
 
Therefore, this result suggests that this enzyme is more likely to use the 1,10-cyclisation 
rather than the 1,6-cyclisation pathway. 
Similarly, the incubation of 8nor-FDP (140) with DCS gave a product containing a ten 
member ring 345 (Scheme 98), which supports the idea that DCS operates by 1,10 
cyclisation. 
Ketone 346 and alcohol 349 obtained in the incubation of 8OH-FDP (141) do not provide any 
information about the mechanism of cyclisation by DCS, but they allowed the study of an 
intermediate that was not studied before uncovering the stereochemistry induced by the 
enzyme. 
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Chapter 5 
General conclusions 
 
 
 
 
 
 
 
 
 
192 
 
5. General conclusions 
A variety of alkyl and fluorine substituted analogues of farnesyl diphosphate (FDP) were 
synthesised using mostly well-established methodologies. In addition, novel synthetic 
protocols were developed to prepare hydroxy and nor analogues of FDP, the latter sequence 
featuring addition of a cuprate to a highly unstable allylic bromide. 
Although alkyl-modified FDP analogues have been used as inhibitors and alternative 
substrates surrogates for class I prenyl transferases, their competency under catalysis by 
sesquiterpene synthases was little known prior to this study. This research demonstrates for 
the first time that methylated FDPs are good/excellent substrates of sesquiterpene synthases 
effecting catalysis via initial 1,10-cyclisation of native FDP. The resulting C16 homo 
germacrenoids were all characterised by NMR spectroscopy and GC-MS spectroscopy. This 
work was further extended to the production of several fluoro-germacrenoids via enzymatic 
turnover of the corresponding fluorinated FDPs.  
Even though terpene synthases catalyse mechanistically complex carbocationic reactions, 
often leading to polycyclic products with spectacular 3D chemical architectures, their low 
turnovers numbers together with the instability and volatility of their products have largely 
prevented their use as biocatalysts in purely synthetic efforts. Recent advances in metabolic 
engineering and synthetic biology have rendered engineered microbes capable of producing 
natural sesquiterpenoids (e.g. artemisinin) in industrial scale quantities.
264
 However, these 
sustainable approaches do not yet support the production of non-canonical terpenes. Against 
this backdrop, a substantial part of this project was devoted to find novel methodologies for 
the in vitro production of unnatural terpenoids. In this project two alternative procedures are 
developed, (1) batch incubations and extraction with deuterated solvents,
243
 and (2) 
incubation and extraction in continuous flow,
298
 that allow production of highly valuable 
fluorinated and C16 homo sesquiterpenoids in the amounts needed for in vivo testing 
(Rothamsted Research) and NMR spectroscopic characterisation.   
In addition, two novel mechanistic probes containing hydroxy groups, were designed to act as 
active site carbocationic traps, and prepared to re-investigate the reaction mechanism for the 
putative dual 1,10/1,6-cyclase(+)--cadinene synthase (DCS).136 This mechanistic study was 
carried out following the newly developed extraction protocol with deuterated solvents. 
Direct NMR spectroscopic analysis of the enzymatic product supports a pure 1,10-cyclisation 
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for DCS. Furthermore, the stereochemistry of the final cadinene cation intermediate was for 
the first time revealed by NOE and 2D NMR spectroscopic techniques. 
The improved methodology in continuous flow has opened the possibly of utilising terpene 
synthases as biocatalysts to obtain and in situ functionalise natural/unnatural terpenes. 
Nevertheless, issues in scaling up the enzymatic reactions must be addressed on the future. 
Different techniques such as immobilisation of terpene synthases on a solid phase within a 
flow reactor, or batch incubations combined with supercritical CO2 extractions of the volatile 
products, can be tested to further improve the methodology.   
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CHAPTER 6 
DETAILED EXPERIMENTAL PROCEDURES 
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6. Synthetic procedures 
6.1 General synthetic procedures 
All chemicals were purchased from Sigma-Aldrich, Acros Chemicals or Alpha Aesar unless 
otherwise stated. Anhydrous tetrahydrofuran, diethyl ether, toluene, acetonitrile, hexane, 
dimethylformamide and dichloromethane were dried using molecular sieves (3 Å), previously 
activated at 200 ºC for at least 24 h
299
 or were obtained from a MBraun SPS800 solvent 
purification system. Reactions were performed under N2 atmosphere unless otherwise stated. 
Glassware was cleaned and dried at 200 ºC for at least for 16 h before use.  
1
H NMR and 
13
H NMR spectrum were measured on a Bruker Avance 500 NMR 
spectrometer, Bruker Avance DPX400 spectrometer, Bruker Fourier 300 and a Bruker DPX 
250 spectrometer. 
1
H NMR spectrum are reported as chemical shifts in parts per million 
downfield from tetramethylsilane, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, bs = broad singlet, bd = broad doublet), coupling constant, integration 
and assignment, respectively. All the coupling constants are reported in Hz. 
13
C spectrum are 
reported as chemical shift downfield from tetramethylsilane. Assignments are made to the 
limitations of COSY, DEPT 90/135, gradient HSQC and gradient HMBC spectrum. 
19
F and 
31
P NMR spectrum were recorded on a Jeol Eclipse +300 NMR spectrometer or Bruker 
Avance 500 NMR spectrometer and are reported in chemical shift downfield from CFCl3 and 
85% H3PO4 respectively followed by multiplicity and coupling constant in Hz if appropriate. 
IR spectrum were recorded on a Perkin-Elmer 1600 series FTIR spectrometer and samples 
were prepared as thin films of neat liquid on potassium bromide discs (st = stretching) EI
+
 
mass spectrum were measured on a Micromass LCT premiere XE mass spectrometer. ES
-
 
mass spectrum were measured on a Micromass LCT premiere XE spectrometer fitted with a 
Waters 1525 Micro binary HPLC pump. Reverse phase HPLC was performed on a system 
comprising of a Dionex P680 pump and a Dionex UVD170U detector unit. GCMS was 
performed on a Hewlett Packard 6890 GC fitted with a J&W scientific DB-5MS column (30 
m x 0.25 mm internal diameter) and a Micromass GCT Premiere detecting in the range m/z 
50-800 in EI+ mode with scanning once a second with a scan time of 0.9 s. Injections were 
performed in split mode (split ratio 5:1) at 50 °C. Chromatograms were begun with an oven 
temperature of 50 °C rising at 4 °C min-1 for 25 min (up to 150 °C) and then at 20 °C min-1 
for 5 min (250 °C final temperature). 
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Flash column chromatography refers to the procedure of Still
300
 and vacuum chromatography 
was performed according to the method of Green.
301
 All reactions and separations were 
monitored by thin layer chromatography using pre-coated aluminium plates of silica 
G/UV254 (Fluka) TLC. TLC plates were visualised with UV light (254 nm) and TLC stain 
solution: CAM (40g of ammonium pentamolybdate + 1.6 g of cerium(IV) sulfate + 800ml of 
diluted sulfuric acid (1:9, with water, v/v)) or phosphomolybdic acid (10% solution in EtOH).  
Ion exchange resin DOWEX 40-W was received from Aldrich in H
+
 form. The resin was 
converted into ammonium form by continuous washing with concentrated NH4OH over 24 h 
and equilibrated with ion-exchange buffer (25 mM NH4HCO3 containing 2% i-PrOH). After 
use, the resin was regenerated by washing with aqueous HCl solution (5 M), water, 
concentrated NH4OH and equilibrated with ion exchange buffer. Amberlyst (A26, H
+
 form) 
was regenerated after use by thorough washing with  NaOH solution (0.1 M), water and 
aqueous HCl solution (1 M) respectively. 
Diphosphates were prepared from the corresponding alcohols using a modification of the 
procedure described by Davisson.
302
  
 
6.2 Synthesis of 14Me-FDP (137) 
6.2.1 Preparation of ethyl 7-methyl-3-oxo-oct-6-enoate (133) 
 
 
To a suspension of NaH (1.6 g 60% in mineral oil, 40.0 mmol) in anhydrous THF (33 mL) at 
0 ºC ethyl acetoacetate (3.12 g, 24.0 mmol) and then n-Buli (16.2 mL, 2.2 M in hexanes, 35.6 
mmol) were added. This solution was stirred for a further 30 min then a cooled solution of 
3,3-dimethylallyl bromide (3.0 g, 20.0 mmol) in anhydrous THF (10 mL) was added via 
syringe. The reaction was quenched by the addition of saturated aqueous NH4Cl solution (20 
mL). Organic material was extracted with hexane (3 x 15 mL) and the combined organic 
extracts were washed with water (3 x 20 mL), brine (3 x 20 mL), dried over MgSO4 and 
concentrated under reduced pressure. Purification was performed by flash chromatography on 
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silica gel using a mixture of hexane and ethyl acetate (gradient of solvents from 20:1 to 10:1) 
as eluent. The compound was isolated as yellow oil (3.2 g, 80%).   
HRMS EI
+ 
[M
+
] found 198.1256, C11H18O3 requires 198.1256. IR KBr (cm
-1
) 2979 (C-H st), 
2916 (C-H st), 2360, 2342, 1746 (C=O st), 1717 (C=O st), 1646 (C=C st), 1446 (C-O st), 
1410, 1367, 1313, 1236, 1178, 1096, 1039. 
1
H NMR (400 MHz, CDCl3) δ 5.03 (s, 1 H, 
C=CH), 4.16 (q, J = 7.0, 2 H, OCH2CH3), 3.40 (s, 2 H, O=CCH2C=O), 2.53 (t, J = 7.0, 2 H, 
CH2CH2C=O), 2.25 (dd, J = 14.0, 7.0, 2 H, C=CHCH2), 1.64 (s, 3 H, CHCH3), 1.58 (s, 3 H, 
CHCH3), 1.25 (t, J = 7.0, 3 H, OCH2CH3).
13
C NMR (101 MHz, CDCl3) δ 202.7 (C=O), 
167.3 (C=OOEt), 133.2 (C=CH), 122.3 (C=CH), 61.4 (C=OCCH2), 49.5 (C=OCH2COOEt), 
43.1 (CH2), 25.7 (CH2), 22.3 (OCH2CH3), 17.7 (CH3C=CH), 14.2 (CH3C=CH). 
 
6.2.2 Preparation of (3Z)-1-ethoxycarbonyl)-6-methylhepta-1,5-dien-2-yl 
trifluoromethanesulfonate (159) 
 
 
To a stirred solution of 133 (2.9 g, 14.7 mmol) in anhydrous DCM (440 mL) at 0 ºC, lithium 
trifluoromethane sulfonate (2.8 g, 17.7 mmol) and triethylamine (2.6 mL, 18.7 mmol) were 
added. After 1 h, trifluoromethane sulfonic anhydride (5.0 g, 17.7 mmol) was added to the 
solution and the resulting orange solution was stirred at this temperature for 1 h. The reaction 
was quenched by the addition of saturated aqueous NH4Cl solution (70 mL).  Organic 
material was extracted with DCM (3 x 40 mL) and the combined organic extracts were 
washed with saturated aqueous NaHCO3 solution (3 x 100 mL) and brine (3 x 100 mL), dried 
over MgSO4 and concentrated under reduced pressure. The crude product was purified by a 
flash chromatography column on silica with a mixture of hexane and ethyl acetate (30:1) as 
eluent. The compound was isolated as yellow oil (4.0 g, 83%).     
IR: KBr (cm
-1
) 2917 (C-H st), 2360, 2342, 1733 (C=O st), 1683 (C=C st), 1428 (C-F st), 
1370 (C-O st), 1206 (S=O st), 1142, 1027, 923 (C=C-H). 
1
H NMR (250 MHz, CDCl3) δ 5.74 
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(s, 1H, C=OTfCHC=O), 5.04 (t, J = 6.0 , 1 H, (CH3)2C=CH), 4.24 (q, J = 7.0 , 2H, 
OCH2CH3), 2.45-2.33 (m, 2H, CHCH2CH2), 2.26 (dd, J = 14.0, 7.0 , 2H, CHCH2CH2), 1.70 
(s, 3H, HC=C(CH3)2), 1.61 (s, 3H, HC=C(CH3)2), 1.30 (t, J = 7.0 , 3H, OCH2CH3).
13
C NMR 
(101 MHz, CDCl3) δ 162.6 (C=O), 158.6 (CO), 134.6 (C=CH), 120.8 (C=CH), 112.1 
(COTfCHCOOEt), 61.3 (OCH2CH3), 34.6 (CH2), 25.7 (CH2), 24.6 (OCH2CH3), 17.7 
(CH3C=CH), 14.1 (CH3C=CH).
19
F NMR (300 MHz, CDCl3) δ -74.7.  
 
6.2.3 Preparation of (2E)-ethyl 3-ethyl-7-methylocta-2,6-dienoate (134) 
 
 
To a stirred suspension of CuI (9.2 g, 48.8 mmol) in anhydrous THF (140 mL) at 0 ºC, under 
argon atmosphere, ethyl magnesium bromide (16 mL, 3M, 48.8 mmol) was added. The 
resulting black solution was stirred for 30 min. Then the solution was cooled to -78 ºC and 
the triflate 159 (4.0 g, 12.2 mmol) was added. After 1 h the reaction was completed and was 
quenched by the addition of saturated aqueous NH4Cl solution (50 mL). The copper salts 
formed during the quench were dissolved by adding NH4OH (35%, 50 mL) to the biphasic 
mixture and gentle stirring for 1 h. The blue coloured aqueous layer was extracted with 
diethyl ether (3 x 50 mL). Combined organic extracts were washed with 10% aqueous 
NH4OH solution (3 x 100 mL), water (2 x 100 mL) and brine (3 x 100 mL). The organic 
material was dried over MgSO4 and concentrated under reduced pressure. The crude product 
was purified by flash chromatography with a mixture of hexane and ethyl acetate (gradient 
from 30:1 to 20:1). The title compound was isolated as yellow oil (3.3 g, 88%).
 
HRMS EI
+ 
[M] found 210.1615, C13H22O2 requires 210.1620. IR: KBr (cm
-1
) 2972 (C=C-H 
st), 2931 (C-H st), 2360, 2342, 1716 (C=O st), 1644 (C=C st), 1456, 1378 (C-O st), 1309, 
1274, 1205, 1144, 1039. 
1
H NMR (250 MHz, CDCl3) δ 5.54 (s, 1 H, (Et)C=C(CHC=OOEt), 
5.02 (s, 1 H,(CH3)2C=CH), 4.07 (q, J = 7.0, 2 H, OCH2CH3), 2.55 (q, J = 7.5, CH2CH3 2 H), 
2.09 (bs, 4 H, 2 x CH2), 1.62 (s, 3 H, HC=CCH3), 1.54 (s, 3 H, HC=CCH3), 1.21 (t, J = 7.0, 3 
H, OCH2CH3), 1.00 (t, J = 7.5, 3 H, CH2CH3). 
13
C NMR (63 MHz, CDCl3) δ 166.6 
(C=OOEt), 165.7 (EtCC=CH), 132.6 (C(CH3)2), 123.3 (CHC=OOEt), 114.9 (C=CH), 59.6 
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(OCH2), 38.1 (CH2), 26.4 (CH2), 25.8 (CH2CH3), 25.5 (OCH2CH3), 17.8 (CH3C), 14.4 
(CH3C), 13.1 (CH2CH3).  
 
6.2.4 Preparation of (E)-3-ethyl-7-methylocta-2,6-dien-1-ol (160) 
 
 
To a stirred solution of the ester 134 (2.3 g, 10.1 mmol) in anhydrous toluene (50 mL), 
diisobutylaluminiumhydride (1.5 M in toluene, 20.2 mL, 30.3 mmol) was added. The solution 
was kept at this temperature and stirred for 1 h. The reaction was diluted with DCM (30 m) 
and quenched by the addition of HCl (2M, 40 mL). This mixture was warmed up to room 
temperature and stirred vigorously for 16 h. The clear aqueous layer was extracted with DCM 
(3 x 50 mL), the combined organic extracts were washed with water (3 x 50 mL) and brine (3 
x 50 mL). The organic extracts were dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by flash chromatography column with a mixture of 
hexane and ethyl acetate (10:4) as eluent. The title compound was isolated as yellow oil (1.5 
g, 85%). 
HRMS EI
+ 
[M
+
 + Na] found 191.1412, C11H20ONa requires 191.1410. 
1
H NMR (250 MHz, 
CDCl3) δ 5.36 (t, J = 7.0, 1 H, C(Et)=CHCOH), 5.10 (m, 1 H, (CH3)2C=CH), 4.15 (d, J = 7.0, 
2 H, CH2OH), 2.06 (m, 6 H, 2 x CH2, CH2CH3), 1.68 (s, 3 H, CHCH3), 1.60 (s, 3 H, CHCH3), 
0.98 (t, J = 7.5, 3 H, CH2CH3). 
13
C NMR (63 MHz, CDCl3) δ 145.8 (C(Et)), 131.8 
((CH3)2C=C), 124.2 (CHCH2OH) , 122.9 (CH), 59.2 (CH2OH), 36.5 (CH2), 26.7 (CH2), 25.8 
(CH2CH3), 23.7 (CH2CH3), 17.8 (CH3CH), 13.8 (CH3CH). 
 
6.2.5 Preparation of (E)-1-bromo-3-ethyl-7-methylocta-2,6-diene (161) 
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To a stirred solution of the alcohol 160 (1.5 g, 9.1 mmol) in anhydrous THF (46 mL) at -45 
ºC was added a freshly distilled Et3N (2.5 mL, 18.3 mmol) and methanosulfonyl chloride (1.3 
g, 11.8 mmol). After 45 min LiBr (3.2 g, 36.7 mmol) was added, then the mixture was 
warmed to 0 ºC and left at this temperature for 1 h. The mixture was diluted with hexane (20 
mL) and quenched by the addition of saturated NH4Cl solution (20 mL). Organic material 
was extracted with hexane (3 x 20 mL), combine organic extracts were washed with saturated 
aqueous NaHCO3 solution (3 x 20 mL), water (3 x 20 mL) and brine (3 x 20 mL), dried over 
MgSO4 and concentrated under reduced pressure. The crude reaction was analysed by 
1
H 
NMR spectroscopy and used immediately in the next step without further purification. 
 
1
H NMR (400 MHz, CDCl3)  5.49 (t, J = 8.5, 1 H, CHCH2CBr), 5.09 (s, 1 H, 
(CH3)2C=CH), 4.04 (d, J = 8.5, 2 H, CH2Br), 2.26 -1.93 (m, 6 H, 2 x CH2, CH2CH3), 1.69 (s, 
3 H, CHCH3), 1.60 (s, 3 H, CHCH3), 1.04 (t, J = 7.5, 3 H,CH2CH3). Data in agreement with 
previously published data by Rawat et al.
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6.2.6 Preparation of (E)-ethyl 7-ethyl-11-methyl-3-oxododeca-6,10-dienoate 
(162) 
 
 
To a suspension of NaH (0.7 g 60% in mineral oil, 31.4 mmol) in anhydrous THF (24 mL) at 
0 ºC, ethyl acetoacetate (3.7 g, 28.6 mmol) was added and the solution was stirred for 20 min. 
Then n-Buli (2.2 M in hexanes, 13.4 mL, 29.5 mmol) was added and this solution was further 
stirred for 30 min. A cooled solution of the crude bromide 161 (2.2 g) in anhydrous THF (5 
mL) was added to the orange-red solution. After 1 h the reaction was quenched by the 
addition of saturated aqueous NH4Cl solution (15 mL). Organic material was extracted with 
hexane (3 x 15 mL) and the combined organic extracts were washed with water (3 x 15 mL) 
and brine (3 x 15 mL). The organic material was dried over MgSO4 and concentrated under 
reduced pressure. Purification was performed by flash chromatography column with a 
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mixture of hexane and ethyl acetate (gradient of solvents from 15:1 to 10:1) as eluent. The 
product was isolated as yellow oil (2.0 g, 78% yield). 
HRMS ES
+ 
[M-CO2Et] found 208.1836, C14H24O requires 208.1827. 
1
H NMR (400 MHz, 
CDCl3)  5.02-4.96 (m, 2 H, 2 x C=CH), 4.14 (q, 2 H, J = 7.0, C=OOCH2CH3), 3.36 (s, 2 H, 
C=OCH2C=O), 2.51 (t, J = 8.5, 2 H CH2CH2C), 2.25 (q, 2 H, J = 7.0, CH2CH3), 1.98-1.94 
(m, 6 H, 3 x CH2 ), 1.6 (s, 3 H, CCH3), 1.53 (s, 3 H, CCH3), 1.21 (t, J = 7.0 , 3 H, 
COOCH2CH3), 0.89 (t, J = 7.5 , 3 H, CH2CH3).
13
C NMR  (126 MHz, CDCl3) δ 202.5 
(C=OOEt), 167.2 (C=O), 142.7 (C=CH), 131.5 (C=CH), 124.4 (C=CH), 121.8 (C=CH), 61.4 
(C=OOCH2CH3), 49.5 (C=OCH2CO2Et), 43.5 (CH2CH3), 36.6 (CH2), 27.0 (CH2), 25.7 
(CH2), 23.3 (CH2), 22.0 (COOCH2CH3) , 17.8 (CCH3), 14.2 (CCH3), 13.2 (CH2CH3). 
 
6.2.7 Preparation of (1Z,5E)-1-(ethoxycarbonyl)-6-ethyl-10-methylundeca-1,5,9-
trien-2-yl diethyl phosphate (163) 
 
 
To a suspension of NaH (100 mg 60% mineral oil, 2.5 mmol) at 0 ºC in anhydrous diethyl 
ether (12 mL), 162 (0.5 g, 1.8 mmol) was added and the resulting solution was stirred for 20 
min. Diethyl chlorophosphate (0.5 g, 2.8 mmol) was added to the colourless solution. After 1 
h the reaction was quenched by the addition of saturated aqueous NH4Cl solution (5 mL). 
Organic material was extracted with diethyl ether (3 x 5 mL), combine organic extracts were 
washed with saturated aqueous NaHCO3 solution (3 x 10 mL) and brine (3 x 10 mL). The 
organic material was dried over MgSO4 and concentrated under reduce pressure. The crude 
was analysed by 
1
H NMR, judged sufficiently pure and used immediately without further 
purification. 
1
H NMR (500 MHz, CDCl3) δ 5.34 (s, 1 H, C=CHC=OOEt). 5.10-5.4 (m, 2 H, 2 x C=CH), 
4.31 – 4.19 (m, 4 H, (CH3CH2)2P=O), 4.14 (q, J = 7.0, 2 H, OCH2CH3), 2.45 (t, J = 7.5, 2 H, 
CH2), 2.28 (dd, J = 15.0, 7.0, 2 H, CH2), 2.10-1.98 (m, 6 H, 3 x CH2), 1.67 (s, 3H, CH3), 1.59 
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(s, 3H, CH3), 1.35 (t, J = 7.0, 6 H, (CH3CH2)2P=OO), 1.26 (t, J = 7.0, 3 H, OCH2CH3), 0.95 
(t, J = 7.5, 3 H, CH2CH3). 
 
6.2.8 Preparation of (2E,6E)-ethyl 7-ethyl-3,11-dimethyldodeca-2,6,10-trienoate 
(164) 
 
 
This methylation was performed according to the method described by Coates
303
. To a stirred 
suspension of CuI (1.4 g, 7.0 mmol) in anhydrous ether (7 mL) at 0 ºC under Ar atmosphere, 
MeLi (1.6 M in hexane, 9 mL, 14.4 mmol) was added. After 20 min the reaction mixture was 
cooled to -78 ºC and a solution of the compound 163 (1.1 g of crude) in anhydrous ether (7 
mL) was added via syringe over 5 min. After 2 h the reaction was warmed to -45 ºC and MeI 
(0.5 mL, 1.2 mmol) was added. The solution was stirred for another 45 min at this 
temperature. Reaction was quenched by the addition of saturated aqueous NH4Cl solution (8 
mL). The copper salts formed during quench were dissolved by diluting the reaction with 
ether and addition of NH4OH (35%, 50 mL), then the biphasic mixture was gentle stirred for 
1 h. Organic material was extracted from the blue colour aqueous layer with ether (3 x 20 
mL) and the combined organic extracts were washed with 10% aqueous NH4OH solution (3 x 
25 mL), water (3 x 25 mL), brine (3 x 25 mL), dried over MgSO4 and concentrated under 
reduced pressure. The crude product was purified by flash column chromatography with a 
mixture of hexane and ethyl acetate (10:1) as eluent. The product was isolated as yellow oil 
(0.3 g, 65%). 
HRMS ES
+ 
[M] found 278.2243, C18H20O2 requires 278.2246. 
1
H NMR (250 MHz, CDCl3) 
δ 5.72-5.60 (s, 1 H, CHC=OOEt), 5.16-4.96 (m, 2 H, 2 x C=CH), 4.10 (q, J = 7.0, 2 H, 
C=OOCH2CH3), 2.23-2.10 (bs, 6 H, 3 x CH2), 2.09-1.91 (m, 5 H, CH3C=CH, CH2), 1.73-
1.63 (s, 3 H, (CH3)2C=CH), 1.63-1.54 (s, 3 H (CH3)2C=CH), 1.24 (t, J = 7.0, 3 H, 
C=OOCH2CH3), 1.03-0.83 (t, J = 7.5, 3 H, CH2CH3). 
13
C NMR (63 MHz, CDCl3) δ 167.0 
(C=OOEt), 159.8 (C=CH), 142.1 (C=CH), 131.5 (C=CH), 124.5 (C=CH), 122.5 (C=CH), 
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115.7 (C=CH), 59.6 (OCH2CH3), 41.4 (CH2), 36.6 (CH2), 27.0 (CH2), 25.8(CH2), 23.3 
(CH3C=CH), 19.0 (CH3)2C=CH), 17.8 (CH3)2C=CH), 14.5 C=OOCH2CH3, 13.3 CH2CH3). 
 
6.2.9 Preparation of (2E, 6E)-7-ethyl-3,11-dimethyldodeca-2,6,10-trien-1-ol 
(165) 
 
 
To a stirred solution of the ester 164 (300 mg, 1.0 mmol) in anhydrous toluene (6 mL) at 
-78 ºC, diisobutylaluminium hydride (1.5 M, 2.3 mL, 3.4 mmol) was added. The mixture was 
stirred for 1 h. The mixture was diluted with DCM (20 mL) and quenched with HCl (2 M, 20 
mL). The biphasic mixture was stirred for 16 h at room temperature. Organic material was 
extracted with DCM (3 x 20 mL) and the pooled organic extracts were washed with brine (3 
x 40 mL), dried over MgSO4 and concentrated under reduce pressure. The crude product was 
purified by flash chromatography column using a mixture of hexane and ethyl acetate (2:1) as 
eluent. The title compound was isolated as yellow oil (150 mg, 60% yield). 
HRMS ES
+ 
[M] found 236.2118, C16H28O requires 236.2140. 
1
H NMR (250 MHz, CDCl3) δ 
5.48-5.35 (t, J = 7.5, 1 H, C=CH), 5.17-5.00 (m, 2 H C=CH, C=CHCH2OH), 4.22-4.09 (d, 2 
H, CH2OH), 2.22-1.93 (m, 10 H, 4 x CH2, CH2CH3), 1.72-1.65 (bs, 6 H, (CH3)2C=C, 
CH3C=C), 1.63-1.57 (s, 3 H, (CH3)2C=C), 1.02-0.89 (t, J = 7.5, 3 H, CH3CH2).
 13
C NMR (63 
MHz, CDCl3) δ 141.4 (C=CH), 139.9 (C=CH), 131.4 (C=CH), 124.6 (C=CH), 123.5 
(C=CH), 123.4 (C=CH), 59.5 (CH2OH), 40.0 (CH2CH3), 36.6 (CH2), 27.1 (CH2), 26.1 (CH2), 
25.8 (CH2), 23.3 (CH3C=C), 17.8 ((CH3)2=C), 16.4 ((CH3)2=C), 13.4 (CH3CH2). 
 
6.2.10 Preparation of (2E,6E)-7-ethyl-3,11-dimethyldodeca-2,6,10-trien-1-yl acetate 
(352) 
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To a stirred solution of alcohol 165 (15 mg, 0.06 mmol) in DCM (1 mL) at room temperature 
in an open flask, pyridine (20 μL, 0.25 mmol) and acetic anhydride (18 μL, 0.2 mmol) were 
added. The mixture was stirred overnight. The reaction was diluted with DCM (12 mL) and 
quenched by the addition of 10% HCl aqueous solution (8 mL). Organic material was 
extracted with DCM (2 x 15 mL), combined organic extracts were washed with saturated 
NaHCO3 aqueous solution (3x 10 mL), brine (3 x 20 mL), dried over Na2SO4 and solvent was 
removed under reduce pressure. The crude product was purified by clash chromatography 
column with mixture of hexane and ethyl acetate (40:1) as eluent to afford the product as pale 
yellow oil (16 mg, 90%). 
HRMS EI
+
 [M] found 278.2250, C18H30O2 requires 278.2246.
 1H NMR (400 MHz, CDCl3) δ 
5.35 (t, J = 8.0, 1H, C=CH), 5.08 (m, 2 H, 2 x C=CH), 4.59 (d, J = 7.0, 2 H, CH2OAc), 2.22 – 
1.93 (m, 13 H, 5 x CH2, OC=OCH3), 1.70 (s, 3 H, CH3), 1.68 (s, 3 H, CH3), 1.60 (s, 3 H, 
CH3), 0.95 (t, J = 7.5, 3 H, CH2CH3).
13
C NMR (63 MHz, CDCl3) δ 171.3 (OC=OCH3), 
141.5 (C=CH), 139.7 (C=CH), 131.4 (C=CH), 124.6 (C=CH), 123.3 (C=CH), 118.4 (C=CH), 
61.5 (CH2OAc) , 40.7 (OC=OCH3), 40.0 (CH2), 36.6 (CH2), 27.1 (CH2), 25.8 (CH2), 23.3 
(CH2), 21.2 (CH3), 17.8 (CH3), 16.6 (CH3), 13.4 (CH3). 
 
6.2.11 Preparation of a mixture of (E)-β -, (Z)-α - and (E)- α- 14Me-farnesenes 
 
 
The following procedure is similar to the one reported by Keinan.
304
 To a stirred solution of 
acetate 352 (10 mg, 0.04 mmol) in anhydrous THF (1 mL) at room temperature, 
Tetrakis(triphenylphosphine)palladium (5 mg, 0.005 mmol) was added and the solution was 
stirred for 4 h. Reaction mixture was diluted in hexane (3 mL). The resulting solution was 
passed through short pad of silica. Farnesene mixture was eluted with hexane (5 mL) and 
solvent was removed by continuous evaporation with stream of N2 to afford the title mixture 
of compounds (3 mg, 38%). The oil was dissolved in pentane and analysed by GC-MS. 
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6.2.12 Preparation of (2E,6E)-1-tris-(ammonium)-diphosphate -7-ethyl-3,11-
dimethyldodeca-2,6,10-triene (137) 
 
 
To a stirred solution of the alcohol 165 (150 mg, 0.6 mmol) in anhydrous DMF (8 mL) at 
0 ºC, S-collidine (0.5 mL, 3.8 mmol) and methanesulphonyl chloride (0.07 mL, 0.9 mmol) 
were added sequentially. After 20 min of stirring at this temperature, lithium chloride (0.4 g, 
9.6 mmol) was added to the solution. After 2 h the milky solution was quenched by the 
addition of cold water (6 mL). The biphasic mixture was diluted with pentane. Organic 
material was extracted with pentane (3 x 5 mL), organic extracts together were washed with 
saturated aqueous CuSO4 solution (3 x 15 mL), water (3 x 15 mL), saturated aqueous 
NaHCO3 solution (3 x 15 mL), dried over MgSO4 and concentrated under reduced pressure. 
The crude was used in the next step without further purification. 
Tris-(tetrabutylammonium) hydrogendiphosphate (1.2 g, 1.3 mmol) was placed in a round 
bottom flask and then a solution of crude allylchloride (170 mg) in acetonitrile (2 mL) was 
added. The reaction was stirred at room temperature for 16 h. Then the acetonitrile was 
concentrated under reduce pressure. The remaining yellow oil was dissolved in buffer (4 mL, 
25 mM NH4HCO3, 2% isopropanol) and pass thought an ion exchange column DOWEX 40 
W (NH4
+
 form). The ion exchange column was monitored by TLC using a mixture of 
isopropanol / buffer / NH4OH (6:2:2) as eluent. The fractions containing product were 
collected and freeze dried. The yellow solid was triturated with dry methanol and 
concentrated. The yellow solid was washed with CHCl3 and the remaining white solid was 
dried under reduce pressure. The white solid was crystallised in methanol affording white 
crystals (85 mg, 39% yield over two steps). 
HRMS ES
-
 [M + 2H] found 395.1400, C16H29O7P2 requires 395.1389. 
1
H NMR (500 MHz, 
D2O) δ 5.46-5.34 (m, 1 H, C=CH), 5.20-5.06 (m, 2 H, C=CH, C=CHCH2OH), 4.49-4.36 (m, 
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2 H, CH2OPP), 2.19-1.88 (m, 10 H, CH2CH3, 4 x CH2), 1.70-1.54 (m, 9 H, 2 x (CH3)2=C, 
CH3C=C), 0.94-0.87 (m, 3 H CH3CH2). 
31
P NMR (202 MHz, MeOD) δ -9.00 – -9.32 (d, J = 
19.0), -9.59 – -9.91 (d, J = 19.0). Data in agreement with previously published data by Rawat 
et al.
199
 
  
6.3 Synthesis of 15Me-FDP (138) 
6.3.1 Preparation of (E)-ethyl 7,11-dimethyl-3-oxododeca-6,10-dienoate (177) 
 
 
To a suspension of NaH (60% dispersion in mineral oil, 1.7 g, 46.2 mmol) in anhydrous THF 
(30 mL) at 0 ºC, a solution of ethyl acetoacetate (5.0 g, 4.9 mL, 39 mmol) in anhydrous THF 
(20 mL) was added, followed, after 30 min, by the addition of n-BuLi (2.5 M solution in 
hexanes, 18.3 mL, 46.2 mmol). The resulting mixture was stirred for 30 min and then geranyl 
bromide (3.0 g, 14 mmol) was added drop-wise via syringe. The resulting mixture was 
allowed to stir for 1h and then the reaction was quenched by addition of saturated aqueous 
NH4Cl solution (100 mL, 0.1 M).  Organic material was extracted with hexane (2 x 50 mL), 
combine organic extracts were washed with water (2 x 50 mL), brine (50 mL) and dried over 
MgSO4. Solvent was removed under reduced pressure and the yellow residue was purified by 
flash chromatography column with a mixture of hexane and ethyl acetate (20:1) as eluent to 
afford the title compound as colourless oil (14.8 g, 81%).  
HRMS ES
+
 [M] found 266.1888. C16H26O3 requires 266.1882. 
1
H NMR δ (500 MHz, 
CDCl3) 5.1 (m, 2 H 2 x C=CH), 4.23 (q, 2 H, J = 7.0, OCH2CH3), 3.4 (s, 2 H O=CCH2C=O), 
2.6 (t, 2 H, J = 7.0, CH2), 2.3 (m, 2 H, CH2), 2.1 (m, 2 H CH2), 2.0 (t, 2 H, J = 7.0, CH2), 1.7 
(s, 1 H, CCH3), 1.65 (s, 1 H, CCH3), 1.63 (s, 1 H CCH3), 1.32 (t, 3 H, J = 7.0, OCH2CH3). 
13
C NMR δ (125 MHz, CDCl3) 209.1 (C=OOEt), 168.1 (C=O), 136.8 (C=CH), 131.5 
(C=CH), 124.1 (C=CH), 122.1 (C=CH), 61.3 (C=OCH2C=OOEt), 49.4 (CH2), 43.0 (CH2), 
39.6 (CH2), 26.6 (CH2), 25.7 (CH3), 22.2 (CH2), 17.8 (CH3), 15.6 (CH3), 14.1 (CH3). 
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6.3.2 Preparation of (2E,6E)-ethyl 7,11-dimethyl-3-ethyldodeca-2,6,10-trienoate (179) 
 
 
To a solution of β-keto ester 5.15 (290 mg, 1.1 mmol) and lithium trifluoromethanesulfonate 
(340 mg, 2.2 mmol) in anhydrous DCM (25 mL) at 0 °C, Triethylamine (0.3 mL, 2.4 mmol) 
and trifluoromethanesulfonic anhydride (0.4 mL, 2.4 mmol) were added and the mixture was 
stirred at 0 °C for 2 h. Saturated aqueous NH4Cl solution was added (20 mL) and then the 
organic material was extracted with DCM (3 x 10 mL), combine organic extracts were 
washed with water (30 mL) and brine (30 mL) before drying over MgSO4 solvent 
evaporation under reduced pressure. The vinylic triflate (178) was isolated as dark oil which 
was used in the next step without further purification. 
To a stirred suspension of CuI (230 mg, 1.2 mmol) in anhydrous THF (20 mL) at 0 °C under 
argon atmosphere, ethyl magnesium bromide (2.0 M in diethyl ether, 0.6 mL, 1.2 mmol) was 
added and the mixture was stirred for 30 min. The stirred opaque black solution was then 
cooled to -78 °C. A solution of the enol triflate (400 mg, 1.0 mmol) in anhydrous THF (10 
mL) was added via a cannula and the reaction was stirred at this temperature for 2.5 h. The 
reaction was quenched by the addition of saturated aqueous NH4Cl solution (20 mL). 
Resulting emulsions were dissolved by diluting with diethyl ether (40 mL), addition of 
concentrated NH4OH (30 mL) and stirring over night. Organic material was extracted with 
ethyl acetate (3 x 10 mL) and the pooled organic extracts were washed with water (2 x 30 
mL), brine (30 mL), dried over MgSO4 and solvent was removed under reduce pressure. 
Crude product was purified by flash chromatography column with a mixture of hexane and 
ethyl acetate (20:1) as eluent. The title compound was isolated as colourless oil (120 mg, 
41% over two steps).  
HRMS ES
+
 [M + H] found 279.2336. C18H31O2 requires 279.2324. 
1
H NMR δ (500 MHz, 
CDCl3) 5.49 (s, 1 H, C=CH), 4.98 (m, 2 H, C=CH), 4.03 (q, 2 H, J = 7.0, OCH2CH3), 2.53 (q, 
2 H, J = 7.5, CH3CH2), 1.85 - 2.05 (m, 6 H, 3 x CH2), 1.95 (t, 2 H, J = 7.0 CH2), 1.65 (s, 3 H, 
CCH3), 1.48 (s, 3 H, CCH3), 1.46 (s, 3 H, CCH3), 1.16 (t, 3 H, J = 7.0, OCH2CH3), 0.9 (t, 3 
H, J = 7.5, CH2CH3).
13
C NMR δ (125 MHz, CDCl3) 166.5 (C=O), 165.5 (C=CH), 136.1 
(C=CH), 131.2 (C=CH), 124.2 (C=CH), 123.0 (C=CH), 114.9 (C=CH), 59.4 OCH2CH3), 
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39.7 (CH2), 38.0 (CH2), 26.7 (CH2), 26.1 (CH2), 25.7 (CH3), 25.3 (CH2), 17.7 (CH3), 16.0 
(CH3), 14.3 (CH3), 13.0 (CH3).  
 
6.3.3  Preparation of (2E,6E) 7,11-dimethyl-3-ethyldodeca-2,6,10-trien-1-ol (180) 
 
 
To a stirred suspension of ethyl ester 179 (145 mg, 0.5 mmol) in anhydrous THF (10 mL) at -
78 °C was added DIBAL-H (1.5 M in toluene, 870 μL, 1.3 mmol), the solution was stirred at 
this temperature for 2 h. The reaction was quenched by addition of HCl (2M, 10 mL). 
Organic material was extracted with diethyl ether (2 x 10 mL) and the combine organic 
extracts were washed with water (20 mL), brine (20 mL) and dried over MgSO4. Solvent was 
removed under reduced pressure. Crude product was purified by flash chromatography 
column with hexane and ethyl acetate (4:1) as eluent to give the title compound as colourless 
oil (86 mg, 69% yield).  
HRMS ES
+
 [M] found 236.2130, C16H28O requires 236.2140. 
1
H NMR (400 MHz, CDCl3) δ 
5.38 (t, J = 7.0 , 1 H, C=CH), 5.20 – 5.01 (m, 2 H, 2 x C=CH), 4.16 (d, J = 7.0, 2 H, CH2OH), 
2.22 – 1.93 (m, 10 H, 5 x CH2), 1.68 (s, 3 H, CCH3), 1.60 (s, 6 H, 2 x CCH3), 0.99 (t, J = 7.5, 
3 H, CH2CH3).
 13
C NMR δC (62.5 MHz, CDCl3) 141.3 (C=CH), 139.8 (C=CH), 131.3 
(C=CH), 124.4 (C=CH), 123.3 (C=CH), 123.3(C=CH), 59.5 (CH2OH), 39.9 (CH3CH2), 36.5 
(CH2), 26.9 (CH2), 26.0 (CH2), 25.7 (CH2), 23.2 (CH3C=C), 17.7 (CH3)2C=C), 16.4 
(CH3)2C=C), 13.4 (CH3CH2). 
 
6.3.4 Preparation of trisammonium (2E,6E)-3-ethyl-7,11-dimethyldodeca-2,6,10-
trienyl diphosphate (138)  
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To a stirred solution of the alcohol 180 (110 mg, 0.5 mmol) in anhydrous DMF (6.2 mL) at 0 
ºC, LiCl (0.3 g, 7.3 mmol), S-collidine (350 μL, 0.28 mmol) and mesylchloride (54 µL, 0.69 
mmol) were added. The milky solution formed after 15 min was stirred for an additional 2.5 
h. The mixture was diluted in cold pentane (4 mL) and cold water (25 mL). Organic material 
was extracted with pentane (3 x 10 mL), combine organic extracts were washed with 
saturated solution of CuSO4 (3 x 10 mL), saturated aqueous NaHSO4 solution (2 x 10 mL), 
brine (2 x 10 mL) and dried over MgSO4. The solvent was removed under reduced pressure 
and the crude product was used in the next step without further purification. 
To a solution of the crude allylic chloride in anhydrous CH3CN (1.3 mL), tris-
(tetrabutylammonium) hydrogendiphosphate (1 g, 1.1 mmol) was added and the mixture was 
stirred at room temperature for 15 h. Solvent was removed under reduced pressure and the 
residue was dissolved in ion-exchange buffer (25 mM NH4HCO3 containing 2% i-PrOH, 1 
mL). This solution was slowly passed through an ion exchange column DOWEX 50W-X8 
(100-200 mesh) (NH4
+
 form) that had been pre-equilibrated with ion exchange buffer. Once 
ion exchange was complete, fractions containing product (as judged by TLC run using as 
eluent a mixture of i-PrOH:c.NH3:H2O 6:3:1) were lyophilised to dryness. The white solid 
was extracted with MeOH (3 x 10 mL) and the MeOH concentrated affording yellow solid 
which was cleaned with diethyl ether (3 x 3 mL) to afford pure white solid (34 mg, 18%).The 
pellet was further purified by reverse-phase HPLC (150 × 21.2 mm Phenomenex Luna 
column, eluting with 10% B for 20 min, then a linear gradient to 60% B over 25 min and 
finally a linear gradient to 100% B over 5 min.; solvent A: 25 mM NH4HCO3 in water, 
solvent B: CH3CN, flow rate 5.0 mL/min, detecting at 220 nm). Once purification was 
complete the solution was again lyophilised to dryness giving the title compound as a fluffy 
white solid (68 mg, 36% yield).  
HRMS ES
-
 [M + 2D] found 395.1403, C16H29O7P2 requires 395.1389. 
1
H NMR (500MHz, 
D2O) δ 5.32 ( m, 1 H, C=CH), 5.10 ( m, 1 H, C=CH), 5.06 ( m, 1 H C=CH), 4.36 (m, 1 H 
CH2OH), 1.88 – 2.09 ( m, 10 H, 5 x CH2), 1.55 (s, 3 H, CH3), 1.49 (s, 6 H, 2 x CH3), 0.86 (t, 
3 H, J = 7.5, CH3CH2). 
31
P NMR δ (202.5 MHz, D2O) -10.41 (d, JPP = 22.5), -8.30 (d, JPP = 
22.5). Data in agreement with previously published by Gibbs et al.
305
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6.4 Synthesis of 14,15-diMeFDP (139) 
6.4.1 Preparation of (2E,6E)-ethyl 3,7-diethyl-11-methyldodeca-2,6,10-trienoate (189) 
 
 
To a stirred solution of β-keto ester 162 (0.35 g, 1.5 mmol) and lithium 
trifluoromethanesulfonate (780 mg, 5.0 mmol) in anhydrous DCM (38 mL) under argon at 0 
°C, Triethylamine (0.7 mL, 5 mmol) and trifluoromethanesulfonic anhydride (0.32 mL, 1.9 
mmol) were added. The mixture was stirred at 0 °C for 2 h. The reaction was quenched by 
the addition of saturated aqueous NH4Cl solution (20 mL) and then diluted with DCM (20 
mL). Organic material was extracted with DCM (2 x 10 mL), combined organic material was 
washed with water (30 mL) and brine (30 mL), dried over MgSO4 and solvent was removed 
under reduced pressure. The crude vinylic triflate was recovered as dark oil which was 
judged to be sufficiently pure by thin layer chromatography to carry on the next step without 
further purification. 
To a stirred suspension of CuI (950 mg, 5 mmol) in anhydrous THF (12 mL) under argon 
atmosphere at 0°C, ethylmagnesium bromide (3.0 M in diethyl ether, 3.3 mL, 10 mmol) was 
added drop-wise. The solution was stirred for 30 minutes, whereupon an opaque black colour 
was formed. The stirred reaction mixture was then cooled to -78 °C and a solution of the enol 
triflate (580 mg, 1.3 mmol) in anhydrous THF (4 mL) was added via cannula. The reaction 
was stirred at this temperature for 2.5 h. The reaction was quenched by the addition of 
saturated aqueous NH4Cl solution (20 mL). Resulting emulsions were dissolved by addition 
of concentrated aqueous NH4OH solution and stirring over night. The aqueous layer was 
extracted with ethyl acetate (3 x 10 mL) and the combined organic extracts were washed with 
water (2 x 30 mL) and brine (30 mL) and dried over MgSO4. Solvent was removed under 
reduced pressure. The residual oil was purified by flash chromatography column with a 
mixture of hexane and ethyl acetate (19:1) as eluent. The title compound was isolated as 
colourless oil (185 mg, 52%).  
HRMS EI
+
 found 292.2407, C19H32O2 requires 292.2402. 
1
H NMR (400 MHz, CDCl3) δ 
5.55 (s, 1 H, C=CH), 5.11 – 4.87 (m, 2 H, 2 x C=CH), 4.07 (q, J = 7.0, 2 H, OCH2CH3), 2.55 
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(q, J = 7.5, 2H, CH2CH3), 2.22 – 2.05 (m, 4 H, 2 x CH2), 2.00 – 1.89 (m, 6 H, 3 x CH2), 1.61 
(s, 3 H, CH3), 1.53 (s, 3 H, CH3), 1.21 (t, J = 7.0, 3 H, CH2CH3), 1.01 (t, J = 7.5, 3 H, 
CH2CH3), 0.89 (t, J = 7.5, 3 H, CH2CH3).
13
C NMR (62.5 MHz, CDCl3) δ 166.4 (C=OOEt), 
165.5 (C=CH), 141.9 (C=CH), 131.3 (C=CH), 124.3 (C=CH), 122.5 (C=CH), 114.8 (C=CH), 
59.1 (OCH2CH3), 38,3 (CH2), 36.4 (CH2), 26.8 (CH2), 25.8 (CH2), 25.7 (CH2), 25.3 (CH2), 
23.1 (CH3), 17.7 (CH3), 14.3 (CH3), 13.2 (CH3), 13.0 (CH3). 
 
6.4.2 Preparation of (2E,6E)-3,7-diethyl-11-methyldodeca-2,6,10-trien-1-ol (187) 
 
 
To a stirred suspension of the ethyl ester 189 (180 mg, 0.6 mmol) in anhydrous toluene (3.1 
mL) at -78 °C, DIBAL-H (1.5 M in toluene, 1.3 mL, 1.8 mmol) was added. The resulting 
solution was stirred at this temperature for 2 h. The reaction was quenched by addition of 
HCl 2M (10 mL), diluted with DCM (10 mL) and stirred for 1 h at room temperature. The 
aqueous layer was extracted with DCM (2 x 10 mL) and the pooled organic material was 
washed with saturated aqueous NaHCO3 solution (3 x 10 mL), brine (2 x 15 mL), dried over 
MgSO4 and concentrate under reduced pressure. The crude product was purified by flash 
chromatography column with hexane and ethyl acetate (3:1) to afford the title compound as 
colourless oil (160 mg, 73% yield).  
HRMS APCI [M-OH] found 233.2275,C17H29 requires 233.2269. 
1
H NMR (400MHz, 
CDCl3) δ 5.38 (t, 1 H, J = 7.0, C=CH), 5.09 (m, 2 H, 2 x C=CH), 4.16 (d, 2 H, J = 7.0, 
CHCH2), 1.97-2.13 (m, 12 H, 6 x CH2), 1,68 (s, 3 H, CCH3), 1.60 (s, 3 H, CCH3), 0.94-1.01 
(m, 6 H, 2 x CH2CH3). 
13
C NMR δC (62.5 MHz, CDCl3) 145.69 (C=CH), 141.25 (C=CH), 
131.26 (C=CH), 124.46 (C=CH), 123.43 (C=CH), 122.89 (C=CH), 59.09 (CH2OH), 36.75 
(CH2), 36.51 (CH2), 26.96 (CH2), 26.22 (CH2), 25.65 (CH2), 23.54 (CH2), 23.21 (CH3), 17.68 
(CH3), 13.65 (CH3), 13.20 (CH3). 
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6.4.3 Preparation of trisammonium (2E,6E)-3,7-diethyl-11-methyldodeca-2,6,10-
trienyl diphosphate (139) 
 
 
To a stirred suspension of LiCl (270 mg, 6.4 mmol) in anhydrous DMF (5.3 mL) at 0 °C, S-
collidine (0.3 mL, 2.4 mmol) and menthansulfonyl chloride (50 µL, 0.64 mmol) were added 
and the solution was stirred for 15 min during which time a white cloudy precipitate was 
formed. A solution of the alcohol 187 (100 mg, 0.40 mmol) in dry DMF (1 mL) was added 
drop-wise and the reaction mixture was stirred at 0 °C for 3 h. The mixture was diluted in 
cold pentane (10 mL) and cold water (15 mL) was added. The organic material was extracted 
with pentane (3 x 10 mL). The combined organic extracts were washed with saturated 
aqueous CuSO4 solution (3 x 10 mL), saturated aqueous NaHSO4 solution (2 x 10 mL), brine 
(2 x 10 mL) and dried over MgSO4. The solvent was removed under reduced pressure and the 
crude allylic chloride was used in the next step without further purification. 
To a solution of the crude allylic chloride in anhydrous CH3CN (1 mL), tris-
(tetrabutylammonium) hydrogendiphosphate (0.7 g, 1.8 mmol) was added. The mixture was 
stirred at room temperature for 15 h. The solvent was removed under reduced pressure and 
the residue was dissolved in ion-exchange buffer (25 mM NH4HCO3 containing 2% i-PrOH, 
1 mL). This solution was slowly passed through a column containing DOWEX 50W-X8 
(100-200 mesh) cation exchange resin (NH4
+
 form) that had been pre-equilibrated with two 
column volumes of ion-exchange buffer. The column was slowly eluted with ion-exchange 
buffer. Once ion exchange was complete, fractions containing product (as judged by TLC in 
6:3:1 i-PrOH:c.NH3:H2O) was lyophilised to dryness. The resulting white solid was triturated 
with MeOH (3 x 10 mL) and the combined organic extracts were concentrated to dryness 
under reduced pressure affording yellow solid which was cleaned with diethyl ether (3 x 3 
mL) to give the title compound as a white solid (64 mg, 36%). The solid residue from the 
triturating step was further purified by reverse-phase HPLC (150 × 21.2 mm Phenomenex 
Luna column, eluting with 10% B for 20 min, then a linear gradient to 60% B over 25 min 
and finally a linear gradient to 100% B over 5 min.; solvent A: 25 mM NH4HCO3 in water, 
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solvent B: CH3CN, flow rate 5.0 mL/min, detecting at 220 nm). Once purification was 
complete the solution was again lyophilised to dryness giving the title compound as a fluffy 
white solid (34 mg, 19% yield).  
HRMS ES
-
 [M+2H] found 409.2539, C17H29O7 requires 409.2545. 
1
H NMR (400MHz, D2O) 
δ 5.32 (t, J = 6.5, 1 H, C=CH), 5.07 (t, J = 6.0, 2 H, 2 x C=CH), 4.37 (m, 2 H CH2OH), 1.92-
2.03 (m, 12 H, 6 x CH2), 1,56 (s, 3 H, CH3), 1.50 ( s, 3H, CH3), 0.8-0.91 (m, 6 H, 2 x 
CH2CH3). 
31
P NMR (202.5 MHz, D2O) δ -10.41 (d, JPP = 22.5), -8.30 (d, JPP = 22.5). 
 
6.5 Synthesis of 12Me-FDP (136) 
6.5.1 Preparation of 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyloxy)-tetrahydro-
2H-pyran (207) 
 
 
To a stirred solution of 3,4-Dihydropyran (2.3 g, 27.0 mmol) and farnesol (5 g, 22.5 mmol) in 
DCM (50 mL) at room temperature, para-toluene sulfonic acid (0.18 g, 1.3 mmol) was 
added. The mixture was stirred for 15 h. reaction was quenched by the addition of aqueous 
saturated NaHCO3 solution (20 mL). Organic material was extracted with DCM (3 x 10 mL). 
The pooled organic extracts were washed with brine (3 x 20 mL), dried over MgSO4 and the 
solvents removed under reduce pressure. The crude product was purified by flash 
chromatography column with a mixture of hexane and ethyl acetate (60:1) as eluent to afford 
the title compound as colourless oil (5.9 g, 86%).  
HRMS ES
+
 [M+H] C20H35O2 calculated: 307.2637; found: 307.2630. 
1
H NMR (300 
MHz, CDCl3) δ 5.37 (t, J = 6.5 , 1 H, C=CHCH2), 5.17 – 5.06 (m, 2 H, 2 x C=CHCH2 ), 4.64 
(t, J = 3.5 , 1 H, OCHO), 4.25 (dd, J = 12.0, 6.5 , 1 H, CHCH2O), 4.04 (dd, J = 12.0, 7.5 , 1 
H, CHCH2O), 3.91 (dt, J = 11.0, 7.0, 3.5, 1 H, OCH2CH2), 3.52 (dt, J = 8.5, 5.0 , 1 H, 
OCH2CH2), 2.19 – 1.93 (m, 8 H, 4 x CH2), 1.90 – 1.72 (m, 2 H, CH2), 1.69 (s, 6 H, CH3), 
1.61 (s, 6 H, CH3), 1.58 – 1.47 (m, 4 H, CH2).
13
C NMR (75 MHz, CDCl3) δ 140.3 (C=CH), 
135.3 (C=CH), 131.3 (C=CH), 124.3 (C=CH), 123.9 (C=CH), 120.5 (C=CH), 97.8 (OCHO), 
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63.7 (C=CHCH2O), 62.3 (OCH2CH2) , 39.7 (CH2), 39.6 (CH2), 30.7 (CH2), 26.7 (CH2), 26.2 
(CH2), 25.7 (CH2), 25.5 (CH2) , 19.6 (CH3), 17.7 (CH3), 16.4 (CH3), 16.0 (CH3). 
 
6.5.2 Preparation of (2E,6E,10E)-2,6,10-trimethyl-12-(tetrahydro-2H-pyran-2-
yloxy)dodeca-2,6,10-trien-1-ol (204) 
 
 
To a stirred suspension of selenium oxide (210 mg, 1.9 mmol) in DCM (40 mL) at 0 ºC, 70% 
aqueous solution of tert-butyl hydroperoxide (8 mL, 58.5 mmol) was added. After 10 min a 
solution of 207 (5.8 g, 19 mmol) in DCM (10 mL) was added via a syringe. The solution was 
warmed to room temperature and allowed to stir for another 12 h. The reaction was diluted 
with water (30 mL). Organic material was extracted with DCM (3 x 20 mL), the combined 
organic extracts were washed with brine (3 x 40 mL), dried over MgSO4 and solvent was 
removed under reduce pressure. The crude product was purified by flash chromatography 
column with a mixture of hexane and ethyl acetate (gradient from 60:1 to 40:1) to afford the 
title compound as yellow oil (1.3 g, 21%). 
HRMS ES
+
 [M+Na] C20H34O3Na calculated: 345.2406; found: 345.2402.  
1
H NMR 
(300 MHz, CDCl3) δ 
1
H NMR (300 MHz, CDCl3) δ 5.36 (m, 2 H, C=CHCH2), 5.10 (t, J = 
7.0, 1 H, C=CHCH2), 4.62 (t, J = 3.5, 1 H, OCHO), 4.31 – 4.16 (m, 1 H, CHCH2O), 4.02 (m, 
3 H, CHCH2O, HOCH2), 3.88 (m, 1 H, OCH2CH2), 3.51 (m, 1 H, OCH2CH2), 2.23 – 1.96 (m, 
8 H, 4 x CH2), 1.87 – 1.76 (m, 2H, CH2), 1.66 (d, J = 5.5, 6 H, 2 x CH3), 1.59 (s, 3 H, CH3), 
1.55 – 1.46 (m, 4 H, 2 x CH2). 
13
C NMR (75 MHz, CDCl3) δ 140.2 (C=CH), 134.8 (C=CH), 
134.7 (C=CH), 125.8 (C=CH), 124.2 (C=CH), 120.6 (C=CH), 97.7 (OCHO), 68.9 
(C=CHCH2O), 63.6 (C=CHCH2O), 62.3 (OCH2CH2), 39.6 (CH2), 39.3 (CH2), 30.7 (CH2), 
26.2 (CH2), 26.1 (CH2), 25.5 (CH2), 19.6 (CH2), 16.4 (CH3), 16.0 (CH3), 13.7 (CH3).  
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6.5.3 Preparation of 2-((2E,6E,10E)-3,7,11-trimethyltrideca-2,6,10-trienyloxy)-
tetrahydro-2H-pyran (205) 
 
 
To a stirred solution of the alcohol 204 (320 mg, 1.0 mmol) in anhydrous THF (5 mL) at –45 
ºC, freshly distilled Et3N (264 µl, 2.0 mmol) and methanesulfonyl chloride (167 µL, 1.4 
mmol) were added. After 45 min, LiBr (403 mg, 5.9 mmol) was added to the milky solution. 
The mixture was warmed up to room temperature and left at this temperature for 1.5 h. The 
mixture was diluted with hexane (10 mL) and quenched by the addition of saturated aqueous 
NH4Cl solution (10 mL). Organic material was extracted with hexane (3 x 10 mL). The 
combined organic extracts were washed with saturated aqueous NaHCO3 solution (3 x 20 
mL), water (3 x 20 mL) and brine (3 x 20 mL), dried over MgSO4 and solvent was removed 
under reduce pressure. The crude colourless oil was immediately used in the next step 
without further purification. 
To a stirred suspension of CuI (375 mg, 1.9 mmol) in anhydrous Et2O (4 mL) under Ar 
atmosphere at 0 ºC, MeLi (1.6 M in hexane, 3.1 mL, 4.9 mmol) was added. After 20 min the 
reaction mixture was cooled to –78 ºC and a solution of the crude allylic bromide 203 (400 
mg), in of anhydrous diethyl ether (7 mL), was added via a syringe over 5 min. After 30 min 
the reaction was completed as judged by TLC. The reaction was quenched by the addition of 
saturated aqueous NH4Cl solution (8 mL). Copper salts were dissolved by the addition of 
concentrated NH4OH (10 mL) and stirring the biphasic mixture for 12 h. The organic 
material was extracted with ether (3 x 15 mL) and the combined organic extracts were 
washed with 10% aqueous NH4OH solution (3 x 25 mL), water (3 x 25 mL), brine (3 x 25 
mL), dried over MgSO4 and solvent was removed under reduce pressure. The crude product 
was purified by flash chromatography column with a mixture of hexane and ethyl acetate 
(gradient from hexane to 70:1) as eluent, to afford the title compound as yellow oil (160 mg, 
53% yield over two steps). 
HRMS ES
+
 [M+Na] C21H36O2Na calculated: 343.2613; found: 343.2615. 
1
H NMR 
(300 MHz, CDCl3) δ 5.36 (t, J = 6.5, 1 H, C=CHCH2), 5.10 (m, 2 H, 2 x C=CHCH2), 4.63 (t, 
J = 3.5, 1 H, OCHO), 4.24 (dd, J = 12.0, 6.5, 1 H, CHCH2O), 4.02 (dd, J = 12.0, 7.5, 1 H, 
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CHCH2O), 3.89 (dt, J = 7.0, 4.0 , 1 H, OCH2CH2), 3.50 (dt, J = 7.0, 4.0 , 1 H, OCH2CH2), 
2.18 – 1.92 (m, 10 H, 5 x CH2), 1.83(m, 2 H, CH2), 1.68 (s, 3 H, CH3), 1.59 – 1.44 (m, 10 H, 
2 x CH2, 2 x CH3), 0.97 (t, J = 7.5 , 3 H, CH3CH2). 
13
C NMR (126 MHz, CDCl3) δ 140.5 
(HC=C), 136.9 (HC=C), 135.4 (HC=C), 124.1 (HC=C), 122.9 (HC=C), 120.7 (HC=C), 97.9 
(OCHO), 63.8 (CHCH2O), 62.4(OCH2CH2), 39.9 (CH2), 39.8 (CH2), 32.5 (CH2), 30.9 (CH2), 
26.7 (CH2), 26.4 (CH2), 25.7 (CH2), 19.8 (CH2), 16.6 (2 x CH3), 16.2 (CH3), 13.0 (CH3).  
 
6.5.4 Preparation of (2E,6E,10E)-3,7,11-trimethyltrideca-2,6,10-trien-1-ol (209) 
 
 
To a stirred solution of 205 (160 mg, 0.5 mmol) in MeOH (5 mL) pyridine para-
toluenesulfonic acid (400 mg, 1.6 mmol) was added. The solution was stirred for 24 h, 
diluted with diethyl ether (20 mL) and quenched by the addition of saturated aqueous 
NaHCO3 solution (20 mL). Organic material was extracted with diethyl ether (5 x 10 mL), the 
combined organic extracts were washed with brine (3 x 20 mL), dried over MgSO4 and 
solvent was removed under reduce pressure. The crude product was purified by flash 
chromatography column with hexane and ethyl acetate (gradient from 70:1 to 50:1) to afford 
the title compound as colourless oil (100 mg, 81%). 
HRMS ES
+
 [M+H] C16H29O calculated: 237.2218; found: 237.2211. 
1
H NMR (250 
MHz, CDCl3) δ 5.35 (t, J = 7.0, 1 H, C=CHCH2), 5.03 (m, 2 H, 2 x C=CHCH2), 4.08 (d, J = 
7.0, 2 H, CH2OH), 2.22 – 1.80 (m, 10 H 5 x CH2), 1.61 (s, 3 H, CH3), 1.53 (s, 6 H, 2 x CH3), 
0.91 (t, J = 7.5 , 3 H, CH2CH3). 
13
C NMR (126 MHz, CDCl3) δ 139.9 (HC=C), 136.9 
(HC=C), 135.4 (HC=C), 123.8 (HC=C), 123.3 (HC=C), 122.7 (HC=C), 59.4 (CH2OH), 39.7 
(CH2), 39.6 (CH2), 32.3 (CH2), 26.6 (CH2), 26.3 (CH2), 16.3 (CH3), 16.0 (CH3), 15.9 (CH3), 
12.8 (CH3).  
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6.5.5 Preparation of trisammonium (2E,6E,11E)-11-ethyl-11-methyldodeca-2,6,10-
trienyl diphosphate (136) 
 
 
To a stirred solution of the alcohol 209 (70 mg, 0.3 mmol) in anhydrous DMF (4 mL) at 0 ºC, 
s-collidine (221 µL, 1.8 mmol) and methanesulfonyl chloride (34 µl, 0.4 mmol) were added. 
After 20 min stirring at this temperature, lithium chloride (201 mg, 4.7 mmol) was added to 
the solution. After 3 h the reaction was quenched by the addition of cold water (3 mL). The 
biphasic mixture was diluted with pentane (5 mL) and organic material was extracted with 
pentane (3 x 3 mL), the combined organic extracts were washed with saturated aqueous 
CuSO4 solution (3 x 10 mL), water (3 x 10 mL), saturated aqueous NaHCO3 solution (3 x 10 
mL), dried over MgSO4 and solvent were removed under reduce pressure. The crude product 
was used in the next step without further purification. 
To a stirred solution of crude allylic chloride (72 mg) in acetonitrile (2 mL), tris-
(tetrabutylammonium)hydrogen diphosphate (800 mg, 0.8 mmol) was added. The reaction 
was stirred at room temperature for 16 h. Acetonitrile was removed under reduced pressure, 
the remaining yellow oil was dissolved in buffer (4 mL, 25 mM of NH4HCO3, 2% 
isopropanol) and passed thought an ion exchange column DOWEX 40 W (NH4
+
 form). The 
eluent from the ion exchange column was monitored by TLC (isopropanol / buffer / NH4OH 
6:2:2). Fractions containing product were collected and freeze dried. The yellow solid was 
triturated with anhydrous methanol (4 x 8 mL), the combined methanol extracts were 
concentrated under reduce pressure. The yellow solid was washed with diethyl ether (3 x 1 
mL), the remaining white solid was dried under vacuum to afford the title compound as a 
white solid (48 mg, 36%). The solid was dissolved in H2O (11 mL) to afford 10 mM stock 
solution. 
HRMS ES
-
 [M+2H] C16H29O7P2 calculated: 395.1389; found: 395.1385. 
1
H NMR (400 
MHz, D2O) δ 5.37 (t, J = 6.0, 1 H, C=CHCH2), 5.07 (m, 2 H, 2 x C=CHCH2), 4.41 (t, J = 6.0, 
2 H, CH2OP=OO2), 2.16 – 1.81 (m, 10 H, 5 x CH2), 1.65 (s, 3 H, CH3), 1.53 (bd, J = 8.0 , 6 
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H, 2 x CH3), 0.90 (t, J = 7.5, 3 H, CH2CH3) ppm; 
31
P NMR (202.5 MHz, D2O) δ  –9.9 (bd, 
JPP = 56.5 ).  
 
6.6 Synthesis of 8nor-FDP (140) 
6.6.1 Preparation of (E)-2-((3,7-dimethylocta-2,6-dien-1-yl)oxy)tetrahydro-2H-pyran 
(223) 
 
 
To a stirred solution of geraniol (10.0 g, 65.0 mmol) in DCM (200 mL), DHP (10.9 g, 13 
mmol) and PPTS (160 mg, 0.6 mmol) were added. The colourless solution was stirred for 16 
h and then quenched with saturated NaHCO3 solution (60 mL). The organic material was 
extracted with DCM (2 x 30 mL). The combine organic extracts were washed with brine (3 x 
100 mL), dried over MgSO4 and concentrated under reduced pressure. Purification of the 
crude product by vacuum chromatography with hexane and ethyl acetate as eluent (40:1 to 
30:1) gave the title compound as a colourless oil (13.8 g, 89%). 
HRMS ES
+ 
[M+H] found 239.2022, C15H27O2 requires 239.2011. 
1
H NMR (300 MHz, 
CDCl3) δ 5.35 (t, J = 7.0, 1 H, C=CH), 5.08 (t, J = 6.0, 1 H, (CH3)2=CH), 4.66 – 4.57 (bs, 1 
H, OCHO), 4.23 (dd, J = 12.0, 6.0, 1H, C=CHCH2O), 4.02 (dd, J = 12.0, 7.5 , 1 H, 
C=CHCH2O), 3.95-3.85 (m, 1 H, OCH2CH2), 3.58 – 3.40 (m, 1 H, OCH2CH2), 2.16 – 1.97 
(m, 4 H 2 x CH2), 1.90 – 1.73 (m, 2 H, CHCH2), 1.67 (s, 6 H, 2 x CH3C), 1.62 – 1.44 (m, 7 H 
CH3, 2 x CH2 from OTHP). 
13
C NMR (75 MHz, CDCl3) δ 140.4 (C=CH), 131.7 (C=CH), 
124.1 (C=CH), 120.6 (C=CH), 97.9 (OCHO), 63.7 (C=CHCH2O), 62.4 (OCH2CH2), 39.7 
(CH2), 30.8 (CH2), 26.5 (CH2), 25.8 (CH2), 25.6 (CH2), 19.7 (CH3), 17.8 (CH3), 16.5 (CH3). 
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6.6.2 Preparation of (2E,6E)-2,6-dimethyl-8-((tetrahydro-2H-pyran-2-yl)oxy)octa-2,6-
dien-1-ol (222) 
 
 
To a stirred solution of THP protected geraniol 223 (2 g, 8.4 mmol) in DCM (20 mL) at 0ºC, 
SeO2 (93 mg, 0.84 mmol), t-BuOOH (3.7 mL, 26.8 mmol) and salicylic acid (110 mg, 0.89 
mmol) were added. Reaction mixture was kept at this temperature for 5 h and then water (10 
mL) was added. The organic material was extracted with DCM (3 x 15 mL), combine organic 
extracts were washed with saturated aqueous NaHCO3 solution (2 x 15 mL), brine (3 x 15 
mL), dried over MgSO4 and concentrate under reduce pressure. Purification of the crude 
product by flash chromatography column with hexane and Ethyl acetate (3:1) as eluent gave 
the title compound as pale yellow oil (1.3 g, 60%).   
HRMS EI
+ 
[M + Na] found 277.1768, C15H26O3Na requires 277.1780.
 1H NMR (400 MHz, 
CDCl3) δ 5.38 – 5.28 (m, 2 H, 2 x C=CH), 4.60 (bs, 1 H, OCHO), 4.21 (dd, J = 11.5, 6.0, 1 
H, C=CHCH2O), 4.05 – 3.97 (m, 1 H, C=CHCH2O), 3.95 (s, 2 H, CH2OH), 3.86 (t, J = 8.0 , 
1 H, OCH2CH2), 3.53 – 3.45 (m, 1 H, OCH2CH2), 2.18 – 2.11 (m, 2 H, CH2), 2.09 –2.02 (m, 
2 H, CH2), 1.98 – 1.75 (m, 4 H, CH2), 1.65 (s, 3 H, CH3), 1.63 (s, 3 H, CH3), 1.57 – 1.49 (m, 
2 H, CH2).
13
C NMR (75 MHz, CDCl3) δ 139.8 (C=CH), 135.2 (C=CH), 125.4 (C=CH), 
120.9 (C=CH), 97.8 (OCHO), 68.8 (CH2OH), 63.7 (C=CHCH2O), 62.3 (OCH2CH2), 39.2 
(CH2), 30.7 (CH2), 25.8 (CH2), 25.5 (CH2), 19.5 (CH2), 16.4 (CH3), 13.7 (CH3). 
 
6.6.3 Preparation of 2-(((2E,6E)-3,7,10-trimethylundeca-2,6,9-trien-1-
yl)oxy)tetrahydro-2H-pyran (217) 
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To a stirred solution of alcohol 222 (200 mg, 0.8 mmol) in THF at -45 ºC (4 mL), Et3N (200 
µL, 1.57 mmol) and mesyl chloride (84 µL, 1.1 mmol) were added, reaction was kept at this 
temperature for 1h. Then LiBr (406 mg, 4.7 µL) was added and the milky solution was warm 
to 0 ºC and stirred for 4 h. Water was added to the reaction and organic material was 
extracted with diethyl ether (3 x 8 mL). Combined organic extracts were washed with 
aqueous saturated NaHCO3 solution (3 x 10 mL), brine (3 x 10 mL), dried over MgSO4 and 
concentrate under reduce pressure. The crude bromide was used without further purification 
in the next step.  
To a suspension of CuI (295 mg, 1.6 mmol) in THF (3 mL) at 0 ºC), (2-methylprop-1-en-1-
yl) magnesium bromide (0.5 M in THF, 7.9 mL, 3.9 mmol) was added and the reaction was 
stirred for 30 min. The black solution was cooled to – 78 ºC and a solution of crude bromide 
(260 mg) in THF (4 mL) was added via cannula. The reaction was stirred at this temperature 
for 1 h and then quenched by the addition a saturated aqueous NH4Cl solution (5 mL). The 
white precipitate formed was dissolved by the addition of concentrate NH4OH (5 mL), 
dilution with diethyl ether (10 mL) and stirred the biphasic mixture overnight. The organic 
material was extracted with diethyl ether (6 x 10 mL) and the combined organic extracts were 
washed with 10% aqueous NH4OH solution (2 x 15 mL), brine ( 3 x 20 mL), dried over 
MgSO4 and  concentrated under reduce pressure. Purification of the crude product by flash 
chromatography column with hexane and ethyl acetate (gradient from 40:1 to 30:1) as eluent 
gave the title compound as colourless oil (200 mg, 87%). 
HRMS EI
+ 
[M+Na] found 315.2314, C19H32O2Na requires 315.2300.
 1H NMR (400 MHz, 
CDCl3) δ 5.35 (t, J = 7.0, 1 H, C=CH), 5.14 – 5.07 (m, 2 H, 2 x C=CH), 4.64 – 4.61 (m, 1 H, 
OCHO), 4.23 (dd, J = 11.5, 6.5, 1 H, CH2OCH), 4.07 – 3.98 (m, 1 H, CH2OCH), 3.89 (ddd, J 
= 11.0, 8.0, 3.5, 1 H, OCH2CH2), 3.55 – 3.44 (m, 1 H, OCH2CH2), 2.63 (d, J = 7.0, 2 H, 
C=CHCH2C), 2.16 – 2.00 (m, 4 H, 2 x CH2), 1.84 (m, 2 H, CH2), 1.71 (s, 3 H, CH3), 1.67 (s, 
3 H, CH3), 1.61 (s, 3 H, CH3), 1.57 (s, 3 H, CH3), 1.55 – 1.46 (m, 4 H, 2 x CH2). 
13
C NMR 
(101 MHz, CDCl3) δ 140.4(HC=C), 135.0 (HC=C),, 132.6 (HC=C), 123.8 (HC=C), 122.7 
(HC=C), 120.7 (HC=C), 97.9 (OCHO), 63.8 (CH2OCH), 62.4 (OCH2CH2), 39.8 (CH2), 38.3 
(CH2), 30.8 (CH2), 26.4 (CH2), 25.9 (CH2), 25.6 (CH2), 19.7 (CH3), 17.8 (CH3), 16.6 (CH3), 
16.3 (CH3).    
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6.6.4 Preparation of (2E,6E)-3,7,10-trimethylundeca-2,6,9-trien-1-ol (216) 
 
 
To a stirred solution of THP ether 217 (150 mg, 0.5 mmol) in methanol (4 mL) PPTS (202 
mg, 0.8 mmol) was added in a open air flask. The resulting clear solution was stirred for 16 h. 
After this time the methanol was concentrated under reduce pressure and the resulting oil was 
dissolve in diethyl ether (10 mL). The ethereal extract was washed with saturated aqueous 
NaHCO3 solution (3 x 6 mL), brine (2 x 6 mL), dried over MgSO4 and concentrated under 
reduce pressure. The crude product was purified by flash chromatography column with 
hexane and ethyl acetate (2:1) as eluent to afford the title compound as colourless oil (75 mg, 
68%). 
HRMS EI
+ 
[M-OH] found 190.1725, C14H22 requires 190.1722.
 1H NMR (400 MHz, CDCl3) 
δ 5.41 (t, J = 7.0 , 1 H, C=CH), 5.11 (m, 2 H, 2 x C=CH), 4.14 (d, J = 7.0, 2 H, CHCH2OH), 
2.64 (d, J = 7.5, 2 H, CHCH2C), 2.18 – 1.99 (m, 4 H, 2 x CH2), 1.71 (s, 3 H, CH3), 1.67 (s, 3 
H, CH3), 1.61 (s, 3 H, CH3), 1.57 (s, 3 H, CH3).
13
C NMR (63 MHz, CDCl3) δ 140.0 (C=CH), 
135.2 (C=CH), 132.7 (C=CH), 123.7 (C=CH), 123.5 (C=CH), 122.7 (C=CH), 59.5 
(CHCH2OH), 39.7 (CHCH2C), 38.3 (CH2), 26.4 (CH2), 25.9 (CH3), 17.8 (CH3), 16.4 (CH3), 
16.3 (CH3). 
 
6.6.5 Preparation of (2E,6E)-3,7,10-trimethylundeca-2,6,9-trien-1-yl acetate (356) 
 
 
To a stirred solution of alcohol 216 (17 mg, 0.08 mmol) in DCM (1 mL) at room temperature, 
pyridine (66 μL, 0.8 mmol) and acetic anhydride (40 μL, 0.4 mmol) were added, in a open air 
flask. The mixture was stirred overnight. The reaction was diluted with DCM (10 mL) and 
quenched by the addition of 10% HCl aqueous solution (10 mL). Organic material was 
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extracted with DCM (3 x 10 mL), combined organic extracts were washed with saturated 
NaHCO3 aqueous solution (3 x 15 mL), brine (3 x 15 mL), dried over Na2SO4 and solvent 
was removed under reduce pressure. The crude product was purified by flash 
chromatography column with mixture of hexane and ethyl acetate (60:1) as eluent to afford 
the product as pale yellow oil (17 mg, 61%). 
HRMS EI
+ 
[M] found 250.1928, C14H22 requires 250.1933. 
1
H NMR (250 MHz, CDCl3) δ 
5.33 (t, J = 7.0, 1 H, C=CH), 5.19 – 5.02 (m, 2 H, 2 x C=CH), 4.58 (d, J = 7.0, 2 H, 
CHCH2OAc ), 2.64 (d, J = 7.5, 2 H, CHCH2C), 2.20 – 1.97 (m, 7 H, 2 x CH2, C=OCH3), 1.70 
(m, 6 H, 2 x CH3 ), 1.61 (s, 3 H, CH3), 1.57 (s, 3 H, CH3).
13
C NMR (63 MHz, CDCl3) δ 
171.3 (C=O), 142.4 (C=CH), 135.2 (C=CH), 132.7 (C=CH), 123.6 (C=CH), 122.7  (C=CH), 
118.4 (C=CH), 61.6 (CH2OAc), 39.7 (CH2), 38.3 (CH2), 26.4 (CH2), 25.9 (CH3), 21.2 (CH3), 
17.8 (CH3), 16.6 (CH3), 16.3 (CH3). 
 
6.6.6 Preparation of a mixture of (E)-β -, (Z)-α - and (E)- α-8nor-farnesenes 
 
 
The following procedure is similar to the one reported by Heathcock.
306
 The mixture of 
alcohol (12 mg, 0.06 mmol), pyridinium p-toluenesulfonate (7 mg, 0.03 mmol) in 
dichloroethane (1.5 mL) was stirred in a seal tube at 150 ºC for 10 min. The reaction mixture 
was cooled to room temperature, diluted with dichloroethane (2 mL). Organic material was 
washed with water (2 x 2 mL), brine (2 x 2 mL) and dried over Mg2SO4. The organic material 
was passed through short pad of silica and de compound was eluted with pentane (3 mL). The 
sample was analysed directly by GC-MS     
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6.6.7 Preparation of trisammonium (2E,6E)-10-methylundeca-2,6,9-trienyl 
diphosphate (140) 
 
 
To a stirred solution of the alcohol 216 (53 mg, 0.3 mmol) in anhydrous DMF (5 mL) at 0 ºC, 
s-collidine (2.35 mL, 19 mmol) and methanesulfonyl chloride (364 µL, 4.7 mmol) were 
added. After 20 min stirring at this temperature, lithium chloride (2.1 g, 50.0 mmol) was 
added to the solution. After 3 h at this temperature, the reaction was quenched by the addition 
of cold water (30 mL). The biphasic mixture was diluted with pentane and organic material 
was extracted with pentane (3 x 20 mL), the combined organic extracts were washed with 
saturated aqueous CuSO4  solution (3 x 30 mL), water (3 x 30 mL), saturated aqueous 
NaHCO3 solution (3 x 20 mL), dried over MgSO4 and solvent were removed under reduce 
pressure. The crude chloride was used in the next step without further purification. 
To a stirred solution of crude allylic chloride (750 mg) in acetonitrile (13 mL) tris-
(tetrabutylammonium) hydrogen diphosphate (7 g, 7.8 mmol) was added. The reaction was 
stirred at room temperature for 16 h. Acetonitrile was removed under reduced pressure, the 
remaining yellow oil was dissolved in buffer (15 mL, 25 mM of NH4HCO3, 2% isopropanol) 
and passed thought an ion exchange column DOWEX 40 W (NH4
+
 form). The eluent from 
the ion exchange column was monitored by TLC (isopropanol / buffer / NH4OH 6:2:2). 
Fractions containing product were collected and freeze dried. The yellow solid was diluted in 
buffer (15 mL). The crude was purified by reverse-phase HPLC (150 × 21.2 mm 
Phenomenex Luna column, eluting with 10% B for 20 min, then a linear gradient to 60% B 
over 25 min and finally a linear gradient to 100% B over 5 min.; solvent A: 25 mM 
NH4HCO3 in water, solvent B: CH3CN, flow rate 5.0 mL/min, detecting at 220 nm) in 
injections of 1.5 mL.  The flow through of the HPLC was freeze dried and title compound 
was recovered as a white solid (60 mg, 57% over two steps). 
HRMS ES
-
 [M + 2H] found 352.0857, C16H29O7P2 requires 352.0852. 
1
H NMR (400 MHz, 
D2O) δ 5.42 (t, J = 7.0, 1 H, C=CH), 5.20 (dd, J = 12.5, 7.5, 2 H, 2 x C=CH), 4.43 (t, J = 6.5, 
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2 H, CH2OH), 2.65 (d, J = 7.5, 2 H, CHCH2C(CH3)=CH), 2.12 (dd, J = 15.0, 7.0, 2 H, CH2), 
2.08 – 2.02 (m, 2 H, CH2), 1.67 (s, 6 H, 2 x CH3), 1.59 (s, 3 H, CH3), 1.57 (s, 3 H, CH3).
 31
P 
NMR (202.5 MHz, D2O) δ -12.06 (d, JPP = 18.0), -10.69 (d, JPP = 18.0). Data in agreement 
with previously publish data by Gibbs et al.
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6.7 Synthesis of 14OH-FDP (142) 
6.7.1 Preparation of 1,1-diethoxy-2-methylpropan-2-ol (360) 
 
 
To a stirred solution of ethyl diethoxyacetate (3.0 g, 17.0 mmol) in anhydrous THF (40 mL) 
at -78 ºC methyl magnesium bromide (5.7 mL, 3M, 17.0 mmol) was added drop-wise. The 
resulting solution was stirred at this temperature for 2.5 h. The reaction mixture was then 
diluted with diethyl ether (20 mL) and quench by the addition of 20% solution of NH4Cl (30 
mL). The organic material was extracted with hexane (3 x 30 mL), combined organic extracts 
were washed with brine (3 x 40 mL), dried over MgSO4 and solvent was removed under 
reduce pressure. The crude product was purified by vacuum chromatography with hexane and 
ethyl acetate (7:1) as eluent, to afford the title compound as colourless oil (1.01 g, 41% 
yield). 
HRMS EI
+ 
[M + Na] found 185.1148, C8H18O3Na requires 185.1154. 
1
H NMR (300 MHz, 
CDCl3) δ 4.08 (s, 1 H, CH), 3.80 (dq, J = 9.0, 7.0, 2 H, OCH2CH3), 3.53 (dq, J = 9.0, 7.0, 2 
H, OCH2CH3), 1.17 (t, J = 7.0, 6 H, 2 x OCH2CH3), 1.12 (s, 6 H, 2 x CH3).
13
C NMR (75 
MHz, CDCl3) δ 108.8 (HOC(CH3)2), 72.7 (HC(OEt)2), 66.1 (2 x OCH2CH3), 24.0 (2 x 
OCH2CH3), 15.6 (2 x CH3). 
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6.7.2 Preparation of 1,1-diethoxypropan-2-one (267) 
 
 
To a stirred suspension of CuI (4.1 g, 21.0 mmol) in anhydrous THF (80 mL) at 0°C, 
methylmagnesium bromide (1.6 M in diethyl ether, 30 mL, 48.0 mmol) was added drop-wise. 
The solution was stirred for 30 minutes at this temperature, whereupon yellow precipitate was 
dissolved. The mixture was cooled to – 78 ºC and then a solution of ethyl diethoxyacetate 
(2.0 g, 9.7 mmol) in anhydrous THF (10 mL) was added. The reaction mixture was stirred for 
2 h and quenched by the addition of saturated aqueous NH4Cl solution. The mixture was 
diluted with diethyl ether (30 mL) and concentrate NH4OH (20 mL) was added, the biphasic 
mixture was stirred for 30 min. Organic material was extract with diethyl ether (3 x 30 mL), 
the combined organic extracts were washed with brine (2 x 50 mL), dried over MgSO4 and 
concentrate under reduce pressure. The crude product was purified by vacuum 
chromatography with hexane and ethyl acetate (10:1) as eluent to afford the title compound 
as a colour less oil (0.9 g, 62%).  
HRMS EI
+
 [M] found 146.0940, C7H14O3 requires 146.0943. 
1
H NMR (400 MHz, CDCl3) δ 
4.52 (s, 1 H, CH(OEt)2), 3.69 (dq, J = 9.5, 7.0, 2 H OCH2CH3), 3.55 (dq, J = 9.5, 7.0 , 2 H, 
OCH2CH3), 2.19 (s, 3 H, CH3), 1.24 (t, J = 7.0, 6 H, OCH2CH3).
13
C NMR (101 MHz, 
CDCl3) δ 204.5 (C=O), 102.9 (CH), 63.4 (OCH2CH3), 24.6 (CH3), 15.3 (OCH2CH3). 
 
6.7.3 Preparation of (E)-N-cyclohexyl-1,1-diethoxypropan-2-imine (268) 
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To a flame round bottom flask containing activated molecular sieves 4Å, solution of α ,α-
diethoxyacetone 267 (100 mg, 0.7 mmol) in anhydrous DCM (2 mL) and previously distilled 
cyclohexylamine (101 μL, 0.9 mmol) were added. The reaction was stirred for 5 h.  The 
mixture was filtrated through a short pad of celite
®
 and washed with DCM. The solvent was 
removed under reduced pressure to afford the pure title compound as pale yellow oil (162 
mg, 98%).    
HRMS EI
+
 [M + H] found 228.1958, C13H26NO2 requires 228.1964.
 1
H NMR (300 MHz, 
CDCl3) δ 4.54 (s, 1 H, N=CCH(OEt)2), 3.67 (dt, J = 14.0, 7.0, 2 H, OCH2CH3), 3.46 (dt, J = 
14.0, 7.0, 2 H, OCH2CH3), 3.36 – 3.23 (m, 1 H, CH2CHN), 1.83 (s, 3 H, CH3), 1.76 (bd, J = 
12.0, 2 H, CH2), 1.60 (bd, J = 14.0, 2 H, CH2), 1.49 – 1.12 (m, 12 H, 3 x CH2, 2 x 
(OCH2CH3)).
13
C NMR (75 MHz, CDCl3) δ 164.9 (C=N), 106.9 (s, 1H, N=CCH(OEt)2), 63.1 
(CH2CHN) , 58.9 (OCH2CH3), 33.3 (CH2), 25.6 (CH2), 24.9 (OCH2CH3), 15.2 (CH2), 11.2 
(CH3). 
 
6.7.4 Preparation of trimethyl((6-methylhepta-1,5-dien-2-yl)oxy)silane (257) 
 
 
To a stirred solution of DIPA (1.4 mL, 9.9 mmol) in anhydrous THF (4 mL) at 0 ºC, n-butyl 
lithium (3.9 mL, 2.5 M, 9.9 mmol) was added. The reaction mixture was stirred at this 
temperature for 30 min, whereupon pale yellow colour was observed. To the resulting LDA 
solution was cooled to -78 ºC, a solution of 6-methylhept-5-en-2-one (0.5 g, 3.9 mmol) in 
anhydrous THF (6 mL) was added. The mixture was stirred at this temperature for 1 h and 
then freshly redistilled chlorotrimethylsilane (1.1 g, 9.9 mmol) was added. The reaction was 
warmed to 0 ºC and stirred for 45 min. The reaction was quenched by the addition of a 
saturated NH4Cl aqueous solution (5 mL). Organic material was extracted with diethyl ether 
(3 x 5 mL), combined organic extracts were washed with brine (3 x 10 mL), dried over 
MgSO4 and solvent was removed under reduced pressure to afford yellow oil (0.7 g, 90%). 
The sample was analysed by NMR spectroscopy using deactivated CDCl3 as solvent.  
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HRMS EI
+
 [M + H] found 199.1519, C11H23OSi requires 199.1518.
 1H NMR (300 MHz, 
CDCl3) δ 4.91 (t, J = 7.0 , 1 H, ((CH3)2CCH), 3.84 (s, 2 H, C=CH2), 2.02 – 1.76 (m, 4 H, 2 x 
(CH2)), 1.48 (s, 3 H, (CH3)), 1.41 (s, 3 H, (CH3)), 0.01 (s, 9 H, Si(CH3)3).
 13
C NMR δ (75 
MHz, CDCl3) δ 131.86(CH2=COSi), 131.81 ((CH3)2CCH), 123.92((CH3)2CCH), 
90.13(CH2=COSi), 36.75 (CH2), 25.83(CH3), 25.65 (CH3), 17.84 (CH2), 4.22 (SiCH3), 3.08 
(SiCH3), 0.27 (SiCH3). 
 
6.7.5 Preparation of 1-hydroxy-6-methylhept-5-en-2-one (258) 
 
 
To a stirred solution of silyl enolate 257 (0.8, 3.9 mmol) in DCM (20 mL) at -78 ºC, a 
solution of mCPBA (870 mg 70%, 3.5 mmol) in DCM (130 mL) was added drop-wise.  The 
mixture was stirred for 1 h. Another portion of mCPBA (0.3 g, 70%, 1.2 mmol) was added to 
the heterogeneous mixture and stirred for an additional 2 h. A 10% aqueous HCl solution (20 
mL) was added and the biphasic mixture was warmed to 0 ºC and stirred for 1 h. The excess 
of HCl was neutralised with saturated solution of K2CO3 (50 mL) and the mixture stirred 
overnight. The precipitate was filtrated, the organic material was extracted with DCM (3 x 50 
mL), the combined organic extracts were washed with brine, dried over MgSO4 and solvent 
was removed under reduce pressure. The crude product was purified by vacuum 
chromatography with mixture of hexane and ethyl acetate (4:1) as eluent to afford the title 
compound as pale yellow oil (20 mg, 4%).  
HRMS EI
+ 
[M + Na] found 165.0891, C8H14O2Na requires 277.1780. 
1
H NMR (400 MHz, 
CDCl3) δ 5.04 (t, J = 7.0, 1 H, C=CH), 4.22 (s, 2 H, CH2OH), 3.12 (bs, 1 H, CH2OH), 2.43 (t, 
J = 7.5, 2 H, CH2CH2C=O), 2.31 (q, J = 7.0, 2 H, CH2CH2C=O), 1.67 (s, 3 H, CH3), 1.61 (s, 
3 H, CH3).
13
C NMR (101 MHz, CDCl3) δ 209.7 (C=O), 133.7 (C=CH), 122.0 (C=CH), 68.4 
(CH2OH), 38.6 (CH2), 25.8 (CH2), 22.5 (CH3), 17.8 (CH3). 
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6.7.6 Preparation of ethyl 4,4-diethoxy-3-oxobutanoate (272) 
 
 
To a stirring suspension of sodium hydride (20.0 g, 97,8 mmol) in anhydrous THF (170 mL) 
a mixture of anhydrous ethyl acetate (13 mL, 127 mmol) and ethyl diethoxyacetate (20.0 g, 
98.0 mmol) was added over 20 min. Then, the reaction was refluxed for 3 h before allow 
cooling to room temperature and additional stirring for 16 h. The reaction was quenched by 
the rapid addition of aqueous acetic acid (100 mL, 15% v/v) at 0 ºC and the organic material 
was extracted with diethyl ether (3 x 30 mL). The combined organic layers were washed 
sequentially with water (2 x 40 mL), brine (3 x 40 mL), dried over MgSO4 and then 
concentrated in vacuum to afford the title compound (17.3 g, 81%) as a mixture of tautomers 
272, 272a, 272b (0.3:1:1).  
HRMS EI
+ 
[M + Na] found 241.1043, C10H18O5Na requires 241.1052. 
1
H NMR (300 MHz, 
CDCl3) δ 4.87 (d, J = 1.0, 1 H, C=CH 5.40b), 4.65 (d, J = 1.0, 1 H, C=CH, 5.40a), 4.19 (m, J 
= 20.0, 7.0, 1.0, 2 H, C=OOCH2), 3.82 – 3.43 (m, 5 H, 2 x OCH2, HC(CH2)2), 2.32 (s, 2 
H,C=OCH2C=O, 5.40), 1.34 – 1.14 (m, 9 H, 3 x CH3). 
13
C NMR (75 MHz, CDCl3) δ 198.9 
(C=OOCH2), 167.3 (C=OCH), 102.1(CH), 63.6 (C=OOCH2), 61.4 (OCH2), 44.3 
(C=OCH2C=O), 15.2 (CH3), 14.2 (2 x CH3). 
 
6.7.7 Preparation of 1,1-diethoxy-6-methylhept-5-en-2-one (269) 
 
 
To a suspension of NaH (0.76 g, 19.1 mmol, 60% in mineral oil) previously washed with 
anhydrous hexane (3 x 5 mL) in anhydrous THF (80 mL) at 0 ºC a solution of 272 (4.5 g, 19 
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mmol) in THF (15 mL) was added drop-wise, the mixture was further stirred for 1 h. Then a 
solution of the allylic bromide (2.8 g, 19.1 mmol ) in anhydrous THF (5 mL) was added 
dropwise. Reaction was warm to room temperature and stirred for 16 h. The reaction was 
cooled to 0 ºC, quenched by the addition of saturated solution of NH4Cl (25 mL) and the 
organic material was extracted with diethyl ether (3 x 20 mL). Combined organic extracts 
were washed with brine (3 x 50 mL), dried over MgSO4 and concentrated under reduce 
pressure to afford 5 g of crude α-keto ester. The crude product was dissolved in absolute 
EtOH (233 mL) and water (400 mL) was added to the solution. Then a solution 5% NaOH 
(240 mL) was added, the resulting cloudy solution was refluxed for 4 h. The reaction was 
neutralised with aqueous solution of HCl (6M) and concentrated under reduce pressure. The 
organic material was extracted with diethyl ether (4 x 100 mL), the combine organic layers 
were washed with brine (3 x 70 mL), concentrated under reduce pressure to afford 1.2 g (30% 
over two steps) of pure compound. 
HRMS ES
+ 
[M] found 214.1569, C12H22O3 requires 214.1571. 
1
H NMR (250 MHz, CDCl3) 
δ 5.05 (t, J = 7.0, 1 H, C=CH), 4.54 (s, 1 H, HC(OEt)2), 3.76 – 3.43 (m, 4 H, 2 x OCH2CH3), 
2.58 (t, J = 7.5, 2 H, CH2C=O), 2.23 (dd, J = 14.5, 7.0, 2 H, HCCH2 ), 1.75 – 1.51 (m, 6 H, 2 
x OCH2CH3), 1.22 (t, J = 7.0 , 6 H, 2 x CH3C=). 
13
C NMR (63 MHz, CDCl3) δ 206.2 (C=O), 
123.0 (CH3C=C), 102.7 (HC=C), 63.3 (CH), 37.2(OCH2CH3), 25.7 (CH2), 21.9 (2 x 
OCH2CH3), 17.7 (CH2), 15.2 (2 x CH3). 
 
6.7.8 Preparation of (E)-2-((5-(3,3-dimethyloxiran-2-yl)-3-methylpent-2-en-
1yl)oxy)tetrahydro-2H-pyran (252) 
 
 
To a stirred solution of 223 (13.3 g, 56.0 mmol) in DCM (250 mL) at 0 ºC, a solution of m-
chloroperbenzoic acid (14.4 g, 70-75%, 61.0 mmol) in DCM (150 mL) was added by 
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cannula. The resulting slurry was stirred for 5 h at 0 ºC and then Ca(OH)2 (15 g, 200.0 mmol) 
was added, the suspension was stirred for further 40 min at room temperature. After filtration 
the residue was washed with DCM (50 mL), combine organic filtrate were washed with 
saturated solution of NaHCO3 (2 x 70 mL), brine (3 x 70 mL) and concentrated under reduce 
pressure. Purification of the crude product by vacuum chromatography, with hexane and 
ethyl acetate (30:1) as eluent, gave the title compound as pale yellow oil (9.7 g, 69%).      
HRMS EI
+ 
[M + Na] found 277.1781, C15H26O3Na requires 277.1780. 
1
H NMR (300 MHz, 
CDCl3) δ 5.39 (t, J = 7.0 , 1 H, C=CH), 4.61 (t, J = 3.5 , 1 H OCHCH2), 4.24 (dd, J = 12.0, 
6.5, 1 H, CH2OCH), 4.01 (dd, J = 12.0, 7.5 , 1 H, CH2OCH), 3.95 – 3.80 (m, 1 H, 
OCH2CH2), 3.59 – 3.43 (m, 1 H, OCH2CH2), 2.70 (t, J = 12.5, 1 H, CH from epoxide), 2.28 – 
2.05 (m, 2 H, CH2), 1.85 – 1.48 (m, 11 H, 4 x CH2, CH3), 1.29 (s, 3 H, CH3), 1.25 (s, 3 H, 
CH3). 
13
C NMR (75 MHz, CDCl3) δ 99.3, 99.2, 98.5, 66.4, 66.3, 65.8, 63.9, 63.8, 63.7, 62.4, 
62.3, 61.9, 61.6, 61.2, 61.1, 60.7, 60.0, 59.9, 59.8, 59.7, 58.5, 58.4, 35.3, 35.3, 34.9, 30.6, 
30.5, 25.4, 24.9, 24.6, 24.4, 19.5, 19.4, 19.1, 18.7, 17.0, 16.9, 16.8, 16.7. 
 
6.7.9 Preparation of (E)-4-methyl-6-((tetrahydro-2H-pyran-2-yl)oxy)hex-4-enal (253) 
 
 
To a stirred solution of epoxide 252 (9.7 g, 38.0 mmol) in THF (75 mL) and water (45 mL) at 
0 ºC, periodic acid (9.6 g, 42.0 mmol) and sodium periodate (4.0 g, 19.0 mmol) were added. 
The solution was stirred for 30 min and then brine (50 mL) was added. The organic material 
was extracted with diethyl ether (4 x 60 mL), combine ethereal extracts were washed with (2 
x 80 mL), dried over magnesium sulphate and concentrated under reduced pressure. 
Purification of crude product by vacuum chromatography, with hexane and ethyl acetate 
(30:1) as eluent, gave the title compound as yellow oil. 
HRMS EI
+
 [M + Na] found 235.1306, C12H20O3Na requires 235.1310. 
1
H NMR (300 MHz, 
CDCl3) δ 9.75 (bs, 1 H, HCO), 5.36 (t, J = 7.0, 1 H, C=CHCH2), 4.58 (t, J = 3.5, 1 H, 
OCHO), 4.21 (dd, J = 12.5, 6.5, 1 H, CH2OCH), 3.99 (dd, J = 12.0, 7.0, 1 H, CH2OCH), 3.85 
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(m, 1 H, OCH2CH2), 3.54 – 3.37 (m, 1 H, OCH2CH2), 2.55 (t, J = 8.0, 2 H, CH2), 2.34 (t, J = 
7.5, 2 H, CH2), 1.91 – 1.71 (m, 2 H, CH2), 1.67 (s, 3 H, CH3), 1.53 (m, J = 14.0, 5.5, 4 H, 2 x 
CH2 ). 
13
C NMR (75 MHz, CDCl3) δ 202.2 (C=O), 138.0 (HC=C), 121.7 (HC=C), 98.1 
(OCHO), 63.6 (CH2OCH), 62.4 (OCH2CH2), 41.9 (CH2), 31.6 (CH2), 30.7 (CH2), 25.5 
(CH2), 19.7 (CH2), 16.6 (CH3).  
 
6.7.10 Preparation of (E)-4-methyl-6-((tetrahydro-2H-pyran-2-yl)oxy)hex-4-en-1-ol 
(254) 
 
 
To a stirred solution of the aldehyde 253 (2.3 g, 11.0 mmol) in ethanol (100 mL) at 0 ºC 
sodium borohydride (480 mg, 13.0 mmol) was added. The reaction mixture was stirred for 4 
h. Then a mixture acetone / water (70 mL, 1:10) was added, and the resulting mixture was 
concentrated under reduce pressure. The aqueous residue was extracted with diethyl ether (5 
x 30 mL), the combined ethereal extracts were washed with HCl solution 1 M (2 x 50 mL), 
dried over MgSO4 and concentrated under reduced pressure. The crude product was purified 
by vacuum chromatography, with hexane ethyl acetate (3:1) as eluent, to afford the title 
compound as colourless oil (1.9 g, 83%). 
HRMS EI
+
 [M + Na] found 237.1471, C12H22O3Na requires 237.1467. 
1
H NMR (300 MHz, 
CDCl3) δ 5.37 (t, J = 7.0, 1 H, C=CHCH2), 4.59 (t, J = 3.0, 1 H, OCHO), 4.21 (dd, J = 12.0, 
6.5, 1 H, CH2OCH), 3.99 (dd, J = 12.0, 7.0, 1 H, CH2OCH), 3.91 – 3.78 (m, 1 H, OCH2CH2), 
3.60 (t, J = 6.0, 2 H, CH2OH), 3.54 – 3.42 (m, 1 H, OCH2CH2), 2.08 (t, J = 7.5, 2 H, 
CH2CH2C(CH3)=C), 1.92 – 1.72 (m, 2 H, CH2), 1.66 (s, 5 H, CH3, CH2), 1.59 – 1.44 (m, 4 H, 
2 x CH2).
13
C NMR (75 MHz, CDCl3) δ 140.0 (HC=C), 120.9 (HC=C), 98.0 (OCHO), 63.7 
(CH2OCH), 62.6 (OCH2CH2), 62.4 (CH2OH), 36.0 (CH2), 30.7 (CH2), 30.6 (CH2), 25.5 
(CH2), 19.6 (CH2), 16.4 (CH3). 
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6.7.11 Preparation of (E)-2-((6-iodo-3-methylhex-2-en-1-yl)oxy)tetrahydro-2H-pyran 
(255) 
 
 
To a stirred solution of alcohol 254 (0.7 g, 3.5 mmol) in anhydrous DCM (5 mL), toluene-p-
sulfonyl chloride (890 mg, 4.6 mmol) and pyridine (370 µL, 4.6 mmol) were added. The 
reaction mixture was stirred for 16 hours at room temperature in the dark. Then, the mixture 
was cooled to 0 ºC, diluted with DCM (7 mL) and quenched by the addition of water (7 mL). 
Organic material was extracted with DCM (3 x 5 mL). The combine organic extracts were 
washed with solution 1 M HCl (3 x 10 mL), saturated solution of NaHCO3 (2 x 10 mL), brine 
(3 x 10 mL), dried over Na2SO4 and solvent was removed under reduce pressure. The 
resulting yellow oil was used in the next step without further purification. Crude product was 
dissolved in anhydrous acetone (10 mL) and then anhydrous sodium iodide (2.9 g, 17.8 
mmol) was added. The mixture was stirred at room temperature for 24 h. The acetone was 
concentrated under reduce pressure and Na2S2O3 (5 mL) was added to the residue. Organic 
material was extracted with hexane (4 x 10 mL), the combine organic extracts were washed 
with brine (3 x 20 mL) and dried over MgSO4. Solvent was removed under reduce pressure. 
Purification of the crude product by vacuum chromatography with hexane and ethyl acetate 
(40:1) as eluent gave the title compound as a yellow oil (630 mg, 57%).      
HRMS EI
+ 
[M] found 324.0588, C12H21O2I requires 324.0586.
1
H NMR (300 MHz, CDCl3) δ 
5.40 (t, J = 7.0, 1 H, C=CHCH2), 4.61 (t, J = 3.5, 1 H, OCHO), 4.23 (dd, J = 12.0, 6.5, 1 H, 
CH2OCH), 4.07 – 3.96 (m, 1 H, CH2OCH), 3.94 – 3.82 (m, 1 H, OCH2CH2), 3.56 – 3.42 (m, 
1 H, OCH2CH2), 3.16 (t, J = 7.0, 2 H, ICH2CH2), 2.20 – 2.07 (m, 2 H, CH2CH2C=CH), 2.01 
– 1.88 (m, 2 H, CH2), 1.87 – 1.70 (m, 2 H, CH2), 1.66 (s, 3 H, CH3), 1.63 – 1.45 (m, 4 H, 
CH2). 
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6.7.12 Preparation of (E)-(4-methyl-6-((tetrahydro-2H-pyran-2-yl)oxy)hex-4-en-1-
yl)triphenylphosphonium iodide (251) 
 
 
To a stirred solution of iodide 255 (63 mg, 1.9 mmol) in anhydrous diethyl ether (20 mL), 
previously purified triphenyl phosphine (0.6 g, 2.2 mmol) was added. The solution was 
refluxed for 24 h. The reaction mixture was warmed to room temperature. The white 
precipitate was filtrated, washed with anhydrous cold diethyl ether and dried under high 
vacuum to give the title compound as a white solid (734 mg, 67%).  
HRMS EI
+
 found 459.2463, C30H36O2P requires 459.2453.
1
H NMR (400 MHz, CDCl3) δ 
7.91 – 7.61 (m, 15 H, 3 x Ph), 5.32 (t, J = 6.5, 1 H, C=CHCH2), 4.54 (s, 1 H, OCHO), 4.19 
(dd, J = 12.0, 6.5, 1 H, CH2OCH), 3.96 (dd, J = 12.0, 7.0, 1 H, CH2OCH), 3.87 – 3.77 (m, 1 
H, OCH2CH2), 3.74 – 3.61 (m, 2 H, Ph3PCH2), 3.46 (dd, J = 10.0, 5.5 , 1 H, OCH2CH2), 2.38 
(t, J = 7.0 , 2 H, CH2CH2C=CH), 1.87 – 1.61 (m, 4 H, 2 x CH2), 1.59 – 1.42 (m, 7 H, CH3, 2 
x CH2). 
13
C NMR (75 MHz, CDCl3) δ 137.8 (HC=C), 135.2 (Ph), 133.8 (Ph), 133.6 (Ph), 
130.7 (Ph), 130.5 (Ph), 122.6 (HC=C), 118.6 (Ph), 117.5 (PCH2), 98.5 (OCHO), 63.7 
(CH2OCH), 62.7 (OCH2CH2), 30.8 (CH2), 25.4 (CH2), 22.0 (CH2), 20.3 (CH2), 19.8 (CH2), 
16.5 (CH3).
 31
P NMR δ (202.5 MHz, CDCl3) 25.2 (s) 
 
6.7.13 Preparation of 2-(((2E,6Z)-7-(diethoxymethyl)-3,11-dimethyldodeca-2,6,10-trien-
1-yl)oxy)tetrahydro-2H-pyran (276) 
 
 
To a stirred suspension of Phosphonium salt 251 (200 mg, 0.34 mmol) in anhydrous THF (3 
mL) at – 78 ºC n-BuLi (2.5 M solution in hexanes, 136 µL, 0.3 mmol) was added. The 
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resulting orange solution was stirred for 30 min and then ketone 269 (56 mg, 0.3 mmol) was 
added. The reaction mixture was kept at -78 ºC for 3 h and then warmed to -45 ºC for another 
additional 6 h. The reaction was quenched by the addition of saturated solution of NH4Cl (3 
mL) warmed to room temperature and diluted with diethyl ether (3 mL). The organic material 
was extracted diethyl ether Et2O (3 x 5 mL), organic extracts were washed with Na2S2O3 (3 x 
10 mL), brine (2 x 10 mL), dried over MgSO4 and concentrated under reduce pressure. The 
excess of triphenyl phosphorous oxide was removed by dissolving the oil in cold hexane and 
filtration of the white precipitate followed by evaporation under reduce pressure. The crude 
product (80mg) was dissolved in a mixture THF / acetic acid (5 mL, 3:2) and stirred at room 
temperature for 10 min. The reaction mixture was diluted with 5 mL of water. The organic 
material was extracted with diethyl ether (4 x 10 mL), the combine organic extracts were 
washed with saturated aqueous solution of NaHCO3 (3 x 15 mL), brine (2 x 20 mL) and 
concentrate under reduce pressure. Purification of the crude product by flash chromatography 
column with hexane and ethyl acetate (20:1) as eluent gave the title compound as a mixture 
of isomers 6:4 (25 mg, 30%).     
HRMS EI
+
 [M] found 320.2348, C20H32O3 requires 320.2352. 
1
H NMR (400 MHz, CDCl3) δ 
10.09 (s, 1 H, HC=O, Z isomer), 9.35 (s, 1 H, HC=O, E isomer), 6.42 (t, J = 8.0 , 1 H, 
HC=OC=CH), 5.40 (dd, J = 13.0, 5.5, 1 H, C=CH), 5.07 (dt, J = 14.0, 7.0 , 1 H, C=CH), 4.61 
(dd, J = 4.0, 2.5, 1 H, OCHO), 4.25 (dt, J = 12.0, 6.0, 1 H, CH2OCH), 4.10 – 3.95 (m, 1 H, 
CH2OCH), 3.91 – 3.79 (m, 1 H, OCH2CH2), 3.50 (dd, J = 10.5, 4.5, 1H, OCH2CH2), 2.69 
(dd, J = 15.5, 8.0, 1 H, HC=OC=CHCH2), 2.51 – 2.42 (dd, J = 15.5, 8.0, 1 H, 
HC=OC=CHCH2), 2.22 (ddd, J = 21.0, 150, 7.5, 4 H, 2 x CH2), 2.05 (dd, J = 14.0, 7.0 , 2 H, 
CH2), 1.90 – 1.72 (m, 2 H, CH2), 1.72 – 1.64 (m, 8 H, 2 x CH3, CH2), 1.63 – 1.48 (m, 5 H, 
CH3, CH2).
 13
C NMR (101 MHz, CDCl3) δ 195.3 (HC=O, isomer b), 191.0 (HC=O, isomer 
a), 154.6 (HC=OC=CH, b), 148.8 (HC=OC=CH, a), 143.5 (HC=OC=CH, b), 140.0 
(HC=OC=CH, a) , 138.5 (C=CHCH2OTHP, b), 138.3 (C=CHCH2OTHP, a), 132.6 
(C=CHCH2OTHP, b), 132.4 (C=CHCH2OTHP, a), 123.7 ((CH3)2C=CH, b), 123.6 
((CH3)2C=CH, a), 122.3 ((CH3)2C=CH, b), 122.1 ((CH3)2C=CH, a), 98.1 (OCHO), 63.7 
(CH2OCH, b), 63.6 (CH2OCH, a) , 62.5 (OCH2CH2, b), 62.4 (OCH2CH2, a) , 39.4 (CH2, b), 
38.3(CH2, a), 30.8(CH2, b), 30.5 (CH2, a), 30.2 (CH2, b), 29.8 (CH2, a), 27.4 (CH2), 27.2 
(CH2, b), 27.1 (CH2, a), 25.9 (CH2, b), 25.8 (CH2, a), 25.6 (CH2), 25.0 (CH2, b), 24.4 (CH2, 
a), 19.7 (CH3, b), 19.7 (CH3, a), 17.9 (CH3, b), 17.8 (CH3, a), 16.5 (CH3, b), 16.5 (CH3, a). 
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6.7.14 Preparation of (2Z,6E)-6-methyl-2-(4-methylpent-3-en-1-yl)-8-((tetrahydro-2H-
pyran-2-yl)oxy)octa-2,6-dien-1-ol (277) 
 
 
To a stirred solution of aldehyde 276 (25 mg, 0.1 mmol) in EtOH (1.5 mL) at 0 ºC, Sodium 
borohydride (6 mg, 0.1 mmol) was added. The mixture was stirred for 2 h. The reaction was 
quenched by the addition of acetone (3 mL) and water (5 mL). Organic solvent was removed 
under reduce pressure. The organic material was extracted from the aqueous residue with 
hexane (5 x 5 mL), combined organic extracts were washed with saturated aqueous NaHCO3 
solution (2 x 10 mL) and brine (3 x 10 mL). Solvent was removed under reduce pressure. The 
crude product was purified, and the two isomers separate, by vacuum chromatography with 
mixture of hexane and ethyl acetate (gradient 50:1 to 30:1) as eluent to afford the title 
compound as colourless oil (9 mg, 36%) 
HRMS ES
+ 
[M + Na] found 245.2390, C20H34O3Na requires 345.2406.
 1
H NMR (300 MHz, 
CDCl3) δ 5.37 (m, 2 H, 2 x C=CH), 5.11 (bs, 1 H, C=CH), 4.63 (t, J = 3.5, 1 H, OCHO), 4.24 
(dd, J = 11.5, 6.0, 1 H, CH2OCH), 4.02 (bs, 2 H, CH2OH), 3.93 – 3.82 (m, 1 H, CH2OCH), 
3.74 (t, J = 6.5, 1 H, OCH2CH2), 3.61 – 3.44 (m, 1 H, OCH2CH2), 2.25 – 2.00 (m, 8 H, 4 x 
CH2), 1.89 – 1.77 (m, 2 H, CH2), 1.68 (s, 6 H, CH3), 1.64 – 1.48 (m, 7 H, CH3, 2 x CH2).
13
C 
NMR (126 MHz, CDCl3) δ 139.8 (C=CH), 139.0 (C=CH), 131.7 (C=CH), 127.8 (C=CH), 
124.2 (C=CH), 121.3 (C=CH), 97.9 (OCHO), 63.6 (CH2OCH), 62.2 (OCH2CH2), 60.2 
(CH2OH), 39.5 (CH2), 35.0 (CH2), 30.6 (CH2), 27.1 (CH2), 25.8 (CH2), 25.7 (CH2), 25.5 
(CH2), 19.5 (CH3), 17.7 (CH3), 16.5 (CH3). 
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6.7.15 Preparation of (2Z,6E)-6-methyl-2-(4-methylpent-3-en-1-yl)-8-((tetrahydro-2H-
pyran-2-yl)oxy)octa-2,6-dien-1-yl acetate (278) 
 
 
To a stirred solution of alcohol 277 (21 mg, 0.1 mmol) in DCM (2 mL) at room temperature, 
pyridine (50 μL, 0.6 mmol) and acetic anhydride (50 μL, 0.5 mmol) were added. The mixture 
was stirred at this temperature overnight. The reaction was diluted with DCM (10 mL) and 
10% aqueous HCl solution (5 mL) was added, the mixture was stirred for 15 min at room 
temperature. Organic material was extracted with DCM (3 x 5 mL), combined organic 
extracts were washed with aqueous saturated NaHCO3 solution (3 x 10 mL), brine (2 x 15 
mL) and dried over MgSO4. Solvent was removed under reduced pressure. The crude product 
was purified by flash chromatography column with mixture of hexane and ethyl acetate 
(gradient from 40:1 to 30:1) as eluent to afford the title mixture of compounds as a colourless 
oil (17 mg, 71%).    
HRMS ES
+ 
[M] found 364.2609, C22H36O4 requires 364.2614. 
1
H NMR (300 MHz, CDCl3) 
δ 5.46 (t, J = 7.0, 1 H, C=CH), 5.37 (t, J = 8.0, 1 H, C=CH), 5.10 (s, 1 H, C=CH), 4.62 (t, J = 
3.5, 1 H, OCHO), 4.58 (s, 1 H, CH2OAc isomer), 4.48 (s, 2 H, CH2OAc isomer), 4.24 (dd, J 
= 12.0, 6.5 , 1 H, CH2OCH), 4.07 – 3.95 (m, 1 H, CH2OCH), 3.94 – 3.83 (m, 1 H, 
OCH2CH2), 3.58 – 3.45 (m, 1 H, OCH2CH2), 2.19 (dd, J = 15.5, 7.5, 2 H, CH2), 2.13 – 2.02 
(m, 9 H, CO=OCH3, 3 x CH2), 1.83 (ddd, J = 22.0, 13.0, 7.5, 2 H, CH2), 1.68 (s, 6 H, 2 x 
CH3), 1.64 – 1.46 (m, 7 H, CH3, 2 x CH2).
13
C NMR (75 MHz, CDCl3) δ 171.1 (C=OOCH3), 
139.6 (C=CH), 134.2 (C=CH), 132.1 (C=CH), 130.1 (C=CH), 123.8 (C=CH), 121.0 (C=CH), 
97.9 (OCHO), 68.7 (CH2C=OOCH3), 63.6 (CH2OCH), 62.3 (OCH2CH2), 35.2 (C=OOCH3), 
30.7 (CH2), 28.4 (CH2), 26.9 (CH2), 26.0 (CH2), 25.8 (CH2), 25.5 (CH2), 21.1 (CH2), 19.6 
(CH3), 17.7 (CH3), 16.5 (CH3). 
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6.7.16 Preparation of (2Z,6E)-8-hydroxy-6-methyl-2-(4-methylpent-3-en-1-yl)octa-2,6-
dien-1-yl acetate (249) 
 
 
To a stirred solution of protected alcohol 278 (17 mg, 0.05 mmol) in methanol (2 mL) at 
room temperature, pyridinium p-toluenesulfonate (41 mg, 0.2 mmol) was added. The mixture 
was stirred overnight. The reaction was diluted with diethyl ether (10 mL) and saturated 
aqueous NaHCO3 solution (10 mL) was added. The organic material was extracted with Et2O 
(5 x 10 mL), combined organic extracts were washed with brine (2 x 30 mL), dried over 
MgSO4 and concentrated under reduced pressure. Crude product was purified by flash 
chromatography column with mixture of hexane and ethyl acetate (4:1) as eluent to afford the 
title mixture of isomers as colourless oil (9 mg, 68%). 
HRMS EI
+ 
[M + Na] found 303.1930, C17H28O3Na requires 303.1936. 
1
H NMR (300 MHz, 
CDCl3) δ 5.43 – 5.28 (m, 2 H, 2 x C=CH), 5.04 (bs, 1 H, C=CH), 4.52 (s, 1 H, CH2OAc 
isomer), 4.42 (s, 1 H, CH2OAc isomer), 4.08 (d, J = 7.0 , 2 H, CH2OH), 2.13 (dd, J = 15.5, 
7.7 , 2 H, CH2), 2.02 (s, 9 H, C=OOCH3, 3 x CH2), 1.61 (bs, J = 2.0, 6 H, 2 x CH3), 1.54 (s, 3 
H, CH3).
13
C NMR (126 MHz, CDCl3) δ 171.1 (C=OOCH3), 139.1 (C=CH), 134.5 (C=CH), 
132.2 (C=CH), 130.0 (C=CH), 124.1 (C=CH), 123.9 (C=CH), 68.7 (CH2OAc), 59.5 
(CH2OH), 39.3 (CH2), 28.6 (C=OOCH3), 27.0 (CH2), 26.0 (CH2), 25.8 (CH2), 21.2 (CH3), 
17.8 (CH3), 16.3 (CH3). 
 
6.8 Synthesis of 8OH- FDP (141) 
6.8.1 Preparation of (2E,6E)-8-hydroxy-3,7-dimethylocta-2,6-dien-1-yl acetate (237) 
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To a stirred solution of THP geranyl acetate (1.0 g, 5.1 mmol) in DCM (20 mL), SeO2 (47 
mg, 0.42 mmol), t-BuOOH (1.8 mL, 13.4 mmol) and salicylic acid (60 mg, 0.4 mmol) were 
added at 0 ºC. Reaction mixture was kept at this temperature for 5 h and then water (10 mL) 
was added. The organic material was extracted with DCM (3 x 15 mL), combine organic 
extracts were washed with saturated aqueous NaHCO3 solution (2 x 15 mL), brine (3 x 15 
mL), dried over MgSO4 and concentrate under reduce pressure. Purification of the crude 
product by vacuum chromatography with hexane and Ethyl acetate (gradient from 5:1 to 3:1) 
as eluent gave the title compound as pale yellow oil (480 mg, 44%).   
HRMS EI
+ 
[M + Na] found 235.1308, C12H20O3Na requires 235.1310. 
1
H NMR (300 MHz, 
CDCl3) δ 5.38 – 5.26 (m, 2 H, 2 x C=CH), 4.55 (d, J = 7.0, 2 H, CHCH2C=OAc), 3.95 (s, 2 
H, CH2OH), 2.12 (m, 4 H, 2 x CH2 ), 2.03 (s, 3 H, OC=OCH3), 1.68 (s, 3 H, CH3), 1.63 (s, 3 
H, CH3).
13
C NMR (75 MHz, CDCl3) δ 171.4 (CHCH2C=OOMe), 141.9 (C=CH), 135.3 
(C=CH), 125.2 (C=CH), 118.6 (C=CH), 68.8 (CHCH2C=OOMe), 61.5 (CH2OH), 39.1 
(CH2), 25.7 (CH2), 21.1 (OC=OCH3), 16.5 (CH3) , 13.7 (CH3). 
 
6.8.2 Preparation of (2E,6E)-2,6-dimethyl-8-((tetrahydro-2H-pyran-2-yl)oxy)octa-2,6-
dienal (235) 
 
 
To a stirred solution of alcohol 237 (0.4 g, 1.9 mmol) in DCM (5 mL) containing molecular 
sieves 3Å at 0 ºC, PDC (920 mg, 2.5 mmol) was added and the solution was stirred for 4 h at 
this temperature. The reaction mixture was filtrate through celite® and washed with diethyl 
ether (50 mL). The organic filtrates were concentrate under reduce pressure. The crude 
product was purified by vacuum chromatography with a mixture of hexane and ethyl acetate 
(10:1) as eluent to afford the title compound as pale yellow oil (270 mg, 67%) 
HRMS EI
+ 
[M + H] found 211.1329, C12H19O3 requires 211.1334. 
1
H NMR (300 MHz, 
CDCl3) δ 9.43 – 9.29 (m, 1 H, C=OCH), 6.43 (t, J = 7.0, 1 H, C=CH), 5.35 (t, J = 7.0, 1 H, 
C=CH), 4.56 (d, J = 6.0, 2 H, C=CHCH2OC=O), 2.47 (q, J = 7.0 , 2 H, CHCH2), 2.21 (t, J = 
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7.5, 2 H, CH2), 2.05 – 1.99 (m, 3 H, HC=OCCH3), 1.71 (s, 6 H CH3, OC=OCH3).
13
C NMR 
(75 MHz, CDCl3) δ 195.3 (O=CH), 171.1 (C=OCH3), 153.6 (C=CH) , 140.5(C=CH), 139.7 
(C=CH), 119.6 (C=CH), 61.2 (CHCH2OC=O), 37.8 (CH2), 27.0 (CH2), 21.1(OCH3), 16.5 
(CH3), 9.3 (CH3). 
 
6.8.3 Preparation of (5E,9E)-3,3,5,9-tetramethyl-11-((tetrahydro-2H-pyran-2-
yl)oxy)undeca-1,5,9-trien-4-ol (240) 
 
 
To freshly distilled diethyl ether (2 mL) containing Mg (240 mg, 10.0 mmol) tunings, 
previously activated at 180 ºC, small crystal of I2 and 1,2-dibromoethane (2.8 μL, 0.03 mmol) 
were add. To the pale purple mixture at 0 ºC, a solution of 3, 3-dimethylallyl bromide (0.5 g 
3.3 mmol) and the aldehyde 235 (130 mg, 0.7 mmol) in Et2O (7 mL) were added. The 
mixture was slowly taken to reflux whereupon the purple colour disappeared and a cloudy 
solution was formed. The mixture was refluxed for 2.5 h until clear solution was formed with 
a yellow grey precipitate on the bottom. The reactions was cooled to 0 ºC and quenched by 
the addition of water (15 mL). The organic material was extracted with diethyl ether (3 x 15 
mL), the combined organic extracts were washed with brine (3 x 20 mL), dried over Na2SO4 
and the solvent was removed under reduced pressure. The crude product was purified by 
flash chromatography column with a mixture of hexane and ethyl acetate (1:1) as eluent to 
afford the title compound as colourless oil (110 mg, 71%).  
HRMS EI
+ 
[M-H2O] found 221.1903, C15H24O requires 221.1905, 
1
H NMR (250 MHz, 
CDCl3) δ 5.84 (dd, J = 17.5, 11.0, 1 H, H2C=HC), 5.32 (t, J = 7.0, 1 H, C=CH), 5.24 (t, J = 
6.5, 1 H, C=CH), 5.05 – 4.91 (m, 2 H, H2C=HC), 4.06 (d, J = 7.0 , 2 H, CH2OH), 3.68 (s, 1 
H, CHOH), 2.08 (dt, J = 20.5, 7.5, 4 H, 2 x CH2), 1.60 (s, 3 H, CH3), 1.54 (s, 3 H, CH3), 0.94 
(s, 3 H, CH3), 0.91 (s, 3 H, CH3).
13
C NMR (75 MHz, CDCl3) δ 145.7 (C=CH), 139.0 
(C=CH), 135.3 (H2C=HC), 128.6 (C=CH), 123.9 (C=CH), 113.0 (H2C=HC), 83.7 (C), 59.3 
(CH2OH), 42.0 (CHOH), 39.1 (CH2), 25.8 (CH2), 25.1 (CH3), 22.5 (CH3), 16.2 (CH3), 14.3 
(CH3). 
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6.8.4 Preparation of (2E,6E)-8-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl 
acetate (241) 
 
 
To a stirred solution of farnesyl acetate (5.0 g, 19.0 mmol) in DCM (40 mL) at room 
temperature, selenium dioxide (210 mg, 1.9 mmol) and t-butyl peroxide 70% solution (8.4 
mL, 16.4 mmol) were added. The solution was stirred for 4 h. Then, Water (10 mL) was 
added and the mixture was extracted with DCM (3 x 15 mL). The combined organic extracts 
were washed with 10% NaOH aqueous solution (2 x 30 mL) and brine (3x 40 mL). After 
drying over MgSO4 and concentration under reduce pressure, the crude product was purified 
by flash chromatography column with hexane and ethyl acetate  (gradient from 10:1 to 4:1) 
as eluent to afford two separate acetoxyfarnesyl alcohols, (0.4 g, 8%) and (0.7 g, 13%).     
HRMS EI
+ 
[M + Na] found 303.1924, C17H28O3Na requires 303.1936, 
1
H NMR (500 MHz, 
CDCl3) δ 5.41 – 5.29 (m, 2 H, 2 x C=CH), 5.08 (t, J = 7.0, 1 H, C=CH), 4.58 (d, J = 7.0, 2 H, 
CH2OH), 3.97 (dd, J = 7.5, 6.0 , 1 H, CHOH), 2.33 – 2.05 (m, 6 H, CH2), 2.05 (s, 3 H, 
C=OCH3), 1.71 (s, 3 H, CH3), 1.70 (s, 3 H, CH3), 1.63 (s, 3 H, CH3), 1.61 (s, 3 H, CH3).
13
C 
NMR (126 MHz, CDCl3) δ 171.2 (C=OCH3), 141.9 (C=CH), 137.5 (C=CH), 134.7 (C=CH), 
125.5 (C=CH), 120.3 (C=CH), 118.8 (C=CH), 77.3 (CH2OH), 61.5 (CHOH), 39.2 (CH2), 
34.4 (CH2), 26.0 (CH2), 25.8 (C=OCH3), 21.1 (CH3), 18.1 (CH3), 16.6 (CH3), 11.8 (CH3). 
 
6.8.5 Preparation of (2E,6E)-3,7,11-trimethyldodeca-2,6,10-triene-1,8-diol (238) 
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To a suspension of lithium aluminium hydride (30 mg, 0.8 mmol) in anhydrous diethyl ether 
(1 mL) at 0 ºC, a solution of the acetoxyfarnesyl alcohol 241 (100 mg, 0.35 mmol) in 
anhydrous diethyl ether (2 mL), was added drop-wise via syringe. The grey solution was 
stirred for 20 min. The reaction was diluted with diethyl ether (10 mL), quenched by the 
addition of 10% aqueous HCl solution (4 mL) and stirred for an additional 1 h at room 
temperature. Organic material was extracted with diethyl ether (3 x 10 mL). The combined 
organic extracts were washed with saturated NaHCO3 aqueous solution (3 x 15 mL), brine (3 
x 20 mL), dried over MgSO4 and concentrated under reduce pressure. The crude product was 
purified by flash chromatography column with hexane and ethyl acetate (2:1) as eluent to 
afford the title compound as pale yellow oil (74 mg, 87%).      
HRMS EI
+ 
[M-H2O] found 220.1827, C15H24O requires 220.1827,
 1H NMR (500 MHz, 
CDCl3) δ 5.35 (dt, J = 14.0, 7.0 , 2 H, 2 x C=CH), 5.06 (t, J = 7.0 , 1 H, C=CH ), 4.11 (d, J = 
6.5 , 2 H, CH2OH), 3.95 (t, J = 6.5 , 1 H, CHOH), 2.38 – 1.94 (m, 6 H, 3 x CH2), 1.69 (s, 3 H, 
CH3), 1.65 (s, 3 H, CH3), 1.61 (s, 3 H, CH3), 1.59 (s, 1 H, CH3).
13
C NMR (126 MHz, CDCl3) 
δ 139.0 (C=CH), 137.3 (C=CH), 134.6 (C=CH), 125.7 (C=CH), 124.0 (C=CH), 120.3 
(C=CH), 77.3 (CH2OH), 59.3 (CHOH), 39.2 (CH2), 34.3 (CH2), 25.9 (CH2), 25.8 (CH3), 18.1 
(CH3), 16.3 (CH3), 11.8 (CH3). 
 
6.9 Synthesis of 10F-FDP (290) 
 
 
To a stirred suspension of LiCl (110 g, 2.7 mmol) in anhydrous DMF (3 mL) at 0 °C, S-
collidine (0.2 mL, 1.0 mmol) and methanesulfonyl chloride (20 µL, 250 µmol) were added. 
The resulting solution was stirred for 15 min during which time a white cloudy precipitate 
formed. 10F farnesol (40 mg, 0.2 mmol) was added drop-wise as a solution in anhydrous 
DMF (1.5 mL), the reaction mixture was stirred to 0 °C for 4 h. The mixture was diluted in 
cold pentane (7 mL) and cold water (15 mL). Organic material was extracted with pentane (3 
x 10 mL). Combined organic extracts were washed with saturated CuSO4  aqueous solution 
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(3 x 15 mL), saturated  NaHSO4  aqueous solution(2 x 15 mL) and brine (2 x 20 mL) before 
drying (MgSO4) and filtration. The solvent was concentrated under reduced pressure and the 
crude allylic chloride (43 mg) was used in the next step without further purification. 
To a solution of the crude allylic chloride in anhydrous CH3CN (1 mL) was added tris-
(tetrabutylammonium) hydrogendiphosphate (270 mg, 0.3 mmol) and the mixture was stirred 
at room temperature for 24 h. The solvent was removed under reduced pressure and the 
residue was dissolved in ion-exchange buffer (25 mM NH4HCO3 containing 2% i-PrOH, 4 
mL). This solution was slowly passed through a column containing DOWEX 50W-X8 (100-
200 mesh) cation exchange resin (NH4
+
 form) that had been pre-equilibrated. Once ion 
exchange was complete, fractions containing product were lyophilised to dryness. The 
resulting white solid was triturated with MeOH (3 x 10 mL), the first fraction was discard and 
rest of organic extracts were concentrated to dryness under reduced pressure affording yellow 
solid which was cleaned with CDCl3 (3 x 3 mL) to give the partially pure title compound as a 
white solid (29 mg, 38%). The solid residue from the trituration step was further purified by 
reverse-phase HPLC (150 × 21.2 mm Phenomenex Luna column, eluting with 10% B for 20 
min, then a linear gradient to 60% B over 25 min and finally a linear gradient to 100% B over 
5 min.; solvent A: 25 mM NH4HCO3 in water, solvent B: CH3CN, flow rate 5.0 mL/min, 
detecting at 220 nm). Once purification was complete the solution was again lyophilised to 
dryness giving the title compound as a fluffy white solid (21 mg, 28% yield).  
HRMS ES
- 
[M-H] found 399.1126, C15H26O7FP2 requires 399.1138. 
1
H NMR (400 MHz, 
D2O) δ 5.43 (t, J = 7.0, 1 H, C=CH), 5.19 (t, J = 6.5, 1 H, C=CH), 4.43 (t, J = 6.5, 2 H, 
CH2OPP), 2.35 (dt, J = 25.0, 7.0 , 2 H, CFCH2), 2.12 (dd, J = 13.5, 6.0, 4 H, 2 x CH2), 2.07 – 
2.00 (m, 2 H, CH2), 1.68 (s, 3 H, CH3), 1.60 (s, 3 H, CH3), 1.56 (d, J = 2.9, 3 H, 1 x 
(CH3)2C=CF), 1.53 (d, J = 2.5 , 3 H, 1 x (CH3)2C=CF). 
31
P NMR δ (202.5 MHz, 
2
D2O) -9.5 
(d, JPP = 20.8), -5.7 (d, JPP = 20.8).
19
F NMR (282.8 MHz, CDCl3) δ -113.9 (t, J = 27.5, 
(CH3)2C=CFCH2). Data in agreement with previously publish data by Cane et al.
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6.10  Synthesis of (3E,7E)-4,8,12-trimethyltrideca-1,3,7,11-tetraene    
6.10.1 Preparation of (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienal (361) 
 
 
To a stirred solution of farnesol (60 mg, 27 μmol) in hexane (7 mL) at 0 ºC, MnO2 (490 mg 
5.6 mmol) was added and the mixture was stirred at this temperature for 4 h. The reaction 
mixture was filtrated over neutral celite and the filtrate was concentrate under reduce 
pressure. The crude product was purified by flash chromatography column with hexane and 
ethyl acetate (10:1) as eluent, to afford colourless oil (48 mg, 80%). 
HRMS ES
+
 [M] found 220.1823, C15H24O requires 220.1827. 
1
H NMR (300 MHz, CDCl3) δ 
9.99 (d, J = 8.0, 1 H, HC=O), 5.88 (d, J = 8.0, 1 H, C=CHC=OH), 5.17 – 4.98 (m, 2 H, 2 x 
C=CH), 2.28 – 2.18 (m, 4 H, CH2), 2.17 (bd, J = 1.0, 3 H, CH3C=CHC=OH), 2.11 – 1.93 (m, 
4 H, 2 x CH2), 1.67 (s, 4 H, 2 x CH2), 1.59 (d, J = 2.0, 6 H, 2 x CH3). 
13
C NMR (75 MHz, 
CDCl3) δ 191.4 C=O, 164.1 (HC=C), 136.6 (HC=C), 131.6 (HC=C), 127.4 (HC=C), 124.1 
(HC=C), 122.5 (HC=C), 40.6 (CH2), 39.7 (CH2), 26.6 (CH2), 25.8 (CH2), 25.7 
(CH3C=CHC=OH), 17.7 (CH3), 17.7 (CH3), 16.1 (CH3). 
 
6.10.2 Preparation of (3E,7E)-4,8,12-trimethyltrideca-1,3,7,11-tetraene (362) 
 
 
Methyltriphenylphosphonium bromide (115 mg, 0.3 mmol) and potassium t-butoxide (36 mg, 
0.3 mmol) were dissolved in THF (0.7 mL) at room temperature. The resulting solution was 
stirred at this temperature for 10 min and then the yellow mixture was cooled to -78 ºC. A 
solution of the aldehyde 361 (48 mg, 0.2 mmol) in THF (0.5 mL) was added. After stirring 
the reaction for 1 h at this temperature water (0.4 mL) was added, the white precipitate was 
filtrated and the yellow filtrate was evaporate using a stream of N2. The crude product was 
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purified by flash chromatography column with hexane and diethyl ether (10:1) as eluent to 
afford the title compound as yellow oil (29 mg, 62%).    
HRMS EI
+
 [M] found 218.2038, C16H26 requires 218.2035, 
1
H NMR (300 MHz, CDCl3) δ 
6.59 (dt, J = 17.0, 10.5, 1 H, C=CHCH=CH2), 5.86 (d, J = 11.0, 1 H, C=CHCH=CH2), 5.12 
(bs, 2 H, 2 x C=CH), 5.08 (dd, J = 8.0, 1.5, 1 H, C=CHCH=CH2), 4.98 (dd, J = 10.0, 2.0, 1 
H, C=CHCH=CH2), 2.25 – 1.93 (m, 8 H, 4 x CH2), 1.77 (s, 3 H, CH3), 1.68 (s, 3 H, CH3), 
1.60 (s, 6 H CH3).
13
C NMR (75 MHz, CDCl3) δ 139.6 (C=CH), 135.4 (C=CH), 133.4 
(C=CH), 131.4 (C=CH), 125.5 (C=CH), 124.3 (C=CH), 123.9 (C=CH), 114.6 (CH=CH2), 
39.9 (CH2), 39.7 (CH2), 26.7 (CH2), 26.4 (CH2), 25.8 (CH3), 17.7 (CH3), 16.7 (CH3), 16.0 
(CH3). 
 
6.11 Synthesis of FDP (17) 
6.11.1 Preparation of tris-(tetrabutylammonium)hydrogen diphosphate (171) 
 
 
A solution of 3.5 g (16.0 mmol) of disodium dihydrogen diphosphate in aqueous ammonium 
hydroxide (10%, 17 mL) was passed through a column of Amberliyst (Acidic form). The free 
acid was eluted with water (120 mL). The resulting solution (pH 1.2) was immediately 
titrated to pH 7.3 with 40% (w/w) aqueous tetra-n-butylammonium hydroxide solution. The 
solution was dried by lyophilisation to yield 15.2 g of a white solid. The white solid was 
partially dried by treating with of acetonitrile (3 x 90 mL) and azeotropic removal of solvent 
by rotary evaporation to yield a sticky solid. This material was warmed to 40 ºC in ethyl 
acetate (250 mL) before gravity filtration. The clear, colourless filtrate was concentrated by 
rotary evaporation until White solid stars crashing out and then cooled to -20 ºC. The short, 
white powder was filtrated under N2 and dried under high vacuum. The title compound was 
recovered as a hygroscopic white solid (9.2 g, 65%). 
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HRMS EI
-
 found 176.9356, H3O7P2 requires 176.9354.
1
H NMR (400 MHz, CDCl3) δ 3.38 – 
3.27 (m, 2 H, NCH2), 1.61 (dt, J = 16.0, 8.0, 2 H, CH2), 1.49 – 1.33 (m, 2 H, CH2), 0.93 (t, J 
= 7.5 , 3 H, CH3).
13
C NMR (101 MHz, CDCl3) δ 58.7 (NCH2), 24.2 (CH2), 19.7 (CH2), 13.8 
(CH3).
 31
P NMR (202 MHz, CDCl3) δ -5.67 
 
6.11.2 Preparation of trisammonium (2E,6E)-11-methyldodeca-2,6,10-trienyl 
diphosphate (17) 
 
 
To a stirred solution of farnesol (700 mg, 3.1 mmol) in anhydrous DMF (42 mL) at 0 ºC, s-
collidine (2.35 mL, 19 mmol) and methanesulfonyl chloride (364 µl, 4.7 mmol) were added. 
After 20 min stirring at this temperature, lithium chloride (2.1 g, 50.0 mmol) was added to the 
solution. After 3 h at this temperature, the reaction was quenched by the addition of cold 
water (30 mL). The biphasic mixture was diluted with pentane and organic material was 
extracted with pentane (3 x 20 mL), the combined organic extracts were washed with 
saturated aqueous CuSO4  solution (3 x 30 mL), water (3 x 30 mL), saturated aqueous 
NaHCO3 solution (3 x 20 mL), dried over MgSO4 and solvent were removed under reduce 
pressure. The crude chloride was used in the next step without further purification. 
To a stirred solution of crude allylic chloride (750 mg) in acetonitrile (13 mL) tris-
(tetrabutylammonium)hydrogen diphosphate (7 g, 7.8 mmol) was added. The reaction was 
stirred at room temperature for 16 h. Acetonitrile was removed under reduced pressure, the 
remaining yellow oil was dissolved in buffer (15 mL, 25 mM of NH4HCO3, 2% isopropanol) 
and passed thought an ion exchange column DOWEX 40 W (NH4
+
 form). The eluent from 
the ion exchange column was monitored by TLC (isopropanol / buffer / NH4OH 6:2:2, 
staining with phosphomolibdic acid 10% in EtOH stain). Fractions containing product were 
collected and freeze dried. The yellow solid was diluted in buffer (15 mL). The crude was 
purified by reverse-phase HPLC (150 × 21.2 mm Phenomenex Luna column, eluting with 
10% B for 20 min, then a linear gradient to 60% B over 25 min and finally a linear gradient 
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to 100% B over 5 min.; solvent A: 25 mM NH4HCO3 in water, solvent B: CH3CN, flow rate 
5.0 mL/min, detecting at 220 nm) in injections of 1.5 mL.  The flow through of the HPLC 
was freeze dried and title compound was recovered as a white solid (recover in each injection 
85 mg, 6%) 
HRMS EI
-
 [M+2H] found 381.1237, C15H27O7P2 requires 381.1232,
 1
H NMR (250 MHz, 
D2O) δ 5.38 (t, J = 7.0, 1 H, C=CH), 5.16 – 5.00 (m, 2 H, 2 x C=CH), 4.39 (t, J = 6.5, 2 H, 
CH2OPP), 2.15 – 1.83 (m, 8 H, 4 x CH2), 1.65 (s, 3 H, CH3), 1.59 (s, 3 H, CH3), 1.54 (s, 3 H, 
CH3), 1.52 (s, 3 H, CH3) 
31
P NMR δP (121.6 MHz, D2O ) -5.82 (d, JPP = 15.0), -9.53 (d, JPP = 
15.0). 
 
6.12 Preparation of enzymes 
6.12.1 General methods 
LB media was prepared by dissolving tryptone (3 g), yeast extract purchased from Fluka and 
NaCl (30 g) in 3 L of deionised water.  
Cell lysis buffer was prepared by dissolving of EDTA (5 mM), β-mercaptoethanol (5 mM) 
and tris-base (20 mM). The pH of the resulting solution was adjusted to 7.5 with 0.1 M 
aqueous solution of HCl. In the case of GDS detergent Tween
®
 20 (0.2%) was added to the 
buffer. 
Dialysis buffer was prepared by dissolving tris-base (10 mM), NaCl (50 mM) and β-
mercaptoethanol (5 mM) in deionised water. The pH was adjusted to 7.5 with 0.1 M aqueous 
solution of HCl. In the case of GDS detergent Tween
®
 20 (0.2%) was added to the buffer. 
Binding buffer was prepared by dissolving tris base (50 mM), NaCl (500 mM), ME (10 
mM) and imidazole (5 mM), The pH was adjusted to 8 with 0.1 M aqueous solution of HCl . 
 
6.13 Preparation of AS 
The expression of cDNA for AS and the purification of AS were performed according to 
published procedures.
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6.13.1 Transformation of E. coli BL21 (DE3) with cDNA for wild-type AS 
A 100 μL sample of E. coli BL21(DE3) competent cells (from Dr. Veronica Garcia) in a 
Eppendorf vial was slowly defrost on ice. The vector containing a cDNA for AS and 
ampicillin resistance (1 μL, pZW04) was added to the cell solution. The preparation was left 
on ice for 30 min and then the mixture was thermally shocked by leaving the sample in a 
water bath at 42 ºC for 45 s before returning the vial to the ice bath for 2 min. LB medium (1 
mL) was added to the transformed cells and the solution was incubated with shaking (150 
rpm) at 37 ºC for 1 h. The cells were harvested  by centrifugation (6000 rpm) for 1 min. The 
cells were re-suspended in the minimum amount of LB media and the mixture was spread 
onto an agar plate containing ampicillin. The plate was incubated at 37 ºC for 12 h. 
 
6.13.2 Over expression of AS   
Ampicillin (53 mg) was added to sterilised LB media (100 mL) and the resulting LB-amp 
solution was inoculated with a single colony of pZW04 transformed E. coli BL21(DE3). The 
culture was inoculated at 37 ºC overnight with shaking. The resulting culture was used to 
inoculate LB (4 x 500 mL, 5mL to each flask), containing ampicillin (53 mg each flask). The 
growth of bacteria was monitored by checking the OD of 1 mL of media at 600 nm until it 
reached 0.71, then the culture was induced by the addition of isopropyl-1-thio-β-D-
galactopyranoside (IPTG, 63 mg each flask). The induced cultures were incubated at 37 ºC 
for 3 h. Cells were harvested by centrifugation at 5000 rpm for 20 min, the supernatant 
solution was discarded and the pellets were stored at – 20 ºC. 
 
6.13.3 Base extraction and refolding of aristolochene synthase 
Combined pellet from culture were dissolved in cell lysis buffer (50 mL). The mixture was 
put in an ice bath and sonicated for 15 min (40% amplitude for 3 min with 5 s on/10 s off 
cycles). The resulting mixture was centrifuge at 5000 rpm for 10 min. The supernatant 
solution was discarded and the pellet was resuspended in fresh cell lysis buffer (70 mL). The 
stirred suspension was cooled to 0 ºC and taken to pH 11.5 by the addition of aqueous 
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solution of NaOH (0.1 M). The solution was stirred for 20 min at this temperature. To the 
resulting stirred solution at 0 ºC β-mercaptoethanol (25 μL) was added and then pH was 
reduced to 8 at 0 ºC by the addition of aqueous HCl solution (0.1 M). The mixture was then 
stirred at this temperature for 30 min. The solution was centrifuge at 15000 rpm at 4 ºC for 30 
min. The pellet was discarded and the supernatant was stored at 4 ºC. 
 
6.13.4 Purification of AS by ion-exchange chromatography 
The crude protein was purified by anion exchange chromatography on a Q-Sepharose
TM 
(Amersham Pharmacia Biotech
TM
) High Performance (2.5 × 20 cm) column. The absorbance 
of the eluate was measured at 280 nm to identify fractions containing protein. The cell free 
extract was loaded onto the column and then cell lysis buffer (150 mL) was used to remove 
any unbound protein. Protein was eluted with lysis buffer containing NaCl solution (500 mL 
gradient from 0.1 to 0.6 M) and then the column was washed with high salt lysis buffer 
solution (200 mL, 1 M, NaCl) to elute any remaining protein in the column. The presence of 
protein in fractions was confirmed by SDS-PAGE. 
 
6.13.5 Dialysis and concentration of AS solutions 
Fractions containing protein of the correct molecular weight as judged by SDS-PAGE were 
pooled and dialysed using Spectrum
TM 
Spectra/Por molecular porous dialysis membrane 
(MW = 35000 cut off). The protein solution was dialysed in 3 litre of dialysis buffer at 4 ºC 
for 1 day.  
The resulting protein solution was concentrated at 3 bar in a Amicon
TM 
ultrafiltration 
apparatus containing a millipore 44.5 mm ultrafiltration membrane. The sample was 
concentrate to 4-5 mL and was stored at -20 ºC. 
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6.14 Preparation of GDS  
Transformation of E. coli BL21 (DE3) with cDNA for wild-type GDS-His6, Over expression, 
base extraction and refolding were performed following the same procedure as for AS. 
  
6.14.1 Purification of GDS  
The solution containing the protein was dialysed overnight. Then the solution was loaded 
onto a Ni Sepharose
TM
 6 Fast Flow column (GE Healthcare, 12 mL, the column was eluted 
under gravity controlled drip flow). After 30 min, the column was washed with 4 CV of 
binding buffer followed by a gradient from 50 to 500 mM imidazole in binding buffer (20 
CV) then a wash with 500 mM imidazole in binding buffer (10 CV). The protein eluted 
around 50-100 mM imidazole. Fractions were analysed by an SDS-PAGE. The fractions 
corresponding to a molecular weight of 63800 (GDS) were pooled, dialysed overnight and 
then concentrated to a final volume of ~ 5 m. Glycerol was added to the solution of purified 
enzyme (10% v/v) and the enzyme was stored at -20 °C.  
 
6.15 Preparation of DCS and GAS 
The preparation of these two enzymes was performed in the same manner as in the case of 
AS by Dr Veronica Gonzalez and Dr Sabrina Touchet.  
 
6.16 Determination of the enzyme concentration (Bradford protein assay) 
Bradford protein assay was used to determine the concentration of the enzyme in solution.
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6.17 Chemoenzymatic flow chemistry 
6.17.1 General methods 
Concentrations of sesquiterpenoids were measured using gas chromatography with flame 
ionisation detection (GC-FID) employing a manual injector and a VF-1ms column (15 m x 
0.25 mm (0.25 mm). Carrier gas was helium (flow rate: 1 mL min
–1
, split ratio 10:1) and 
chromatograms were started at 50 °C (injector temperature: 250 °C) held for 5 min at that 
temperature, then rising at 10 °C min
–1
 to 250 °C (held for 5 min) with the detector at 250 °C. 
For quantification of incubation products, the pentane used to overlay the incubations was 
spiked with α-humulene (35 μM, 1 mL) as an internal standard. FID integrations relative to 
the internal standard were used to calculate percentage conversions from the substrate. The 
linear response of the instrument against α-humulene was checked in the range between 5 and 
100 μM (Figure 60). 
 
Figure 60. Linear response of the GC-FID against -humulene. 
 
All batch reactions were performed in glass vials and kept at 30 ºC in an Eppendorf shaker 
thermomixer confort at 300 rpm. Volumes of organic material were measured using Hamilton 
syringe and aqueous volumes were measured using automatic pipettes. Solutions of standard 
were prepared in a volumetric flask. 
Enzymatic transformations were performed in a flow reactor apparatus illustrated in Figure 
61. Apparatus includes: 1 mL Hamilton syringe (organic phase), 1 mL disposable plastic 
syringe (aqueous phase), 2 syringe pumps KD-Scientific KDS-200-CE, tube with adaptors 
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for syringes, T-connector, tube reactor, temperature controlled water bath Buchi B481 and for 
experiments including sonication: ultrasonic bath Grant XB2 (50-60).  
 
Figure 61. Schematic of the flow reactor apparatus used. 
 
All experiments were performed in suitable aqueous incubation buffer for each enzyme, 
containing FDP and variable enzyme concentration. Pentane (1 mL), which was previously 
spiked with 35 µL of  α-humulene solution (1 mM) as internal standard except in the case of 
(-)-germacrene D where pentane was spiked with 35 µL of a 10 mM α-humulene solution, 
was used to extract the organic material in the aqueous incubation media.  
Standard batch experiments were performed in a glass GC-MS vial. To an enzyme solution in 
aqueous incubation buffer (500 μL), FDP (17.5µL of solution 10 mM, 0.35 mM) was added. 
The resulting mixture was overlayed with pentane solution containing internal standard (1 
mL). The vial was sealed and incubated for 30 min at 30 ºC with gentle agitation. Then, the 
biphasic mixture was vortexed for 1 min and the resulting emulsion was frozen with liquid 
nitrogen. After defrosting, the resulting biphasic mixture was separated and the pentane was 
analysed by GC-FID. 
In a standard flow experiment, the aqueous incubation mixture was prepared in an identical 
manner to a batch experiment. The aqueous incubation was loaded in a disposable syringe 
and connected to the flow reactor. Pentane solution was load in a Hamilton syringe and 
connected to the flow reactor. The two solutions were passed through the flow reactor and 
collected in the collecting vial at the end. The reaction loop was evacuated by the injection of 
water at the same flow rate. The organic material was separated from the biphasic mixture 
and analysed by GC-FID.   
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The conversion was calculated by comparison of the integrals of the standard and the 
enzymatic product using the equation shown in Figure 62. 
100



pst
pst
CI
IC
Conversion
 
Figure 62. Cst: concentration of standard , Ip: integral for the product,  Ist: integral for the 
standard, Cp: concentration of product in organic layer assuming full conversion. 
 
6.17.2 Representative GC-FID traces gas chromatograms 
6.17.3 (+)-Aristolochene synthase (AS) 
Gas chromatogram of the pentane extractable products isolated from the flow reaction with 
AS using a internal reactor diameter of 0.8 mm with sonication. This enzyme generates a 
small portion of intermediate (-)-germacrene A. The conversion achieved in this case was 
88%. 
 
 
Figure 63. Gas chromatogram of the pentane extractable products arising from the incubation 
of AS and FDP in flow.  
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Gas chromatogram of pentane extractable products of the control experiment in batch with 
sonication, achieving in this case a conversion of 43%. 
 
 
 
Figure 64. Gas chromatogram of the pentane extractable products arising from the incubation 
of AS and FDP in batch. 
 
14Me FDP has been shown before to give the intermediate 14-methyl-germacrene A when 
incubated with AS. GC-FID chromatogram of the products isolated from the flow reaction of 
14Me-FDP with AS using 0.8 mm internal reactor diameter under sonication. The conversion 
achieved in this case was 11%. 
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Figure 65. Gas chromatogram of the pentane extractable products arising from the incubation 
of 14Me-FDP and AS in batch.  
 
Gas chromatogram of the pentane extractable products of the control experiment in batch 
with sonication, achieved in this case a conversion of 6%. 
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Figure 66. Gas chromatogram of the pentane extractable products arising from the incubation 
of 14Me-FDP and AS in batch. 
 
Gas chromatogram of the pentane extractable products isolated from the flow reaction of 
12Me_FDP with AS using 0.8 mm internal reactor diameter under sonication. The conversion 
achieved in this case is 63%. The identity of the products contain in the mixture obtained in 
this case is unknown. 
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Figure 67. Gas chromatogram of the pentane extractable products arising from the incubation 
of 12Me-FDP and AS in flow.  
 
Gas chromatogram of pentane extractable products the control experiment in batch with 
sonication, achieving in this case a conversion of 22%. 
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Figure 68. Gas chromatogram of the pentane extractable products arising from the incubation 
of 12Me-FDP and AS in batch.  
 
Gas chromatogram of the pentane extractable products isolated from the flow reaction of 
15Me-FDP with AS using 0.8 mm internal reactor diameter under sonication. The conversion 
achieved in this case was 15 %. The product was identified as 15-Me-aristolochene. 
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Figure 69. Gas chromatogram of the pentane extractable products arising from the incubation 
of 15Me-FDP and AS in flow 
 
Gas chromatogram of the pentane extractable products of control experiment in batch with 
sonication, achieving in this case a conversion of 9%. 
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Figure 70. Gas chromatogram of the pentane extractable products arising from the incubation 
of 15Me-FDP and AS in batch 
 
6.17.4 (+)--Cadinene synthase (DCS) 
Gas chromatogram of the pentane extractable products isolated from the flow reaction with 
DCS using 0.45 mm internal reactor diameter with sonication. The conversion achieved in 
this case was 56%. 
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Figure 71. Gas chromatogram of the pentane extractable products arising from the incubation 
of DCS and FDP in flow. 
  
Gas chromatogram of the pentane extractable products from control experiment in batch with 
sonication, achieving in this case a conversion of 30%. 
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Figure 72. Gas chromatogram of the pentane extractable products arising from the incubation 
of DCS with FDP in batch. 
  
Gas chromatogram of the pentane extractable products isolated from the flow reaction of 
14Me-FDP with DCS using 0.45 mm internal reactor diameter under sonication. The 
conversion achieved in this case was 14%. The structure of the product obtained has not yet 
been determined. 
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Figure 73. Gas chromatogram of the pentane extractable products arising from the incubation 
of 14Me-FDP and DCS in flow. 
 
Gas chromatogram of the pentane extractable products isolated from control experiment in 
batch with sonication, achieving in this case a conversion of 9%. 
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Figure 74. Gas chromatogram of the pentane extractable products arising from the incubation 
of 14Me-FDP and DCS in batch. 
 
6.18 Identification of enzymatic products 
6.18.1 General considerations 
TLC plates, used for purification, were previously deactivated by immersion in 10% Et3N 
solution in diethyl ether and allowed to dry for 48 h. Berberine.HCl was used as visualisation 
agent. Preparative TLC plates were sprayed with a solution of berberine.HCl 5% in diethyl 
ether and allowed to dry at least for 1 h. 
Samples were applied to the preparative TLC plate using a glass pipette. The level of the 
crude compound in the TLC plate was homogenised by eluting the plate a few centimetres 
using diethyl ether as eluent, after allowing the ether to evaporated the plate was fully eluted 
with resolving solution. After the plate was eluted the product bands, were visualised with 
UV light and the bands corresponding to the product was scratched from the plate. The silica 
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was extracted with diethyl ether. The diethyl ether used in this procedure was previously 
distilled from sodium to remove stabilisers that would contaminate the desired products. 
The concentration of pentane solutions of sesquiterpenoids used as samples for biological 
testing, were measured using a Varian 3900 GC-flame ionisation detection (FID) system with 
same temperature program described in the previous section. Samples necessarily could not 
contain an internal standard and so an external standard was used in these cases. 
Samples of unknown concentration were injected (25 µL) and the area resulting from the 
integration of the sesquiterpene peak was used to estimate concentration. The area was used 
in an equation extrapolated from a calibration curve obtained with aromadendrene and 10F-
farnesine mixture (calibration curves were performed by Dr Sabrina Touchet).  
 
6.18.2 General procedure for qualitative analytical incubations  
FDP (or FDP analogue) (9 μL, 10 mM) was diluted with 250 μL of optimised incubation 
buffer. Reaction was initiated by addition of enzyme solution (15 μL, 50 μM) was added 
followed by pentane (1 mL) and the mixture was gently agitated on a shaker at room 
temperature overnight. The olefin products were extracted by vortexing the biphasic mixture 
for 30 seconds. The organic extract was analysed by gas chromatography-mass spectrometry 
(GC-MS) as described in general synthetics procedures. The identification of germacrene A 
(and its homologues) by GC-MS was made by increasing the temperature of the injection port 
from 50 ºC to 250. 
 
6.18.3 General procedure for preparative incubations of FDP and analogues with 
sesquiterpene synthases. 
All preparative incubations were performed using this method unless otherwise stated. 
Preparative incubations were performed in an ACE sealed tube. To a freshly prepared 
suitable incubation buffer (without β-mercaptoethanol) for each enzyme (vide supra, section 
3.1) (30 mL,), stock solution of enzyme was added to achieve a final enzyme concentration of 
12 μM. To the enzyme solution, farnesyl diphosphate (or analogue) stock solution (10 mM) 
was added as evenly as possible using an automatic pipette to achieve a final concentration of 
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0.4 mM. CDCl3 (previously deactivated on basic alumina, 4 mL) was carefully deposited on 
the bottom of the sealed tube with a pipette to minimise contact with the aqueous incubation 
media. The sealed tube was closed and incubated in a shaker at 250 rpm for 24 h at 30 ºC. 
The biphasic mixture was rotated at 4 ºC in a rotator over night extract sesquiterpenes. The 
resulting emulsion was frozen in liquid nitrogen and allowed to defrost at room temperature 
whereupon a biphasic mixture was formed. The biphasic mixture was separated with a phase 
separator (IST) and passed through a short plug of MgSO4 and another of neutral alumina. 
The sealed tube was washed with an additional portion of CDCl3 (2 mL). The organic layer 
was collected in an NMR tube and excess of solvent was removed under gentle stream of 
nitrogen until a suitable volume for analysis (0.4 mL) was obtained.  
 
6.19 (+)-Germacrene A synthase (GAS) 
6.19.1 Incubation of 14Me-FDP (137) with GAS 
 
 
Incubation of GAS (30 mL DCS incubation buffer solution, 12 μM, 23 mg) with 14Me-FDP 
(1,2 mL, stock solution of 10 mM, 5.4 mg)  was performed following the general procedure 
described above. The final solution of (R)-14Me-germacrene A (292) in CDCl3 was analysed 
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by variable temperature 
1
H NMR spectroscopy without further purification. The data was 
identical to the previously isolated (S)-14Me-germacrene A (320) vide infra. 
1
H NMR 500 MHz, CDCl3, -50 ºC (δ, m, J in Hz) 
Conformer H-12 H-12’ H-13 H-15 H-16 H-1 H-5 
292ª 4.64 (s) 4.56 (s, 
1H) 
1.70 (bs) 1.47 (s) 0.88 (t, 
7.5) 
4.71 (dd, 
12.0, 
4.0) 
4.53 (bs) 
292B 4.64 (s) 4.60 (s,) 1.70 (bs) 1.43 (s) 0.85 (t, 
7.5) 
4.91 
(dd,18.5, 
10.5) 
5.01 (dd, 
9.0, 4.0 ) 
292C 4.64 (s) 4.53 (bs) 1.70 (bs) 1.44 (s) 0.94 (t, 
7.5) 
4.91 
(dd,18.5, 
10.5) 
5.22 (t, 
7.5) 
 
Table 15. Assignment of resonances in the 
1
H NMR spectrum of 292.  
 
6.19.2 Incubation of 10F-FDP (290) with GAS 
10F-FDP analogue was provided by Dr Juan A. Faraldos. Incubation of GAS (30 mL DCS 
incubation buffer solution, 12 μM, 23 mg) with 10F-FDP (1.2 mL, stock solution of 10 mM, 
5.4 mg) was performed following the general procedure. 300 was purified by preparative 
TLC. 
 
1
H NMR (500 MHz, CDCl3) δ 4.97 (dt, J = 40.5, 8.0, 1H). 
19
F NMR (565 MHz, CDCl3) δ 
109.9 (d, J = 41.5, CF=C). m/z (EI
+
): 222.2 (50%, M
+
), 179.1 (8%, M
+
-C2F), 154.1 (17%, 
M
+
-C5H8), 139.1 (98%, M
+
-C6H11), 125.1 (31%, M
+
-C7H13), 111.1 (100%). 
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6.20 Aristolochene synthase (AS) 
6.20.1 Incubation FDP (17) with AS 
 
 
AS incubation buffer solution (300 mL, 12 μM AS, 140 mg) was added to an oven dried 
glass trap equipped with glass stopper (typically used as a liquid nitrogen trap in a high 
vacuum apparatus), aqueous enzyme solution (580 μM,, 4 mL) was then added followed by 
the addition of aqueous FDP solution (10 mM, 12 mL). CHCl3 (30) mL was deposited in the 
bottom of the trap and the biphasic mixture was incubated for 12 h. Workup of the incubation 
was done as indicated in the general procedure. Once the aqueous layer media was separated 
from the organic material, extraction process was repeated two additional times with fresh 
aliquots of CHCl3. Each aliquot was concentrated separately under reduce pressure (to ca. 5 
mL) and the final volume of solvent was removed under stream of nitrogen in an NMR tube. 
Each extract was weighted (i. e. compounds were concentrated to dryness to measure yield in 
this instance) and analysed separately by NMR spectroscopy: first
 
extraction 11 mg (45 %), 
second extraction 7 mg (28%), third extraction 4 mg (16%) and combined material after 
solvent removal 18 mg (73%) of pure 56. 
1
H NMR (300 MHz, CDCl3) δ 5.32 (dd, J = 3.5, 2.0, 1 H, C=CH), 4.71 (s, 2 H, C=CH2), 2.29 
– 1.77 (m, 7 H, 3 x CH2, HC(CH3)C=CH2), 1.74 (s, 3 H, CH3), 1.31 (m, 5 H, 2 x CH2, 
HCCH3), 0.97 (s, 3 H, CH3), 0.84 (d, J = 6.5, 3 H, , HC(CH3)C=CH2).
13
C NMR (75 MHz, 
CDCl3) δ 150.8 (C=CH2), 144.6 (C=CH), 118.9 (C=CH), 108.4 (C=CH2), 44.3 (CHCH3), 
43.4 (CH2), 38.9 (CCH3), 37.9 (HCC=CCH3), 32.7 (CH2), 31.5 (CH2), 31.3 (CH2), 28.0 
(CH2), 21.0 (H2C=CCH3), 18.2 (CH3), 15.8 (CH3). m/z (EI
+
): 204.2 (14%, M
+
), 189.167 
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(100%, M
+
-CH3), 161.134 (26%, M
+
-C3H7), 147 (20%, M
+
-C4H9), 133 (26%, M
+
- 2xCH3, 
isoproprenyl), 105.1 (54%), 91 (22%).   
 
6.20.2 Incubation of 14Me FDP (137) with AS 
 
 
 
To a general AS incubation buffer (200 mL 20mM Tris, 5mM β-ME, 5mM MgCl2, 15% 
glycerol) in a 500 mL glass bottle, 14Me-FDP was added (76 mg, 0.17 mmol) the mixture 
was stirred until solution. Enzyme solution (390 µM, 5 mL) was added and the aqueous 
incubation mixture was overlaid with pentane (15 mL). The cloudy solution was slowly 
stirred for 12 h. After this time, a further batch of enzyme solution (390 µM, 2 mL) was 
added and the mixture was stirred for an additional 12 h. The organic layer was separated and 
organic material was extracted from the aqueous solution with pentane (3 x 30 mL). The 
pooled organic extracts were dried over MgSO4, filtered and then the solvent was 
concentrated under reduce pressure until volume was approximately of 5 mL. Final removal 
of the solvent was done under stream of nitrogen. The sample was purified by preparative 
TLC with pentane as eluent obtaining 320 as pale yellow oil (6 mg, 17%). Assignments of the 
protons down-field were made by comparison with previous reported spectrum of (+)-
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germacrene A
310
 and assignments of the protons up field were made by extrapolation of the 
relative abundance of each conformer taken from the signals down-field. 
 
1
H NMR 500 MHz, CDCl3, -50 ºC (δ, m, J in Hz) 
Conformer H-12 H-12’ H-13 H-15 H-16 H-1 H-5 
320ª 4.64 (s) 4.56 (s, 
1H) 
1.70 (bs) 1.47 (s) 0.88 (t, 
7.5) 
4.71 (dd, 
12.0, 
4.0) 
4.53 (bs) 
320b 4.64 (s) 4.60 (s,) 1.70 (bs) 1.43 (s) 0.85 (t, 
7.5) 
4.91 
(dd,18.5, 
10.5) 
5.01 (dd, 
9.0, 4.0) 
320C 4.64 (s) 4.53 (bs) 1.70 (bs) 1.44 (s) 0.94 (t, 
7.5) 
4.91 
(dd,18.5, 
10.5) 
5.22 (t, 
7.5) 
 
Table 16. Assignment of resonances in the 
1
H NMR spectrum to 320.  
 
Assignment of each signal to a specific conformer allowed calculation of the conformer 
distribution: conformer 320a 39%, conformer 320b 29% and conformer 320c 32%. 
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6.20.3 Incubation of 14,15diMe-FDP (139) with AS 
 
 
Incubation was performed following the general incubation procedure with 14,15diMe-FDP 
(1.2 mL, stock solution of 10 mM, 5.2 mg) and AS (30 mL AS incubation buffer solution, 
12μM, 14 mg). Final solution was studied by variable temperature 1H NMR spectroscopy 
without further purification. Assignments of 14Me-germacrene A (329), protons down field 
were assigned by comparison with previous reported spectrum of (+)-germacrene A
310 
and 
assignment of the protons up-field were assigned by extrapolation of the relative abundance 
of each conformer taken from the signals down field. 
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1
H NMR 500 MHz, CDCl3, -50 ºC (δ, m, J in Hz) 
Conformer H-12 H-12’ H-13 H-15 H-
17 
H-1 H-5 
329a 4.64 (bs) 4.53 (s) 1.69 (d, 
3.5) 
0.97 – 0.81 (m) 
 
4.71 (dd, 
11.5, 4.0) 
4.47 (dd, 
9.5, 3.5) 
329b 4.64 (bs) 4.59 (s) 1.69 (d, 
3.5) 
0.97 – 0.81 (m) 
 
4.93 – 
4.82 (m) 
4.96 (dd, 
9.5, 4.5) 
329C 4.64 (bs) 4.55 (s) 1.74 (s) 0.97 – 0.81 (m) 
 
4.93 – 
4.82 (m) 
5.17 (dd, 
8.5, 7.0) 
Table 17. Assignment of resonances in the 
1
H NMR spectrum to 329.  
Assignment of each signal to a conformer allowed calculation of the conformer distribution: 
conformer 329a 39%, conformer 329b 29% and conformer 329c 32%. 
 
6.21 (-)-Germacrene D synthase (GDS) 
6.21.1 Incubation of FDP (17) with GDS 
 
 
Incubation of GDS (30 mL DCS incubation buffer solution, 12 μM, 23 mg) with FDP (1,2 
mL, stock solution of 10 mM, 5.2 mg)  was performed following the general procedure. After 
NMR spectroscopic analysis the sample was concentrated to dryness under stream of N2. 49 
was isolated as pale yellow oil (1.7 mg, 61%) 
1
H NMR (400 MHz, CDCl3) δ 5.78 (d, J = 16.0 , 1 H, HC=CHCH), 5.25 (dd, J = 16.0, 10.0 , 
1 H, HC=CHCH), 5.13 (dd, J = 11.5, 5.0, 1 H, CH=CCH2CH3), 4.79 (s, 1 H, H2C=C), 4.74 
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(s, 1 H, H2C=C), 2.47 – 2.32 (m, 2 H, CH2), 2.30 – 2.15 (m, 2 H, CH2), 2.14 – 1.95 (m, 3 H, 
CH2, CHCHCH2), 1.51 (s, 3 H, CH3), 1.44 (m, 3 H, CH2, CHCH(CH3)2), 0.86 (d, J = 6.7 , 3 
H, CH(CH3)2), 0.81 (d, J = 6.8, 3 H, CH(CH3)2). 
13
C NMR (126 MHz, CDCl3) δ 149.1 
(H2C=C), 135.7 (HC=C), 134.1 (HC=CH), 133.7 (HC=CH), 129.9 (HC=C), 109.2 (H2C=C), 
53.1 (CH2CHCH=C), 40.9 (CH2), 34.7 (CH2), 32.9 (CH(CH3)2), 29.4 (CH2), 26.7 (CH2), 20.9 
(CH3), 19.5 (CH3), 16.1 (CH3). m/z (EI
+
): 204 (64%, M
+
), 189 (9%, M
+
-CH3), 146 (15%, M
+
- 
CH3 and isopropyl), 133 (45%), 119 (75%), 105 (81%), 91 (76%) 
 
6.21.2 Incubation of 14Me-FDP (137) with GDS 
 
 
Incubation of GDS (30 mL DCS incubation buffer solution, 12 μM, 23 mg) with 14Me-FDP 
(1,2 mL, stock solution of 10 mM, 5.4 mg)  was performed following the general procedure. 
Analysis of the sample by GC-FID determined the final concentration of 338 finding a total 
concentration of 1.3 mg/mL in 0.9 mL of CHCl3. 
1
H NMR (500 MHz, CDCl3)  5.71 (d, J = 16.0, 1 H, HC=CH), 5.12 (dd, J = 16.0, 10.0, 1 H, 
HC=CH), 4.99 (dd, J = 11.0, 5.0 , 1 H, CH=CCH2CH3), 4.69 (bs, 1 H, H2C=C), 4.71 (bs, 1 H, 
H2C=C), 2.48 (m, 2 H, CH2), 2.30 (dt, J = 15.0, 7.3, 2 H,CHCHCH2), 2.17 – 1.91 (m, 4 H, 2 
x CH2), 1.71 (dq, J = 19.5, 10.0, 4.6 , 1 H, CHCH(CH3)2), 1.59 – 1.35 (m, 4 H, 2 x CH2). 0.87 
(t, J = 7.5, 3 H, CH3CH2), 0.73(d, J = 6.5, 3 H, (CH3)2CH), 0.79 (d, J = 6.5, 3 H, 
(CH3)2CH).
13
C NMR (126 MHz, CDCl3) δ 148.9 (H2C=C), 139.3 (HC=C), 135.5 (HC=CH), 
134.9 (HC=CH), 130.0 (HC=C), 109.4 (H2C=C), 52.8 (CH2CHCH=C), 37.1 (CH2), 34.6 
(CH2), 32.8 (CH2), 28.9 (CH(CH3)2), 26.9 (CH2), 21.4 (CH2), 20.7 (CH3), 19.3 (CH3), 12.6 
(CH3) 
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6.21.3 Incubation of 6F-FDP (289) with GDS 
 
Incubation of GDS (30 mL DCS incubation buffer solution, 12 μM, 23 mg) with 6F-FDP (1,2 
mL, stock solution of 10 mM, 5.4 mg)  was performed following the general procedure. 
Analysis of the sample by GC-FID determined the final concentration of 289 finding a 
concentration of 1.2 mg/mL in 0.9 mL of CHCl3.. 
1
H NMR (600 MHz, CDCl3) δ 6.13 (d, J = 16.0, 1 H, HC=CH), 5.82 (dd, J = 16.0, 9.4, 1 H, 
HC=CH), 4.85 (bs, 1 H, H2C=C), 4.73 (bs, 1 H, H2C=C), 2.79 (bs, 2 H, CH2), 2.41 – 2.27 (m, 
1 H, CHCHCH2), 2.27 – 2.03 (m, 2 H, CH2), 1.89 (bd, J = 37.5, 2 H, CH2CF), 1.64 (m, 3 H, 
CH2, CHCH(CH3)2), 1.44 (s, 3 H, CH3), 0.88 (dd, J = 20.0, 6.0, 6 H, CH(CH3)2). 
13
C NMR 
(150 MHz, CDCl3, resonances measured indirectly by HSQC)  15.4 (CH3) 17.2 (CH3), 20.4 
(CH3), 27.1 (CH2), 28.9 (CH2), 29.4 (CH), 29.5 (CH2), 30.7 (CH2), 31.0 (CH2) 48.9 (CH), 
112.3 (C=CH2), 115.2 (CH3C=CF), 128.3 (CH2=CCH=CH), 138.5 (CH2=CCH=CH), 148.2 
(C=CH2), 154.7 (d, JCF 248.5, C=CF); 
19
F NMR (565 MHz, CDCl3) δ -106.0 (d, J = 42.0 , 
CF=C). m/z (EI
+
): 222.2 (28%, M
+
), 202.2 (22%, M
+
-HF), 179.1 (59%, M
+
-C3H7 
(isopropyl)), 159.1 (100%, M
+
-HF-C3H7). 
 
6.22 --Cadinene synthase (DCS) 
6.22.1 Incubation of 8OH-FDP with DCS 
Incubation of DCS (30 mL DCS incubation buffer solution, 12 μM, 23 mg) with 8OH-FDP 
(1,2 mL, stock solution of 10 mM, 5.4 mg) was performed following the general procedure 
but the organic extract in this case was not passed through a short plug of neutral alumina. 
Two different compounds were isolated from the incubation of this analogue and separated 
by preparative TLC with hexane: ethyl acetate (20:1) as eluent and characterised as 
compound ketone 346 and alcohol 349. 
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1
H NMR (600 MHz, CDCl3)δ 5.54 (bd, J = 4.0 , 1 H, CH3C=CH), 2.75 (p, J = 6.5 , 1 H 
CHCH3), 2.31 (dd, J = 11.0, 5.5, 2 H, C=CHCH), 2.22 – 2.12 (m, 2 H, CH3CHCH, 1 H x 
C=OCH2), 2.09 (t, J = 13.0, 1 H, 1 H x C=OCH2), 2.03 (dtd, J = 10.0, 7.0, 3.0, 1 H, 
HC(CH3)2), 1.99 – 1.94 (bd, 2 H, J = 6.5, CH2CH2CH), 1.83 – 1.75 (m, 1 H, HCHC(CH3)2), 
1.66 (s, 5 H, CH3CH, CH2CH2CH), 1.01 (d, J = 7.0, 3 H,CH3CH ), 0.89 (d, J = 7.0, 3 H 
(CH3)2CH), 0.86 (d, J = 7.0, 3 H, (CH3)2CH). 
13
C NMR (151 MHz, CDCl3) δ 214.5 (C=O), 
134.8 (CH3C=CH), 123.2 (CH3C=CH), 48.0 (CH3CHCH), 47.5 (CHCH(CH3)2), 
43.9(CH3CHCH), 40.2 (C=OCH2), 39.2 (C=CHCH), 31.0 (CH2CH2CH), 27.2 ((CH3)2CH), 
23.8 (CH3C=CH), 21.4((CH3)2CH), 18.9 (CH2CH2CH), 15.1 ((CH3)2CH), 11.5 
(CH3CHC=O). 
 
 
The signals on 
1
H NMR spectrum were assigned by comparison with the ketone and by 
comparison with previously published NMR spectroscopic analysis of -cadinene311,312 and 
-cadinene derivatives.313  
1
H NMR (600 MHz, CDCl3) δ 5.45 (bs, 1 H, C=CH), 5.30 (s, 1 H, OH), 3.97 (bd, J = 7.3, 1 
H, CHOH), 2.71 – 2.62 (m, 1 H, J = 3.5, 13.0 CH2CH2C=C(CH3)), 2.46 (d, J = 11.0 , 1 H, 
C=CHCHCH), 2.16 – 2.09 (m, 1H, CH(CH3)2), 2.03 (bd, J = 8.0 , 1 H, CH2CH2C=C(CH3)), 
275 
 
1.98 – 1.88 (m, 1 H, CHCH(CH3)2), 1.80 (s, 3 H, C=C(CH3)CHOH), 1.68 (s, 3 H, 
(CH3)C=CH), 0.98 (d, J = 6.9 , 3 H, CH(CH3)2), 0.79 (d, J = 6.9, 3 H, CH(CH3)2). 
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